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A B S T R A C T
Background
Patients with head and neck cancer are often malnourished. Surgery for such cancers is complex and may be undertaken after a course
of radiotherapy. As a result, patients may have postoperative complications such as fistulae and wound infections, as well as more
generalised infections such as pneumonia. One possible way to enhance recovery, and reduce the incidence of these complications, is
by improving nutrition. Nutritional formulas that deliver basic nutrients as well as amino acids (arginine and glutamine), ribonucleic
acid (RNA) and/or lipids (omega-3 fatty acids) are known as immunonutrition.
Objectives
Toassess the effects of immunonutrition treatment, compared to standard feeding, onpostoperative recovery in adult patients undergoing
elective (non-emergency) surgery for head and neck cancer.
Search methods
The Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL);
PubMed; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished
trials. The date of the search was 14 February 2018.
Selection criteria
We included randomised controlled trials (RCTs) comparing immunonutrition given either preoperatively, postoperatively or periop-
eratively to adult patients (18 years of age or older) undergoing an elective surgical procedure for head and neck cancer, compared with
a control group receiving either standard polymeric nutritional supplements or no supplements.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. The primary outcomes were: length of hospital stay (days),
wound infection, fistula formation and adverse events/tolerance of feeds, as defined by trial authors. Secondary outcomes were: all-
cause mortality and postoperative complications (as defined by trial authors). We used GRADE to assess the quality of the evidence
for each outcome; this is indicated in italics.
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Main results
We included 19 RCTs (1099 participants). The mean age of participants ranged from 47 to 66 years. Most studies (12/19) had fewer
than 25 patients in each treatment group. Most studies (16/19) used immunonutrition formulas containing arginine, but there was
variation in the actual products and amounts used, and in the length of intervention postoperatively. Follow-up time for outcome
measurement varied considerably across studies, ranging from five days to greater than or equal to 16 months.
Primary outcomes
We found no evidence of a difference in the length of hospital stay (mean difference -2.5 days, 95% confidence interval (CI) -5.11 to
0.12; 10 studies, 757 participants; low-quality evidence). Similarly, we found no evidence of an effect of immunonutrition on wound
infection (risk ratio (RR) 0.94, 95% CI 0.70 to 1.26; 12 studies, 812 participants; very low-quality evidence). Fistula formation may
be reduced with immunonutrition; the absolute risks were 11.3% and 5.4% in the standard care and immunonutrition groups, with a
RR of 0.48 (95% CI 0.27 to 0.85; 10 studies, 747 participants; low-quality evidence). We found no evidence of a difference in terms
of tolerance of feeds (’adverse events’) between treatments (RR 1.33, 95% CI 0.86 to 2.06; 9 studies, 719 participants; very low-quality
evidence).
Secondary outcomes
We found no evidence of a difference between treatments in all-cause mortality (RR 1.33, 95% CI 0.48 to 3.66; 14 studies, 776 par-
ticipants; low-quality evidence). Other postoperative complications such as pneumonia and urinary tract infections were not commonly
reported.
Authors’ conclusions
The risk of postoperative fistula formation may be reduced with immunonutrition, but we found no evidence of an effect of im-
munonutrition on any of the other outcomes that we assessed. The studies included in this review were generally small or at high risk of
bias (or both). We judged the overall quality of the evidence to be low for the outcomes length of hospital stay and all-cause mortality,
and very low for wound infection and adverse events. Further research should include larger, better quality studies.
P L A I N L A N G U A G E S U M M A R Y
Immunonutrition for patients undergoing surgery for head and neck cancer
Review question
This review compared how people recover after surgery for head and neck cancer if they have been given either ’immunonutrition’
or a standard feed before and after or only after the surgery. We looked at how long people stayed in hospital, whether they had any
complications and how many people in each treatment group died.
Background
Head and neck cancer surgery usuallymeans surgery to treat cancer of themouth, throat or larynx (voice box). The surgery is complicated
and people often experience problems such as wound infections and wound breakdown, as well as infections such as pneumonia.
These can lead to a longer stay in hospital. Specific nutrients, for example amino acids (found in protein-based foods), omega-3 fatty
acids (often found in fish oils) and nucleotides (found in many foods) have been investigated for their role in helping people recover
from surgery. When any of these specific nutrients are added to the patient’s feed it is called immunonutrition. We wanted to see
whether feeding people immunonutrition improved recovery (for example, led to a shorter length of stay and fewer complications)
when compared with a standard feed.
Study characteristics
We included 19 studies that recruited 1099 adults in total (studies ranged in size from 8 to 209 participants, but most (12 out of 19)
had fewer than 25 participants per treatment group). The studies focused on people who were given immunonutrition or a standard
feed before and after or only after their surgery. The studies varied in the length of time over which people were given the feeds, but
this was usually at least five days. The evidence is current to February 2018.
Key results
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We did not find evidence of a difference in the length of hospital stay but there was wide variation between the individual studies in
what they showed. We found some evidence that people who had immunonutrition may be about half as likely to have breakdown
of their surgical wound called a fistula (a channel between the inside of the throat and the surface skin). We found no evidence that
immunonutrition had any effect on wound infection (but not all studies were clear in how they measured this) or death. Study feeds
were generally well tolerated and there was no evidence of a difference in adverse events such as diarrhoea between treatment groups.
Other clinical complications such as pneumonia and urinary tract infections were not commonly reported, but there was little evidence
of a reduction with immunonutrition.
Quality of the evidence
Most studies included in this review were small and poorly reported, which means that their results may be less reliable. More studies
are needed that are larger, of better quality and conducted within current healthcare systems.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Immunonutrition compared to standard care for patients undergoing surgery for head and neck cancer
Patient or population: pat ients undergoing surgery for head and neck cancer
Setting: hospitals (internat ional)
Intervention: immunonutrit ion
Comparison: standard care
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with standard care Risk with immunonutri-
tion
Postoperat ive length of
hospital stay (days)
Follow-up: 8 to 90 days
post surgery or hospital
discharge
The mean of re-
ported length of hos-
pital stay (mean val-
ues) across the stan-
dard care groups was
27.0 (17.4 to 36.1) days
The mean of re-
ported length of hospi-
tal stay (mean values)
across the immunonu-
trit ion groups was 23.2
(15.3 to 31.1) days
MD 2.5 lower
(5.11 lower to 0.12
higher)
757
(10 RCTs)
⊕⊕©©
LOW1
There may be a re-
duct ion in the length
of hospital stay of 2.5
days with immunonutri-
t ion, but the est imate is
imprecise (wide CI) and
includes the null value
Wound infect ion
Follow-up: 8 to 90 days
post surgery or hospital
discharge
Study populat ion RR 0.94
(0.70 to 1.26)
812
(12 RCTs)
⊕©©©
VERY LOW1,2
Immunonutrit ion may
have lit t le or no ef fect
on wound infect ion, but
the evidence is very un-
certain
145 per 1000 136 per 1000
(101 to 182)
Fistula formation
Follow-up: 8 to 90 days
post surgery or hospital
discharge
Study populat ion RR 0.48
(0.27 to 0.85)
747
(10 RCTs)
⊕⊕©©
LOW 1
There may be an ap-
proximate halving of
the risk of f istulae for-
mation but the evidence
is of low quality
113 per 1000 54 per 1000
(31 to 96)
4
Im
m
u
n
o
n
u
tritio
n
fo
r
p
a
tie
n
ts
u
n
d
e
rg
o
in
g
su
rg
e
r
y
fo
r
h
e
a
d
a
n
d
n
e
c
k
c
a
n
c
e
r
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Adverse events/ toler-
ance of feeds
Follow-up: 10 to 90
days post surgery or
hospital discharge
Study populat ion RR 1.33
(0.86 to 2.06)
719
(9 RCTs)
⊕©©©
VERY LOW1,3
There may be lit t le or
no dif ference in ad-
verse events such as
diarrhoea between the
treatment groups, but
the evidence is very un-
certain
91 per 1000 121 per 1000
(78 to 188)
All-cause mortality
Follow-up: 30 days to
greater than or equal to
16 months post surgery
Study populat ion RR 1.33
(0.48 to 3.66)
776
(14 RCTs)
⊕⊕©©
LOW1
Immunonutrit ion may
have lit t le or no ef fect
on mortality.18 per 1000 24 per 1000
(9 to 67)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by two levels for imprecision: most studies had small sample sizes and conf idence intervals around the
summary est imates were wide.
2Downgraded by one level for risk of bias: assessment of wound infect ion was poorly reported across studies.
3Downgraded by one level for risk of bias: assessment of adverse events was poorly reported across studies and not all
studies measured the same adverse events.
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B A C K G R O U N D
Description of the condition
The term ’head and neck cancer’ encompasses several sites includ-
ing oral and laryngeal cancers. In 2014, over 11,000 people in the
UK were diagnosed with cancers at these sites (Cancer Research
UK). Surgical treatment of head and neck cancer can be aggressive
and highly complex, and people undergoing these surgeries may
have a 30% to 60% incidence of postoperative complications in-
cluding wound infections and other infections such as pneumo-
nia (Kucur 2015; McMahon 2013; Perisanidis 2012; Yang 2014).
This substantial morbidity has inevitable implications for both pa-
tients and healthcare systems. Furthermore, a recent systematic re-
view and meta-analysis showed that postoperative complications,
especially infections, adversely affect long-term survival (Pucher
2014).
Many patients with head and neck cancer are malnourished for
a number of reasons including mechanical obstruction, tumour-
induced cachexia, poor dietary habits and excessive alcohol con-
sumption. Poor nutrition is known to have an adverse impact on
outcome in this patient group (van Bokhorst 2000). These pa-
tients have well-documented immune defects including T-lym-
phocytopenia and dysfunction, and reduced monocyte HLA-DR
expression (Hadden 1997). These defects, combined with the im-
mune suppressive effects of surgery, may contribute to increased
postoperative complications such as poor wound healing and sep-
sis.
Description of the intervention
Nutrition supports immune function by preventing or reversing
immunosuppression related to malnutrition. Standard commer-
cial nutritional supplements are described as polymeric, which
means they contain whole protein, partially digested starch and
triglycerides, along with electrolytes, trace elements and vitamins.
More recently, specific nutritional components have been com-
bined with standard polymeric enteral feeds with the aim of specif-
ically improving immune function. Immunonutrition describes
enteral feeding formulas usually supplemented with combinations
of the amino acids arginine or glutamine, omega-3 fatty acids
and nucleic acids. Animal models and human studies have sug-
gested that the individual components have beneficial (or poten-
tially beneficial) effects on immune function. There is evidence
that nutritional supplements with immunonutritional additives
can favourably modulate the immune and inflammatory response
both in vitro and in patients with trauma, burns or those under-
going gastrointestinal surgery (Di Carlo 1999; Wu 2001; Zhang
2012). Meta-analysis suggests that immunonutrition reduces in-
fectious complications in critically ill patients (Heyland 2001).
They are usually given in liquid form and are designed to provide
a patient’s ’complete’ nutritional requirements, provided they are
given in an appropriate volume. Immunonutrition and standard-
ised commercial nutrition supplements may be given either orally
or via an enteral feeding tube.
How the intervention might work
Themost studied nutrients in immunonutrition formulas are argi-
nine, glutamine, omega-3 fatty acids and nucleotides. Arginine is
the most common immunonutrient given to patients with head
and neck cancer. It is a non-essential amino acid with a role in
the synthesis of nucleotides, polyamines, nitric oxide and proline.
Arginine may stimulate lymphocyte function and improve wound
healing. Glutamine, also an amino acid, is a fuel for rapidly di-
viding cells in the body, in particular for enterocytes and colono-
cytes. The addition of omega-3 fatty acids to enteral nutrition
feeds reduces proinflammatory mediators in stressed patients and
may reduce infections. The content of each immunonutrition for-
mula varies between products. The biochemical and physiologi-
cal properties of nutrients included in immunonutrition formulas
have been discussed in detail (Worthington 2011).
Why it is important to do this review
Commercial enteral feed products containing specific nutritional
components that may favourably affect immune function have
been designed to improve the outcomes in surgical patients. Stud-
ies of head and neck cancer patients receiving immunonutrition
in the perioperative period have not conclusively demonstrated
benefit. We carried out a systematic review of randomised con-
trolled trials, which was published in 2009, to determine whether
perioperative immunonutrition has a role in the treatment of head
and neck cancer (Stableforth 2009). In that review we examined
10 trials investigating the effects of immunonutrition in patients
treated surgically for head and neck cancer. A reduction in the
length of postoperative hospital stay was seen, but the reason for
this reduction was not clear. Most trials were too small to provide
precise estimates of intervention effects. There were insufficient
data to exclude substantial effects of immunonutrition on clinical
outcomes or biochemical and immunological parameters. Since
the publication of that review in 2009 there have been further
studies that merit evaluation and inclusion in an updated review
(Azman 2015; Casas-Rodera 2008; De Luis 2009; De Luis 2014;
Falewee 2014; Felekis 2010; Ghosh 2012; Hanai 2018; Sorensen
2009; Turnock 2013).
O B J E C T I V E S
To assess the effects of immunonutrition treatment, compared
to standard feeding, on postoperative recovery in adult patients
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undergoing elective (non-emergency) surgery for head and neck
cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), including quasi-randomised
trials. We had planned to subject quasi-randomised trials to a
sensitivity analysis (see Sensitivity analysis). We included studies
irrespective of language or publication status.
We excluded non-randomised studies, such as cohort studies, be-
cause of the increased potential for bias. We also excluded cross-
over trials as this methodology is not suitable for evaluating an
intervention that must be given at a specific time point.
Types of participants
We included all adult patients (18 years of age or older) undergoing
an elective surgical procedure for head and neck cancer under a
general anaesthetic.
Types of interventions
Intervention
The intervention was polymeric nutritional supplements with im-
munonutritional additives given by an oral or enteral route. In or-
der to be included, studies needed to administer the immunonu-
trition either preoperatively or postoperatively or both pre- and
postoperatively. Co-intervention with other oral or parenteral sub-
stances was permitted as long as the dose of immunonutritional
additives was quantified. The content of each immunonutrition
formula can vary between products and we recorded the product
used and its contents for each study.
Control
The control group received either standard care (intravenous flu-
ids) and/or polymeric nutritional supplements.
The comparison was:
• immunonutrition versus standard care (intravenous fluids)
and/or polymeric nutritional supplements.
Types of outcome measures
We assessed the following outcomes in this review, but we did not
use them as a sole basis for excluding studies.
Primary outcomes
• Length of hospital stay: measured in days from the day of
surgery to discharge from hospital.
• Wound infections: as measured by the proportion of
patients in whom any type or degree of wound infection was
recorded, at any point postoperatively.
• Fistula formation: as measured by the proportion of patients
in whom a fistula was recorded at any point postoperatively.
• Adverse events/tolerance of feeds, as defined by trial
authors: as measured by the proportion of patients in whom
adverse events relating to tolerance of feed was recorded, at any
point postoperatively.
Secondary outcomes
We assessed the following secondary outcomes, measured postop-
eratively:
• All-cause mortality: as measured by the proportion of
patients recorded as having died at any point postoperatively.
• Postoperative complications, as defined by trial authors: as
measured by the proportion of patients in whom any type or
degree of complication (other than wound infection, fistula
formation or relating to tolerance of feed) was recorded, at any
point postoperatively.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 14 February 2018.
Electronic searches
The Information Specialist searched:
• the Cochrane ENT Trials Register (searched 14 February
2018);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (searched via CRS Web 14 February 2018);
• PubMed (1946 to 14 February 2018);
• Ovid EMBASE (1974 to 14 February 2018);
• Ovid CAB Abstracts (1910 to 14 February 2018);
• EBSCO CINAHL (1982 to 14 February 2018);
• LILACS, lilacs.bvsalud.org (searched 14 February 2018);
• KoreaMed (searched via Google Scholar 14 February 2018);
• IndMed, www.indmed.nic.in (searched 14 February 2018);
• PakMediNet, www.pakmedinet.com (searched 14 February
2018);
• Web of Knowledge, Web of Science (1945 to 14 February
2018);
• ClinicalTrials.gov (searched via the Cochrane Register of
Studies 14 February 2018);
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• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
14 February 2018);
• ISRCTN, www.isrctn.com (searched 14 February 2018).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, theywere combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in theCochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for ad-
ditional trials and contacted trial authors where necessary. In ad-
dition, the Information Specialist searched PubMed to retrieve
existing systematic reviews relevant to this systematic review, so
that we could scan their reference lists for additional trials. The
Information Specialist also ran non-systematic searches of Google
Scholar to retrieve grey literature and other sources of potential
trials.
Data collection and analysis
Selection of studies
Two review authors independently examined the titles and ab-
stracts of studies identified through the search strategy (either NH
and ST or CA and SJL). Inconsistency between review authors
regarding articles for full-text reading was resolved by consultation
with another review author. We obtained full-text papers for all
studies that could not be excluded on the basis of title and ab-
stract. The same review authors then independently refined their
selection by examining the selected articles and excluding those
not relevant to this review. The review authors recorded agreement
on study inclusion and resolved disagreement by consensus. We
contacted original study authors where further clarity was needed
in order to select a study for inclusion. We documented decisions
on all studies and these are presented in the PRISMA flow chart
(Figure 1).
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Figure 1. Process for sifting search results and selecting studies for inclusion.
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Data extraction and management
We minimally modified a data extraction form from the original
provided by Cochrane. Three authors (NH, ST and SJL) tested
this on several studies selected for inclusion, and revised it for ease
of extraction and to include further useful data items. Two authors
(NH and ST) independently extracted data from each study. The
review authors were blinded to each other’s data.
We extracted data regarding participant demographics, partici-
pant disease status, surgical procedures, control group postopera-
tive care and the intervention (frequency and duration of supple-
mentary feeding). SJL and CA combined the tabulated data and
checked it for inconsistency.
Assessment of risk of bias in included studies
Two review authors (ST and NH) independently assessed risk
of bias. Disagreements were resolved by discussion and consen-
sus, in which the other authors (CA, SJL) arbitrated. We devel-
oped our own risk of bias tool based on the criteria described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), tailored to this review. We developed this tool
as data extraction continued. We then discussed risk of bias for
all studies to ensure uniformity and agreement. Where possible,
we sought study protocols to aid assessment of selective outcome
reporting bias.
We assessed each study according to the following domains:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective reporting; and
• any other potential threats to validity.
To assess risk of bias for these domains we looked for: evidence of,
for example, use of randomisation tables or lists or randomisation
by computer; allocation concealment via, for example, opaque,
sealed envelopes or pharmacy assignment; explicit statements on
blinding (or otherwise) and clear descriptions of who was blinded
(we did not judge blinding of outcome assessment in relation to
mortality, as it would not have been affected by the outcome as-
sessor); specific statements regarding an intention-to-treat (ITT)
analysis being conducted, statements about dropouts, or data pre-
sented in a way that allowed the number of participants included
in analyses to be ascertained; all outcomes in protocols being re-
ported in the manuscript; and factors such as poor recruitment
rates, differences in baseline demographics, inadequate or poorly
defined methods for assessing outcomes such as wound infections
and length of hospital stay.
We classified risk of bias as ’high’, ’low’ or ’unclear’ for each of
these domains.
Measures of treatment effect
Categorical data are presented as a risk ratio (RR) with 95% con-
fidence interval (CI). We present continuous data as a mean dif-
ference (MD) or standardised mean difference (SMD) with 95%
CI, as appropriate.
Unit of analysis issues
The unit of analysis in all included studies was the individual
participant. No studies used cluster-randomisation.
Dealing with missing data
We contacted the nominated trial investigator for the included
studies to obtain anymissing data necessary formeta-analysis (NH
and SJL). We had planned to calculate missing standard devia-
tions from the standard errors or confidence intervals, as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), but this was not required. Where standard de-
viations could not be calculated, we planned to impute these us-
ing the mean of the reported standard deviations from the other
studies, but this was not needed.
Assessment of heterogeneity
We assessed statistical heterogeneity using visual inspection of the
forest plot, the I² statistic (Handbook 2011), and the Chi² test.
We considered an I² value of greater than 50% along with a P
value of less than 0.10 in the Chi² test to be indicative of the need
to further examine heterogeneity (Handbook 2011).
Assessment of reporting biases
We assessed publication bias and other small study effects in a
qualitative manner using a funnel plot.
Data synthesis
We performed analyses in RevMan 5.3 (RevMan 2014). Analyses
comprised only within-study comparisons rather than individual-
level data. Comparisons were based on an intention-to-treat anal-
ysis. We used a random-effects model for the meta-analysis of re-
sults, as there was a high level of clinical heterogeneity among the
included studies. Three authors (NH, ST and SJL) discussed the
results for each outcome measure within each study, to determine
the inclusion of data in the meta-analyses.
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Where complications were reported as percentage incidence, we
converted this into the number of participants who experienced
complications. In the case of Snyderman 1999 we estimated the
number of wound infections, pneumonias and urinary tract infec-
tions per treatment group by visual inspection of ’Figure 2’ within
their manuscript.
All authors participated in double-checking all of the continuous
outcome data entered into RevMan for the included studies.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses as follows (and com-
parison of subgroups using an interaction term if appropriate).
Subgroup analysis of the participants, according to type of surgery:
• anatomical site of surgery;
• type of reconstruction (’primary closure’ versus ’free flap’).
Subgroup analysis of the intervention to assess clinical heterogene-
ity:
• preoperative immunonutrition versus placebo drink;
• postoperative immunonutrition versus postoperative
polymeric feed.
Sensitivity analysis
Sensitivity analyses were based on the risk of bias of the studies (i.e.
the removal of studies judged at high risk of bias for at least two of
the factors assessed), or if they were quasi-randomised trials. We
also considered the appropriateness of comparing random-effects
and fixed-effect estimates of each outcome variable. If publication
bias was suspected we planned to perform a ’trim and fill’ sensitiv-
ity analysis of the primary outcomes. To assess trial influence we
planned to perform sensitivity analyses by sequentially excluding
each study. If it was not possible to conduct an analysis in RevMan
5.3, we would have used Stata (Stata 11, StataCorp).
GRADE and ’Summary of findings’ table
We used the GRADE approach to rate the overall quality of evi-
dence (Ryan 2016). Two authors (CA and SJL) made the GRADE
ratings and any differences were resolved by consensus of all au-
thors. The quality of evidence reflects the extent to which we are
confident that an estimate of effect is correct and we applied this in
the interpretation of results. There are four possible ratings: high,
moderate, low and very low. A rating of high quality of evidence
implies that we are confident in our estimate of effect and that
further research is very unlikely to change our confidence in the
estimate of effect. A rating of very low quality implies that any
estimate of effect obtained is very uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We included a ’Summary of findings’ table (Summary of findings
for the main comparison), constructed according to the recom-
mendations described in Chapter 10 of the Cochrane Handbook
for Systematic Reviews of Interventions (Handbook 2011).
We included the following outcomes in the ’Summary of findings’
table: length of hospital stay, wound infection, fistula formation,
adverse events/tolerance of feeds and postoperative mortality.
R E S U L T S
Description of studies
See tables of Characteristics of included studies; Characteristics of
excluded studies.
Results of the search
The electronic searches retrieved 1434 results. We identified three
further records through scanning the reference lists of included
studies. After screening titles and abstracts, we discarded 708 du-
plicates and 699 irrelevant records. We sought full texts for the
remaining 29 records and retrieved trial information from Clini-
calTrials.gov for one record (NCT03261180).
Upon screening we excluded a further nine records (see
Characteristics of excluded studies). One of the records for which
we sought a full text was the protocol associated with Palma-Milla
2016; as such, only eight studies are shown in the Characteristics
of excluded studies table). One relevant trial is not yet recruiting
(NCT03261180).
Nineteen studies (with 20 publications) met the full inclusion
criteria.We therefore included 19 unique studies comprising 1099
participants, as shown in Figure 1. The searches were completed
in February 2018.
Included studies
We included 19 studies see Characteristics of included studies.
One studywas only published as an abstract (Felekis 2005).Weob-
tained additional unpublished data from 12 studies (Casas-Rodera
2008; De Luis 2002; De Luis 2003; De Luis 2004; De Luis 2005;
De Luis 2007; De Luis 2009; Falewee 2014; Ghosh 2012; Riso
2000; Sorensen 2009; Turnock 2013).
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Design
All of the included studies were randomised trials of an active
(immunonutrition) intervention versus control (see Table 1 for a
description of the interventions used).
Sample sizes
Total sample sizes ranged from 8 to 209 participants (Table 2).
Twelve of the 19 studies had fewer than 25 patients in each treat-
ment group.
Setting
Studies were set in hospitals and conducted in eight countries.
Seventeen studies were single-site studies and one study was mul-
ticentre (Falewee 2014). We identified eight studies from Spain
(Casas-Rodera 2008; De Luis 2002; De Luis 2003; De Luis 2004;
De Luis 2005; De Luis 2007; De Luis 2009; De Luis 2014). Two
studies were from the USA (Snyderman 1999; Sorensen 2009),
two studies from Greece (Felekis 2005; Felekis 2010), and one
from each of the following countries: France (Falewee 2014),
Italy (Riso 2000), Netherlands (Van Bokhorst 2000/2001), New
Zealand (Turnock 2013), Malaysia (Azman 2015), Japan (Hanai
2018), and the UK (Ghosh 2012).
Participants
The 19 studies included in this review represent a total of 1099
participants undergoing head and neck cancer surgery of the upper
aerodigestive tract (sites includedmouth, pharynx and larynx) (see
Characteristics of included studies).
Studies included adults only and themean age of study participants
across studies ranged from 47 to 66 years (Table 2). There were
more males than females in most studies, and the mean body mass
index (BMI) reported across studies ranged from 22.1 to 26.5
(Table 2). The stage of disease was reported in 18 studies with
only one study not reporting this (Felekis 2005; published as an
abstract).
Studies excluded people with a range ofmedical conditions includ-
ing impaired renal or hepatic function (16 studies), ongoing infec-
tions (13 studies) and autoimmune disorders (13 studies), those
on steroid treatment (10 studies) or nutritional oral supplementa-
tion in the previous six months and those who weremalnourished/
had severe cancer cachexia or sarcopenia (seven studies), those who
were well nourished (two studies) or morbidly obese (one study),
patients with contraindications to enteral nutrition/patients with
inborn errors of metabolism relating to the composition of the
formula (two studies), patients treated with chemotherapy and/
or radiation therapy delivered to the head and neck area during
the previous year (three studies) or chemoradiotherapy or other
treatment protocols concurrent to the intervention (one study),
patients testing positive for HIV (three studies), patients with di-
abetes (five studies), and pregnant or breast-feeding women (four
studies).
Interventions
Detailed descriptions of the interventions used in each of the in-
cluded studies are shown inTable 1.Most studies (16/19) used im-
munonutrition formulas that contained arginine, one study used
glutamine powder, one study used an eicosapentaenoic acid (EPA)-
enriched oral nutritional supplement and one used an unspecified
product. When study feeds were given pre-operatively, the length
of intervention ranged from around 5 to 14 days (n = 9 studies).
There was more variation when feeds were given postoperatively,
with a range of around 5 days to an average duration of 22 days
± 12 days (n = 19 studies). Most studies (12/19) based the intake
of study feeds on body weight or ’requirements’, some (n = 5/19)
used a set amount (e.g. 1000 mL per day, or 30 g powder per day)
and others (n = 2/19) did not state the amount. Follow-up time
frames also varied considerably across studies, and ranged from
five days post-operation (De Luis 2003) to greater than or equal
to 16 months (Van Bokhorst 2000/2001 for survival data).
Immunonutrition was given postoperatively in all studies, and
nine studies gave immunonutrition pre-operatively as well as post-
operatively (Table 1). One study with three treatment groups
gave pre-operative immunonutrition alone in one group (Falewee
2014), but data from that group were not included in analyses. A
commercial polymeric feed was used in the control group postop-
eratively in most studies (17/19), some of which contained addi-
tional fibre (Table 1). In six studies the control group received a
standard polymeric feed preoperatively as well as postoperatively
(Falewee 2014; Felekis 2005; Felekis 2010; Ghosh 2012; Sorensen
2009; Van Bokhorst 2000/2001). In one study, two groups (one
of which had received the control feed both pre- and postopera-
tively and the other only postoperatively) were combined in their
analyses (Snyderman 1999).
Outcomes
Of the outcomes considered, mortality was most commonly re-
ported (14 studies; we obtained unpublished data on mortality
for eight studies (Casas-Rodera 2008; De Luis 2003; De Luis
2004; De Luis 2005; De Luis 2007; De Luis 2009; Falewee 2014;
Sorensen 2009), with the remaining data being available in the
paper or abstract), followed by wound infection (12 studies), ad-
verse events/tolerance of feeds (11 studies), length of hospital stay
(10 studies) and fistulae (10 studies).
Excluded studies
We excluded eight studies (see Characteristics of excluded studies).
We excluded one study (Buijs 2010), which was a follow-up of pa-
tients from a study already included in the review (Van Bokhorst
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2000/2001). Buijs 2010 reported on long-term survival (≥ 10
years) andwe felt that includingmortality data from amuch longer
follow-up time period than all other included studies (which mea-
sured mortality in a relatively short period of time post-interven-
tion) would make the results more difficult to interpret.
Three studies were not randomised (De Luis 2013; Linn 1988;
Reis 2016), and four hadno suitable control group (DeLuis 2005a;
De Luis 2010; De Luis 2015; Palma-Milla 2016).
Risk of bias in included studies
The risk of bias for each study is described in detail in the
Characteristics of included studies table. Details of risk of bias
judgements for each study are presented in Figure 2, with an over-
all summary graph in Figure 3. Allocation concealment methods
were most poorly reported, resulting in the greatest number of
’unclear’ risk of bias assessments. Details of methodological qual-
ity are also presented in Table 3.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Random sequence generation
We classed 13 studies at low risk of bias due to acceptable randomi-
sation sequence generation through the use of computer-gener-
ated randomisation, randomisation lists, tables or a “randomiza-
tion generator” (Azman 2015; De Luis 2002; De Luis 2003; De
Luis 2004; De Luis 2005; De Luis 2007; Falewee 2014; Felekis
2010; Ghosh 2012; Riso 2000; Snyderman 1999; Turnock 2013;
Van Bokhorst 2000/2001). In six studies the method of random
sequence generation was not clear or not stated and therefore we
classed this as an unclear risk of bias (Casas-Rodera 2008; De Luis
2009; De Luis 2014; Felekis 2005; Hanai 2018; Sorensen 2009).
Allocation concealment
We considered 16 studies to be at unclear risk of bias due to inad-
equately reported methods of allocation concealment. Of these,
eight reported the use of envelopes but did not state whether or
not they were opaque (Azman 2015; De Luis 2002; De Luis 2003;
De Luis 2004; De Luis 2005; De Luis 2007; Riso 2000; Sorensen
2009). We classed the other eight at unclear risk of bias be-
cause allocation concealment was either not stated (Casas-Rodera
2008; De Luis 2009; De Luis 2014; Felekis 2005; Hanai 2018;
Snyderman 1999; Van Bokhorst 2000/2001), or was not clear as
documented (Felekis 2010).We classed three studies as low risk of
bias due to the use of central telephone assignment (Falewee 2014;
Ghosh 2012), or the use of opaque, sealed envelopes (Turnock
2013).
Blinding
Participants and personnel
Participants can be adequately blinded with this intervention,
therefore we judged studies where patients were not blinded to be
at high risk of bias. Two studies stated that they were not blinded
and we classed them at a high risk of bias (Azman 2015; Turnock
2013), andone study used sachets in the intervention group andno
treatment in the control group, so it was assumed to be unblinded
and at high risk of bias (Hanai 2018). We classed nine studies at
an unclear risk of bias because they either did not state whether or
not participants and personnel were blinded (Casas-Rodera 2008;
Felekis 2005), or they stated that the study was blinded but did
not state who was blinded (De Luis 2004; De Luis 2005; Felekis
2010; Riso 2000), or they described partial blinding (Snyderman
1999; Sorensen 2009). We classed all other studies (seven) as at
low risk of bias.
Outcome assessment
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Judgements for risk of bias in regards to the blinding of outcome
assessment were as described above for blinding of participants and
personnel with two exceptions. De Luis 2014 stated that “Blind-
ing of patients and dietitians involved in patient treatment was
maintained”, but they did not indicate who the outcome asses-
sor was; as such, we judged it at unclear (rather than low) risk of
bias. Hanai 2018 did not indicate who the outcome assessor was
or whether or not anyone was blinded; as such, we judged it at
unclear (rather than high) risk of bias.
Incomplete outcome data
We considered most studies at low risk of bias for incomplete
outcome data, with the exception of three studies that we classed
at an unclear risk of bias because they did not mention whether
or not an intention-to-treat (ITT) analysis had been conducted/
whether any dropouts had occurred, or did not present data in
such a way as to be able to determine the number of participants
included in analyses (Azman 2015; Felekis 2005; Sorensen 2009).
The remaining studies either had no attrition according to the
numbers included in tables/figures, or stated that an ITT analysis
had been conducted or that there were no dropouts/losses to fol-
low-up. (NB: we obtained additional data for one study to enable
an ITT analysis to be conducted; Falewee 2014).
Selective reporting
We classed most studies (17) at an unclear risk of selective report-
ing bias because protocols were not available to judge whether or
not selective reporting had occurred. We classed one study at a
low risk of bias because the primary outcome stated in the proto-
col was reported in the paper (Falewee 2014) (no secondary out-
comes were specified in the protocol so it was not possible to judge
whether selective reporting of secondary outcomes had occurred).
We classed one study at a high risk of bias because not all primary
outcomes stated in the protocol were presented in the manuscript
(Turnock 2013).
Other potential sources of bias
Five studies reported problems with recruitment (Falewee 2014;
Ghosh 2012; Snyderman 1999; Turnock 2013; Van Bokhorst
2000/2001), three reported baseline differences between treat-
ment groups (Ghosh 2012; Snyderman 1999; Van Bokhorst
2000/2001), and six had poorly defined methods for assessment
of wound infection (Casas-Rodera 2008; De Luis 2002; De Luis
2004; De Luis 2007; De Luis 2009; Felekis 2010). We classed
these studies at high risk of bias for these other potential sources
of bias. Of the 10 studies that reported length of hospital stay, six
did not describe how this was determined (De Luis 2002; De Luis
2004; De Luis 2007; De Luis 2009; Riso 2000; Turnock 2013).
The assessment of tolerance of feeds was not based on consistent
descriptions across studies.
One study was available only as an abstract and we judged it at
unclear risk of other bias (Felekis 2005). We classed the remaining
studies at low risk of bias for other potential sources of bias as there
was no evidence for this in the published data (Azman 2015; De
Luis 2003; De Luis 2005; De Luis 2014; Sorensen 2009).
Most studies were small, with sample sizes that were unrealistically
low for detecting clinical complications.
Effects of interventions
See: Summary of findings for the main comparison
Immunonutrition compared to standard care for patients
undergoing surgery for head and neck cancer
Immunonutrition versus standard care
Primary outcomes
Length of hospital stay
Length of hospital stay was reported in 10 studies. The mean
length of stay ranged from 15.3 days to 31.1 days in immunonu-
trition groups and from 17.4 days to 36.1 days in control groups.
We found no evidence of a difference between treatment groups
in the length of hospital stay, but the confidence interval around
the effect estimate was wide (mean difference -2.5 days, 95% con-
fidence interval (CI) -5.11 to 0.12 (P = 0.06); 10 studies, 757
participants) (GRADE: low-quality evidence). The results showed
little evidence of heterogeneity between studies (Chi² = 12.89, P
= 0.17, I² = 30%) (Analysis 1.1).
Wound infections
Wound infections were reported in 12 studies, of which 10 studies
reported events. One study reported ’wound complications’ as the
number with Clavien-Dindo grades above 3, above 2 or all grades
and was not included in the meta-analysis (Hanai 2018). Absolute
risks ranged from 0% (0/45) to 61% (17/28) in the immunonu-
trition groups and from 0% (0/45) to 59% (17/29) in the control
groups. Events were more common (in both treatment groups)
in studies that had used pre- and postoperative intervention (a
total of 95 events among 458 participants) than in studies that
used only postoperative intervention (a total of 14 events among
354 participants). We found no evidence of a difference between
treatment groups for this outcome. The combined risk ratio (RR)
was 0.94 (95% CI 0.70 to 1.26, P = 0.66; 12 studies, 812 partic-
ipants) (GRADE: very low-quality evidence), with little evidence
of heterogeneity between trials (Chi² = 4.12, P = 0.90, I² = 0%)
(Analysis 1.2).
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Fistula formation
Fistula formation was reported in 10 studies, all of which reported
events. The absolute risk was 5.4% (range 0% (0/23) to 7% (7/
105)) in the immunonutrition groups and 11.3% (range 2% (1/
47) to 29% (2/7)) in the control groups. There was a reduction
in fistula formation with immunonutrition compared to standard
care; the combined RR was 0.48 (95% CI 0.27 to 0.85, P = 0.01;
10 studies, 747 participants) (GRADE: low-quality evidence), with
little evidence of heterogeneity between studies (Chi² = 6.99, P =
0.64, I² = 10%) (Analysis 1.3; Figure 4).
Figure 4. Forest plot of comparison: 1 Immunonutrition versus standard care, outcome: 1.3 Fistula
formation.
Adverse events/tolerance of feeds
Adverse events in relation to aspects of tolerance of feeds were re-
ported in 11 studies, and included intolerance to feed (Snyderman
1999) and gastrointestinal intolerance (Falewee 2014), abdominal
distension, abdominal cramps or emesis (Riso 2000), and diar-
rhoea (Azman 2015; Casas-Rodera 2008; De Luis 2002; De Luis
2004; De Luis 2007; De Luis 2009; Hanai 2018). One study
stated that “gastrointestinal tract tolerance of both formula diets
was excellent in both groups, and no dropouts occurred because
of intolerance” (Felekis 2010); for analysis we assumed that there
were zero adverse events in both treatment groups. In two studies,
a control feed was not used and adverse events were documented
only in relation to withdrawals from the immunonutrition treat-
ment groups (one per study); data from these two studies were not
included in themeta-analysis (Azman 2015;Hanai 2018). Among
the nine studies that we included in the meta-analysis, absolute
risks ranged from 0% (0/20) to 40% (18/45) in the immunonu-
trition groups and from 0% (0/20) to 29% (6/21) in the control
groups. There was no evidence of a difference between treatment
groups for this outcome. The combined RR was 1.33 (95% CI
0.86 to 2.06, P = 0.20; 9 studies, 719 participants) (GRADE: very
low-quality evidence), with little evidence of heterogeneity between
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trials (Chi² = 7.11, P = 0.42, I² = 2%) (Analysis 1.4).
Secondary outcomes
All-cause mortality
Mortality was reported in 14 studies (NB: additional unpublished
information was obtained from eight authors) and ranged from
0% (0/105) to 14% (4/28) in the immunonutrition groups, and
from 0% (0/45) to 8% (2/24) in the control groups. The follow-
up timeframes varied considerably across studies, and ranged from
30 days to greater than or equal to 16 months in those studies that
were meta-analysed (NB: one study did not state the follow-up
timeframe). There was no evidence of a difference between treat-
ment groups for this outcome. The combined RR was 1.33 (95%
CI 0.48 to 3.66, P = 0.59; 14 studies, 776 participants) (GRADE:
low-quality evidence), with little evidence of heterogeneity between
studies (Chi² = 3.66, P = 0.45, I² = 0%) (Analysis 1.5).
Postoperative complications
Other clinical complications such as pneumonia and urinary tract
infections were uncommonly reported (Table 4), but there was no
evidence of a reduction (or an increase) with immunonutrition.
Subgroup analysis
The direction of effect for length of stay, wound infection, fistula
formation and mortality did not differ between studies that had
given immunonutrition both pre- and postoperatively and studies
that had given it only postoperatively (Analysis 1.1; Analysis 1.2;
Analysis 1.3; Analysis 1.5).We observed some differences in effect
sizes between the subgroups, but most subgroups included six or
fewer studies (with the exception of eight studies in the postoper-
ative feeding only subgroup for mortality) and P values for sub-
group differences ranged from0.08 for length of stay (Analysis 1.1)
to 0.77 for mortality (Analysis 1.5) (corresponding I² values were
66.6% and 0%, respectively). Studies that had given immunonu-
trition only postoperatively showed a more beneficial effect on fis-
tula formation than those that had given immunonutrition pre-
and postoperatively (RR 0.31, 95% CI 0.14 to 0.71, P = 0.005,
6 studies, 354 participants, and RR 0.72, 95% CI 0.33 to 1.62,
P = 0.43; 4 studies, 393 participants, respectively). There was a
difference in the direction of effect for adverse events/tolerance of
feeds between studies that had given immunonutrition both pre-
and postoperatively and studies that had given it only postopera-
tively, but such a comparison is not warranted as only two studies
were included in the pre- and postoperative feeding analysis.
For wound infections, more events were reported in the six studies
that used pre- and postoperative immunonutrition (n = 48 events
among 247 participants in the immunonutrition group and n =
47 events among 211 participants in the standard care group) than
in the six studies that used only postoperative immunonutrition
(n = 5 events among 178 participants in the immunonutrition
group and n = 9 events among 176 participants in the standard
care group).
Only one study gave pre-operative immunonutrition alone so it
was not possible to conduct a subgroup analysis of preoperative
immunonutrition versus placebo drink (Falewee 2014).
We did not conduct subgroup analyses according to the type of
surgery as data were not presented in such a way in the original
publications as to allow this to be done.
Sensitivity analysis
Wedid not conduct sensitivity analyses in whichwe removed stud-
ies judged at high risk of bias for at least two of the factors assessed
or where we removed quasi-randomised trials because no studies
met these criteria. We calculated random-effects estimates for each
outcome variable due to the extent of clinical heterogeneity. We
did not judge fixed-effect estimates to be appropriate.
Publication bias
Weexaminedpublicationbias for all outcomes by visual inspection
of funnel plots and we have presented three of these: length of
hospital stay (Figure 5), wound infection (Figure 6) and fistula
formation (Figure 7). Study numbers were relatively small for these
outcomes, which made it difficult to definitively assess publication
bias; however, there was a suggestion of publication bias for length
of hospital stay (Figure 5). Given the absence of clear publication
bias, however, we did not conduct a trim and fill analysis for the
primary outcomes.
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Figure 5. Funnel plot of comparison: 1 Immunonutrition versus standard care, outcome: 1.1 Postoperative
length of hospital stay [days].
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Figure 6. Funnel plot of comparison: 1 Immunonutrition versus standard care, outcome: 1.2 Wound
infection.
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Figure 7. Funnel plot of comparison: 1 Immunonutrition versus standard care, outcome: 1.3 Fistula
formation.
D I S C U S S I O N
Summary of main results
Pooled estimates showed no evidence of a difference in the length
of hospital stay between treatment groups. The mean difference
was -2.5 days but the estimate was imprecise (95% confidence
interval (CI) -5.11 to 0.12) and included the null value. There
may be an approximate halving of the risk of fistulae formation
(risk ratio (RR) 0.48) with immunonutrition, but the evidence
was of low quality. Immunonutrition may have little or no effect
on wound infection and mortality, and there was little or no dif-
ference in adverse events such as diarrhoea between the treatment
groups. We did not formally meta-analyse other complications
because of their heterogeneity. The findings are summarised in
Summary of findings for themain comparison. Length of hospital
stay was reduced in 8 of the 10 studies where it was recorded.
No reduction in hospital stay was seen in the largest recent study
(Falewee 2014). Reduced fistula formation was seen in patients
receiving immunonutrition, but no other reductions in clinical
complications such as wound infections were seen. No substantial
differences in the findings were seen when looking at the timing
of intervention (i.e. pre- and postoperative or just postoperative).
Where stated, all but two of the studies looking at in-hospital post-
operative immunonutrition used arginine as an immunonutrient;
Azman 2015 used glutamine and Hanai 2018 used an eicosapen-
taenoic acid (EPA)-enriched supplement. Ten studies evaluated
postoperative nutrition alone and nine studies included pre- and
postoperative nutrition.One study provided only preoperative im-
munonutrition in one of their treatment groups (Falewee 2014),
but the numbers of patients and complications were too small to
draw any conclusions. Studies that gave immunonutrition only
postoperatively showed a larger beneficial effect on fistula forma-
tion than studies that gave it both pre- and postoperatively (RR
0.31 versus 0.72, respectively). One study that gave immunonu-
trition both pre- and postoperatively reported more fistulas with
immunonutrition than standard care (Snyderman 1999). The rea-
sons for this are not clear and are in contrast with all other stud-
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ies (irrespective of timing of intervention), which reported fewer
fistulas with immunonutrition than standard care. The cause of
mortality was often poorly reported and it may be inappropriate
to ascribe any difference in mortality to immunonutrition. How-
ever, no evidence of any effect of immunonutrition on mortality
(which was low) was seen. We did not formally analyse potential
clinical complications such as pneumonia, diarrhoea, cardiovas-
cular effects and the relationship of nutritional status to outcomes
due to either limited data or outcomes not having been recorded.
Overall, most studies were too small to provide precise estimates
of intervention effects.
Overall completeness and applicability of
evidence
Completeness
We attempted to identify and synthesise all existing research to
provide a comprehensive estimate of the effect of immunonutri-
tion on postoperative recovery following head and neck cancer
surgery. We included 19 studies that recruited 1099 participants.
We also conducted the largest systematic review prior to this one,
which included 10 randomised controlled trials (RCTs) that had
recruited 605 participants (Stableforth 2009). One of the trials
(De Luis 2005a), which had been included in our previous re-
view, was not included here as the immunonutrition intervention
was administered at the point of discharge. Another systematic re-
view from 2012 included 14 studies with 601 participants (Casas
Rodera 2012); three of the studies in that review were not relevant
to ours as two studies compared two doses/types of immunonu-
trients (De Luis 2005a; De Luis 2010), and one study, as noted
above, was part of another publication (Buijs 2010). A third sys-
tematic review from 2014 included six studies and 397 partici-
pants, all of which were included in our review (Vidal-Casariego
2014). Despite being the largest systematic review to date, it is
possible that our search strategies may not have identified all of
the existing literature.
We looked at similar outcomes to other systematic reviews, but
we did not analyse further outcomes reported in studies such as
pneumonia, cardiovascular effects and the relationship of nutri-
tional status to outcomes due to limited data.
This review was systematic, using extensive searches of several
databases and inclusive search terms. We did not include unpub-
lished literature, but we felt it unlikely that there are large unpub-
lished trials that demonstrate a substantial effect of immunonutri-
tional interventions in head and neck cancer. We made attempts
to contact senior or corresponding authors as published in the
original papers. We received further data from Dr De Luis, Pro-
fessor Jones (re: Ghosh 2012), Dr Riso and Dr Falewee regarding
research methods and outcomes.
Applicability
Most studies applied exclusion criteria to individuals for study par-
ticipation. These frequently included renal or hepatic impairment,
existing infection and altered immune function. Three studies ex-
cluded participants who were well nourished (De Luis 2003; De
Luis 2005; Van Bokhorst 2000/2001), one excluded those who
were morbidly obese (Snyderman 1999), and seven excluded peo-
ple who were malnourished (Azman 2015; De Luis 2002; De Luis
2004;DeLuis 2007;DeLuis 2009;DeLuis 2014; Turnock 2013).
Studies included in this review were conducted in various coun-
tries, incorporating a range of cultures and healthcare systems.
Eight were undertaken in Spain (seven of which were conducted
by the same group), two in theUnited States, one inNewZealand,
one in Malaysia, one in Japan and the remainder in western Eu-
rope. This may have had an effect on outcomes. For example,
standard healthcare practice (e.g. discharge policies, implementa-
tion of Enhanced Recovery After Surgery (ERAS) protocols, etc.)
is likely to vary across countries, thus making comparisons across
studies less meaningful. In addition, the studies were reported over
an approximate 18-year period during which there are likely to
have been changes in clinical practice. However, it was not pos-
sible from the information provided to assess the impact of this
possibility. There were also differences between studies regarding
patient populations and types of surgery. As such, it remains un-
known who is most likely to benefit from immunonutrition (if
indeed there is a true benefit) based on the included studies.
Quality of the evidence
Assessments of the quality of evidence for each outcome are pre-
sented in Summary of findings for the main comparison.
Methodology
In general studies were poorly reported with a large proportion of
unclear risk of bias assignments for several of the items assessed
(Figure 2; Figure 3). We assigned blinding of outcome assessment
an unclear risk of bias in 11 studies and ’other’ bias a high risk of
bias in 11 studies (examples of ’other’ bias included difficulties in
recruitment/not meeting target sample size, and evidence of some
baseline differences between treatment groups).
The generation of the random allocation sequence was reported in
13 studies (Table 3). In nine studies allocation was concealed using
sealed envelopes but it was not stated whether or not these were
opaque in eight of the studies (one explicitly stated that opaque en-
velopes were used). Concealment of allocation was achieved by us-
ing a central telephone assignment in two studies.Where stated, all
studies were double-blind (as opposed to single-blind), although
there was an overall lack of description of how this was achieved.
One study (published as an abstract; Felekis 2005) did not state
whether an intention-to-treat (ITT) analysis was conducted, and
for another study we obtained additional data from the authors to
enable an ITT analysis to be conducted (Falewee 2014).
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More than half of the studies reported use of sample size or power
calculations (Table 3), but of those that did, several did not meet
the target sample size. Many other studies included small sample
sizes, reducing the power of the study to observe clinically impor-
tant differences in outcomes.
The GRADE rating of the evidence varied for all of the outcomes
assessed, but we classed none as high-quality (Summary of findings
for the main comparison). The main reasons for downgrading the
evidence were small sample sizes and wide confidence intervals
around effect estimates, and poor descriptions of themethods used
for assessing outcomes reported within studies.
Outcome assessment
Infection is the clinical outcome of interest in this research area.
However, this was poorly defined in most studies. Wound infec-
tions were not classified by site or severity in most studies. Sys-
temic infection was also poorly defined. Similarly, persistent post-
operative fistula was not defined in most studies. A more precise
measure of infection and fistula could improve the quality of the
evidence base.Wound infectionswere considerablymore common
(in both treatment groups) in studies that used pre- and postoper-
ative supplementation than in studies that used only postoperative
supplementation, but the reasons for this are not clear. Four of
the six studies that used pre- and postoperative supplementation
and that reported wound infections were from the same research
group, and it is possible that their definition of wound infection
or their length of follow-up meant that fewer wound infections
were captured in their studies.
Blinding of participants with this intervention is possible and
should be undertaken, as an awareness of treatment allocation
may result in participants misreporting outcomes. Length of hos-
pital stay is likely to be influenced by variation in discharge cri-
teria, which may result in differences between studies. This lack
of uniformity across centres may introduce variability for some
outcomes.
Heterogeneity
We observed little evidence of heterogeneity for each outcome
(Chi² ranged from 3.66 to 12.89, P = 0.17 to 0.91, and I² ranged
from 0% to 30%). For length of hospital stay and fistula forma-
tion, if heterogeneity existed it would be more likely to indicate
variation in size of effect as opposed to direction of effect given that
most studies suggested a beneficial effect of immunonutrition on
postoperative recovery outcomes. Visual inspection of the forest
plots and associated data did not indicate that size of study sub-
stantially altered the effect size (although it must be noted that the
majority of studies had sample sizes of fewer than 25 participants
per treatment group).
Potential biases in the review process
Search strategy
Althoughwe believe that our electronic (February 2018) andhand-
searching strategies have identified all relevant studies, it is possi-
ble that we may have missed some available literature or unpub-
lished material. We stopped handsearching at the end of January
2017. We have read reviews and references of recent publications
and in the time period until publication other studies may have
been published or made available. These will be incorporated into
future updates of this review.
Assumptions about the mechanism of effect
The various components of immunonutrition supplements have
been shown in studies done in vitro and in vivo to produce what are
considered beneficial changes in immunological function. How-
ever, there is little evidence from clinical trials that these mecha-
nisms result in reduced postoperative complications. In particular
there is little evidence of the superiority of any given immunonu-
trient over another, for any given dose regimen, or for the time pe-
riods for which the immunonutrients need to be taken to produce
benefit. The small size of most studies and the variety of dosing
regimensmeant that it was not possible to comment on the relative
merits of each type or dose of immunonutrient. Future studies are
required to examine these issues.
Assumptions about the meta-analyses and results
We think it unlikely that we have introduced bias through the
methods used in the review process. The range of outcome metrics
reported across studies was small and did not require conversion
to common units for use in this review. We used a random-effects
model (due to a high level of clinical heterogeneity among included
studies), which may have resulted in smaller studies being granted
a larger weighting than necessary, potentially biasing the overall
meta-analysed results (Handbook 2011). We identified possible
publicationbias fromvisual inspection of the funnel plot for length
of hospital stay (see Figure 5). Some of the studies published by
De Luis et al have similar starting dates and trial designs (see Table
2), however the baseline data are different and in their 2004 paper
they reference their 2002 paper as a different study. In their 2009
paper the patient characteristics (age, sex) and baseline data are
different from their 2007 paper. However, we have been unable
to obtain a response from the authors to clarify that there is no
overlap in participants across studies.
We did not formally assess biochemical changes or immunologi-
cal changes as secondary outcomes (as per the original protocol)
because very few papers commented on such changes, and in each
paper the markers chosen were different and assessed at differing
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time intervals. Meta-analysis of the few papers was thus not pos-
sible. Furthermore, given the expected profound influence of the
operative inflammatory response on levels of such markers, their
interpretation is not straightforward.
Assumptions about study methodology
Studies were not excluded on the basis of methodological quality,
but exclusion of poor-quality studies would tend to move effect
estimates towards the null. The major limitations of the review
relate to the limitations of the literature, and we made a num-
ber of assumptions about the comparability of study methodol-
ogy. In general, complications (especially wound infection) were
poorly defined, and follow-up timeframes differed considerably
across studies (Summary of findings for the main comparison). It
may be difficult to detect any effects on postoperative outcomes in
studies conducted at a late stage of disease. Different interventions
may not have an equal effect, or even the same direction of effect,
for different cancer sites and stages. We stratified our analysis ac-
cording to whether or not immunonutrition was given both pre-
and postoperatively or only postoperatively, but our analyses did
not adjust for differences in the composition or volume of im-
munonutrition formulas provided, nor did they take into account
the length of time for which participants were fed. Few studies
reported on compliance with the intervention, but given that the
feed was usually administered enterally (at least postoperatively)
we assumed good compliance levels. Such diversity across studies
may mean that results varied due to one or more of these factors,
but we feel that this was unlikely to have greatly affected our find-
ings. Of note, seven studies came from one centre, all of which
had relatively small sample sizes (total sample sizes in these seven
trials ranged from 29 to 90 participants). A number of factors that
we were unable to control for also may have affected outcomes,
such as the experience of the surgeon, the length of the operation
and the success of the operation.
Agreements and disagreements with other
studies or reviews
Other reviews have been published on this topic, with sim-
ilarly positive results (Casas Rodera 2012; Stableforth 2009;
Vidal-Casariego 2014). The most recent systematic review and
meta-analysis included six head and neck cancer surgery studies
(Vidal-Casariego 2014). Compared to that review, we observed a
lower reduction in length of hospital stay (2.5 days in our analysis
versus 6.8 days in theirs). As done here, the authors of that review
also conducted analyses based on the timing of administration of
immunonutrition. In contrast with that review, however, we did
notmeta-analyse infections other thanwound infections due to the
diverse range reported in studies. Our finding of little difference
between treatments in wound infections is similar, as is the reduc-
tion in fistula formation with immunonutrition (Vidal-Casariego
2014).
No prior review considered complications directly related to the
immunonutrition intervention, and none were found in this re-
view.
Some studies have reported on the tolerability of immunonutri-
tion, but few in detail. In their systematic review, Vidal-Casariego
et al reported no increase in diarrhoea, although this was based
on very few studies (Vidal-Casariego 2014). Our review suggests
that immunonutrition is generally as well tolerated as standard
supplements in the head and neck cancer surgery patient group,
but this finding is also based on very few studies.
Cost has not been reported in systematic reviews and nor were we
able to assess costs due to a lack of publisheddata. Snyderman 1999
considered costs in their study and suggested that a reduction in
the infection rate between treatment groups (rates were reported
as 23% and 45% in the immunonutrition and standard therapy
groups, respectively) could reduce costs given the difference in
length of hospital stay between those with and without infectious
complications.
Overall, our findings are in agreement with other reviews in
head and neck cancer surgery (Casas Rodera 2012; Stableforth
2009; Vidal-Casariego 2014), as well as reviews in gastrointesti-
nal surgery (Marimuthu 2012; Zhang 2012), and suggest a po-
tential benefit of immunonutrition. However, in agreement with
Vidal-Casariego 2014, the findings for head and neck cancer are
based on poor-quality evidence.
There were insufficient data to exclude substantial effects of im-
munonutrition on other clinical outcomes or biochemical and im-
munological parameters.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Fistula formation was reduced by around 50% but there was no
reduction in length of stay or wound infections and no effect on
mortality. However, our GRADE rating of the evidence quality
ranged from low to very low, primarily due to small sample sizes
and wide confidence intervals around effect estimates, and poor
reporting of methods used to assess outcomes. As such, we cannot
be certain about the results, but if the effects on fistulas are real this
would represent a clinically useful effect. There was no evidence
of detriment from immunonutrition.
The actual volume of feeds taken in these studies was not always
explicitly stated and it is possible that a minimum amount of im-
munonutrition may be needed to achieve clinical benefit. In trials
conducted among patients undergoing surgery in other anatomi-
cal sites where feeding volumes were low, it was suggested that im-
munonutrition may be no better than an isonitrogenous control
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feed (McCowen 2003). It was also suggested that aggressive en-
teral feeding improves outcomes from immunonutrition and that
pre-operative immunonutrition in surgical patients with cancer
might be particularly beneficial (McCowen 2003). In our system-
atic review, seven studies excluded patients who were malnour-
ished. Given that many patients with head and neck cancer are
malnourished, the implications for practice in regard to the find-
ings of this review in such populations remain unknown.
We were unable to relate disease severity to the effect of im-
munonutrition. For example, severe sepsis may not be respon-
sive to any nutritional intervention, whereas mild illness may im-
prove irrespective of feeding. If future trials can consider these vital
points, Level 1 recommendations in favour of immunonutrition
might be justified, although presently such evidence is lacking for
most clinical indications.
The relatively recent implementation of Enhanced Recovery After
Surgery (ERAS) programmes within some healthcare systems may
complicate the assessment of specific interventions such as im-
munonutrition. Enhanced recovery programmes are made up of
a composite of around 20 potentially effective interventions cov-
ering the preoperative, intraoperative and postoperative periods.
Interventions include factors such as the use of minimally invasive
surgical procedures, optimal pain relief, early postoperative feed-
ing and early postoperative mobilisation. It could be expected that
more interventions might have greater effect, but a recent meta-
analysis of enhanced recovery programmes in surgery found that
programmes with more elements were no more successful than
those with fewer elements (Nicholson 2014). For example, studies
with four to seven elements seemed to work as well as those with
11 or more. The difficulty in future studies will be to establish
the contribution of individual interventions such as perioperative
feeding and the specific effect of immunonutrition compared with
standard feeding, when in reality there may be many effective in-
terventions being combined. Of note, the length of hospital stay
in our included studies was generally long compared with cur-
rent practice (Coyle 2016), suggesting that future studies of im-
munonutritionmay have less ’room for improvement’ in outcomes
such as length of hospital stay, possibly due to the use of ERAS
programmes.
Some clinical guidelines recommend the use of immunonutri-
tion in specific populations. For example, immunonutrition has
been recommended in elective surgery patients prior to surgery,
and postoperatively in ’high-risk’ patients (McClave 2013). Oth-
ers suggest that it may benefit patients undergoing major cancer
surgery (including head and neck and gastrointestinal) and se-
vere trauma patients, with recommendations to feed five to seven
days prior to and five to seven days after ’uncomplicated’ surgery
(Weimann 2006). It has also been recommended in some intensive
care patients (e.g. upper gastrointestinal surgery patients and pa-
tients with mild, but not severe, sepsis) (Kreymann 2006). How-
ever, the evidence base in head and neck cancer surgery remains
relatively weak and the GRADE rating of evidence was low for
all of the outcomes assessed. Nonetheless, given that a relatively
recent meta-analysis showed that postoperative infectious compli-
cations adversely affect long-term survival (Pucher 2014), any re-
duction in such complications with immunonutrition might ulti-
mately benefit long-term health.
Implications for research
Systematic reviews andmeta-analyses in some surgical populations
(e.g. gastrointestinal) are suggestive of a benefit of immunonu-
trition on length of hospital stay and complications (Cerantola
2011; Osland 2014; Zhang 2012), but the evidence is less con-
vincing for head and neck cancer surgery, primarily due to a lack of
large, high-quality trials. In addition, the potential for immunonu-
trition to improve outcomes of surgery in the ERAS era remain
largely unknown. As such, recommendations for its use in head
and neck cancer surgery may be premature. Furthermore, and as
noted above, the applicability of the findings tomalnourishedpop-
ulations (such as those undergoing surgery for head and neck can-
cer) is questionable, and this systematic review highlights the need
for further research on the potential effect of immunonutrition in
such populations. There is a clear case for a suitably powered, large
contemporary trial to definitively establish the case for using im-
munonutrition in patients undergoing surgery for head and neck
cancer. Some of the key factors to consider when designing such a
trial include: an adequate (and achievable) sample size to address
the primary outcome(s) (a feasibility or pilot trial may be advis-
able given the issues with recruitment reported in some trials);
an assessment of the extent of malnutrition in the patient popu-
lation (with appropriate stratification if warranted); collection of
detailed information on the volume of immunonutrition study
participants actually receive (with a view to assessing whether a
minimum amount is required to be effective) and whether or not
individual nutritional requirements are met; blinding of partici-
pants and personnel where possible; blinding of outcome assess-
ment; and clear definitions of all outcome measures, particularly
in regard to local or systemic infection.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by year of study]
Snyderman 1999
Methods Design: double-blind, parallel-group randomised controlled trial with≥ 5 days pre- and
≥ 7 days postoperative duration of treatment and 1 month duration of follow-up post-
operation
Participants Setting: University of Pittsburgh Medical Center and the University of Louisville, Ken-
tucky; from 1994 to 1996
Sample size: 141
• Number randomised: 136
• Number completed: 129
Participant (baseline) characteristics:
• Age: Impact group mean age = 63 (SD 9.8) years; standard group mean age = 61
(SD 11.7) years
• Gender: male:female ratio Impact group = 3.3:1; standard group = 2.1:1
• Baseline differences/other characteristics: Quote: “The composition of
treatment groups was similar. There were no significant differences in patient or tumor
characteristics”. No significant differences in preoperative weight, weight loss or
biochemical measures of nutritional status. Quote: “More patients in the Impact group
were randomly assigned to receive preoperative nutritional support (P = .002).”
Inclusion criteria: Quote: “patients with stage II-IV squamous cell carcinoma of the
oral cavity, pharynx, or larynx undergoing oncologic surgery with curative intent and
requiring postoperative nutritional supplementation”
Exclusion criteria: Quote: “malabsorption, immune disorders or immunosuppressive
medications, active infection, and morbid obesity (>130% ideal body weight).”
Interventions 4 arms:
Group I = pre- and postoperative Impact
Group II = postoperative Impact
Group III = pre- and postoperative standard formula
Group IV = postoperative standard formula
Intervention group:
Groups I and II combined as ’Impact’ (n = 82)
Comparator group:
Groups III and IV combined as ’standard’ (n = 47)
Quote: “Standard enteral formulas included Replete, Resource, Isosource, Jevity,
Vivonex, and Osmolite. Replete was used in the majority (78%) of control patients.”
Quote: “Treatment goals consisted of preoperative consumption of a minimum of 500
mL of supplement per day for at least 5 days in treatment groups I and III, and postop-
erative consumption of an average of 1000 mL per day for at least 7 days in all treatment
groups.”
Use of additional interventions: Quote: “All the patients received standard antibiotic
prophylaxis, consisting of 24 to 48 hours of intravenous antibiotics. In most cases, a
regimen of clindamycin (900mg IV every 8 h) was employed. Continuation of antibiotics
for more than 48 hours was only used for the treatment of documented infections.”
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Snyderman 1999 (Continued)
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “Outcome measures included changes in weight, laboratory evaluations of nu-
tritional status, tolerance of tube feedings, infectious and wound healing complications,
and duration of hospitalisation.”
Results presented for: intolerance, postoperative weight, total protein, albumin, trans-
ferrin, haemoglobin, TLC, postoperative infection (total number and site specific per-
centages), wound healing problem, fistula, hospital days, ICU days. Also amino acid and
fatty acids, and cost analysis
Funding sources Quote: “This study was supported by Novartis Nutrition (formerly Sandoz Nutrition),
St Louis Park, Minnesota”
Declarations of interest None stated
Notes Participants lost to follow-up: Quote: “An intent-to-treat analysis was performed on
the entire group (129 patients).”
Recruitment:Quote: “Because of problems with recruitment into the preoperative arms
of the study (groups I and III), patients in the latter part of the study were only randomly
assigned to groups II and IV, thus accounting for differences in sizes of treatment groups.
”
Stratification: Quote: “After meeting entry criteria, patients were stratified for site (lar-
ynx vs. other), stage (T1-3 versus T4, N0 versus N1 to 3), and preoperative weight loss
(0-10 lbs, 11-20 lbs, > 20 lbs)”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation tables
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Partial blinding described
Quote: “Novartis Nutrition provided Im-
pact and Replete (oral and enteral formu-
las) in unlabeled containers for patients in
groups I and III” and “Patients, physicians,
and nurses were blinded to the type of
formula used.” However, whether blinding
was achieved for groups II and IV is not
stated
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Partial blinding described
Quote: “Novartis Nutrition provided Im-
pact and Replete (oral and enteral formu-
las) in unlabeled containers for patients in
groups I and III” and “Patients, physicians,
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Snyderman 1999 (Continued)
and nurses were blinded to the type of
formula used.” However, whether blinding
was achieved for groups II and IV is not
stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data
Quote: “An intent-to-treat analysis was
performed on the entire group (129 pa-
tients).”
Note: 136 patients were randomised and
it was stated that “7 patients did not re-
ceive any therapy and were withdrawn
from the study preoperatively. Reasons for
withdrawal included patient noncompli-
ance and medical or laboratory evidence
of ineligibility.” This equates to ~5% with-
drawal. A ’per-protocol’ analysis was also
conducted and reported
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Quote: “Because of problems with recruit-
ment into the preoperative arms of the
study (groups I and III), patients in the lat-
ter part of the study were only randomly as-
signed to groups II and IV, thus accounting
for differences in sizes of treatment groups.
” However, they do not indicate how many
were in each of the 4 groups (they only
provide totals for the combined groups),
but state that “More patients in the Impact
group were randomly assigned to receive
preoperative nutritional support (P = .002)
.”
Van Bokhorst 2000/2001
Methods Design: double-blind, parallel-group randomised controlled trial with 7 to 10 days pre-
and ≥ 10 days postoperative duration of treatment and 7 days duration of follow-up
(greater than or equal to 16 months of follow-up for survival)
Participants Setting: Department of Otolaryngology - Head and Neck Surgery of the University
Hospital Vrije Universiteit, Amsterdam; from 1 January 1994 through 31 December
1997
Sample size:
• Number randomised: 56
• Number completed: 49
Participant (baseline) characteristics:
• Age: Group 1 = 55 ± 10; Group 2 = 60 ± 8; Group 3 = 59 ± 12
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Van Bokhorst 2000/2001 (Continued)
• Gender: Group 1 = 11 males, 6 females; Group 2 = 7 males, 8 females; Group 3 =
12 males, 5 females; overall total = 30 males, 19 females
• Baseline differences/other characteristics: no difference between groups in age,
tumour stage, tumour location, comorbidity, weight loss, the ratio between combined
mandibular resections and total laryngectomies and the type of reconstructive surgery,
mean duration of surgery, mean blood loss. Preoperatively, groups 2 and 3 reached
110% and 113% of their estimated energy requirements, but patients in group 1
reached 79% (P = 0.007). Baseline weight was lower in group 2 than in the other
groups; baseline serum albumin differed between groups; baseline numbers of
lymphocytes and T lymphocytes (CD3+) and the percentage of T suppressor
lymphocytes (CD8+).
Inclusion criteria: Quote: ”Severely malnourished (preoperative weight loss > 10% of
body weight over the previous 6 mo) head and neck cancer patients eligible for surgery“.
Quote: ”All patients had a histologically proven squamous cell carcinoma of the oral
cavity, larynx, oropharynx, or hypopharynx’
Exclusion criteria: Quote: “Patients were excluded from the study if they were well
nourished (weight loss <10% of body weight); received other investigational drugs or
steroids; had renal insufficiency, hepatic failure, or any genetic immune disorder; or had
a confirmed diagnosis of AIDS.”
Interventions 3 arms:
Quote: “After stratification for type of surgery (combined mandibular resection or total
laryngectomy) and previous radiotherapy (yes or no) the patients were randomly assigned
to 1 of 3 treatment groups.”
Group 1 = no pre-operative and standard postoperative tube feeding
Group 2 = standard pre-operative and postoperative tube feeding (NB: this group used
as the comparator in this review)
Group 3 = arginine supplemented pre-operative and postoperative tube feeding
Quote: “Group 1 received no preoperative nutritional support, group 2 received pre-
operative enteral nutrition with a specially formulated product that closely reflected the
current standard of practice (standard formula), and group 3 received preoperative en-
teral nutrition in which 41% of the casein was replaced by arginine. Nutritional solutions
were isoenergetic and isonitrogenous.”
Standard formula: 62.5 g protein/L, 6.3 g glutamine/L, 9.8 g nitrogen/L, 48.61 g fat/L,
140.63 g carbohydrate/L, 5250 kJ/L
Arginine supplemented formula: 36.85 g protein/L, 12.5 g free arginine/L, 3.7 g glu-
tamine/L, 9.8 g nitrogen/L, 48.61 g fat/L, 153.77 carbohydrate/L, 5250 kJ/L
Quote: “Patients in groups 2 and 3 were given enteral nutrition at home for 7-10 d
preoperatively through a nasogastric feeding tube”
Quote: “Patients in group 1 were stimulated to continue their usual oral diet preopera-
tively”
Quote: “Postoperatively, all patients received tube feeding (1.5 x BEE) starting on the
first postoperative day until and X-ray conducted to assess swallowing ability performed
10 d after surgery showed no leakage from anastomoses”
Intervention group:
Group 3: arginine supplemented pre-operative and postoperative tube feeding (n = 17)
Comparator group:
Group 2: standard pre-operative and postoperative tube feeding (n = 15)
(Data from group 1, n = 17, not used in this review)
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Van Bokhorst 2000/2001 (Continued)
Use of additional interventions: none stated
Outcomes Primary and secondary outcomes:
Primary and secondary outcomes not separated out
Van Bokhorst 2000: quality of life assessed via 2 questionnaires: the disease-specific
EORTC QLQ-C30 and the generic COOP-WONCA. Time points assessed were re-
cruitment (baseline), day before surgery, day of discharge, 6 months post surgery
Van Bokhorst 2001: anthropometric measures included body weight, body composition
(BIA), upper midarm circumference, skinfold thickness and muscle function (hand grip
strength). Biochemical assessment included serum albumin and electrolytes and liver
and kidney function tests
Immune variables included: absolute numbers of leukocytes and lymphocytes, total
lymphocyte count, percentages of monocytes (CD14+), pan T lymphocytes (CD3+)
, T helper lymphocytes (CD4+), T suppressor lymphocytes (CD8+), B lymphocytes
(CD19+), natural killer (NK) cells (CD16/CD56+/CD3) and NK-like T cells (CD16/
CD56+/CD3+). Also measured human leukocyte antigen-DR (HLA-DR) expression in
CD14+ cells, interleukin 6 (IL-6) and tumour necrosis factor (TNF)
Clinical outcomes included perioperative use of blood, blood products and antibiotics;
the occurrence of postoperative complications; the date of normal swallowing as con-
firmed by X-ray and the date of discharge from the hospital. Postoperative complica-
tions were categorised as absent, minor (including minor wound infections, redness and
induration of the wound, pulmonary infections and urinary tract infections) or major
(including wound infections requiring surgical drainage, orocutaneous or pharyngocu-
taneous fistula, flap failure, radiologic signs of anastomotic leakage, respiratory insuffi-
ciency, cardiac failure and septic shock)
Survival (and cause of death where applicable) were assessed after a follow-up period of
≥ 16 months
Time points assessed: Quote: “at recruitment into the study, 1 d preoperatively, 1 d
postoperatively, 4 d postoperatively, 7 d postoperatively, and on the day of discharge.
Follow-up time for survival was ≥ 16 mo.”
Funding sources None stated
Declarations of interest None stated
Notes Participants lost to follow-up:Van Bokhorst 2001 stated “No patient was lost to follow
up” in regards to the survival analysis (page 325)
Sample size: Quote: “To reduce the percentage of major postoperative complications
from 60% to 30% in the nutrition intervention groups, the sample size was calculated
to be 39 patients per study group with 80% power and 5% significance. Because patient
recruitment was much slower than expected, however, recruitment ended on 31 Decem-
ber 1997 for financial reasons.”
Further publication included data on longer-term follow-up: Buijs N, van Bokhorst-
de van der Schueren MA, Langius JA, Leemans CR, Kuik DJ, Vermeulen MA, et al.
Perioperative arginine-supplemented nutrition in malnourished patients with head and
neck cancer improves long-term survival. American Journal of Clinical Nutrition 2010;92
(5):1151-6
Risk of bias
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Van Bokhorst 2000/2001 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned “accord-
ing to a computer-generated randomiza-
tion schedule with an equal probability of
assignment to any of the nutritional regi-
mens.” (Van Bokhorst 2001, page 324)
Allocation concealment (selection bias) Unclear risk No statement as to how allocation was con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Blinding of patients, health care
professionals involved in patient treatment
and assessors was only possible in groups II
and III” (Van Bokhorst 2000, page 438) -
these 2 groups were used in analyses
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Blinding of patients, health care
professionals involved in patient treatment
and assessors was only possible in groups II
and III” (Van Bokhorst 2000, page 438) -
these 2 groups were used in analyses
Incomplete outcome data (attrition bias)
All outcomes
Low risk 49 patients recruited
Quote: (Van Bokhorst 2001) “No patient
was lost to follow up” in regards to the sur-
vival analysis (page 325) No evidence of
attrition bias from published data (figures
and tables present data on relevant out-
comes for 49 patients)
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Some evidence of baseline differences
Sample size not achieved
Quote: “Because patient recruitment was
much slower than expected, however, re-
cruitment ended on 31December 1997 for
financial reasons.”
Riso 2000
Methods Design: double-blind, parallel-group randomised controlled trial with ≥ 10 days (fol-
lowing total laryngectomy) or ≥ 21 days (following partial laryngectomy) duration of
treatment and follow-up to hospital discharge
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Riso 2000 (Continued)
Participants Setting: not stated but authors affiliated toMaggiore dellaCarita Hospital, Novara, Italy.
Stated that the trial was “carried out from January to December 1998”
Sample size:
• Number randomised: 44
• Number completed: 44
Participant (baseline) characteristics:
• Age: enriched group mean age 60.8 (± 9.1); control group mean age 63.2 (± 5.7)
• Gender: male/female: enriched 21/2; control 18/3
• Baseline differences/other characteristics: Quote: “Characteristics of the
patients on enrolment were similar for the two groups”
Inclusion criteria: Quote: “adult patients with oral, pharyngeal and laryngeal cancer
were enrolled.”
Exclusion criteria:Quote: “Exclusion criteria included severely impaired renal function
(serum creatinine concentration > 2.5mg/dl) and hepatic function (total serum bilirubin
concentration > 3 mg/dl), autoimmune disorders, insulin-dependent diabetes mellitus,
ongoing infections.”
Interventions Intervention group:
Enteral diet supplemented with arginine (enriched group) (n = 23)
Comparator group:
Isocaloric, isonitrogenous enteral formula (control group) (n = 21)
Quote: “At surgery, patients were randomly allocated to two groups: a) patients receiving
an enteral diet supplemented with arginine (Nutrison Intensive, Nutricia, Zoetermeer,
The Netherlands) (enriched group); b) patients receiving an isocaloric, isonitrogenous
enteral formula (Nutrison Protein Plus, Nutricia, Zoetermeer,TheNetherlands) (control
group).”
Quote: “Enteral feeding was started within 24 hrs of surgery at a rate of 40 ml/hour.
The infusion rate was progressively increased by 20 ml/hour every 24 hrs until the daily
nutritional goal (31.0 total kcal/kg; 25.0 non-protein kcal/kg; 1.5 g protein/kg) was
reached, on postoperative day (POD) 4. In the first 3 PODs, all patients received calories
and nitrogen by parenteral route to achieve the nutritional goal.”
Use of additional interventions:
Quote: “In the first 3 PODs, all patients received calories and nitrogen by parenteral
route to achieve the nutritional goal.”
Quote: “Prophylactic antibiotic treatment (amoxicillin/clavulanate, 2.2 g bid i.v.) was
given for 7 days postoperatively.”
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “Preoperatively and on postoperative days 1, 4 and 8 the following parameters
were evaluated: serum level of albumin (g/dl), prealbumin (mg/dl), and transferrin (mg/
dl), total number of lymphocytes (106/ml), lymphocyte subsets (CD3, CD4, CD8 and
CD4/CD8 ratio; %), and serum immunoglobulin concentrations (IgG, IgA, IgM; mg/
dl).”
Quote: “All patients were followed-up until discharge. Postoperative complications were
recorded as none, minor (urinary tract infection; respiratory tract infection: abnormal
chest X-ray), and major (fistula; wound infection: spontaneous or surgical purulent
drainage and necrosis; anastomotic leakage). The clinical complicationswere not defined.
Gastrointestinal problems related to enteral feeding were also recorded.”
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Riso 2000 (Continued)
Abstract states that length of hospital stay was also recorded
Funding sources None stated
Declarations of interest None stated
Notes Participants lost to follow-up: no attrition according to figures on outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated (information from
authors)
Allocation concealment (selection bias) Unclear risk Quote: “Concealed (envelopes)” (informa-
tion from authors) but not known if these
were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blindly performed” (infor-
mation from authors) but no indication of
who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “double-blindly performed” (infor-
mation from authors) but no indication of
who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition according to number of par-
ticipants included in figures on outcomes
Selective reporting (reporting bias) Unclear risk Protocol not available. Subgroup analysis
performed on ’malnourished’ subset of pa-
tients (Quote: “Patients with a weight loss
of 10% or more in less than 6months, with
respect to pre-illness body weight”). Un-
clear if this was a pre-planned analysis; 6
patients in the enriched diet group and 7
in the control group were classed as mal-
nourished
Other bias High risk No description of how length of stay was
determined. No sample size calculations
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De Luis 2002
Methods Design: double-blind, parallel-group randomised controlled trial with an average dura-
tion of treatment of 22 days (± 12 days) and duration of follow-up of 14 days postoper-
atively, or 3 months post-discharge for mortality
Participants Setting: author affiliations in Spain (Institute of Endocrinology andNutrition, Medicine
School and Hospital Rio Hortega, Spain; and Hospital Clinico, University of Valladolid,
Valladolid, Spain)
Sample size:
• Number randomised: 47
• Number completed: 47
Participant (baseline) characteristics:
• Age: mean age was 61.4 ± 11.7 years (63.15 ± 12.7 in group 1 and 59.3 ± 10.5 in
group 2)
• Gender: 5 females, 42 males
• Baseline differences/other characteristics: Quote: “Characteristics of the
patients on enrollment were similar for the two groups.”
Inclusion criteria: oral and laryngeal cancer
Exclusion criteria: Quote: “severely impaired hepatic function (total bilirubin concen-
tration > 3.5 mg/dl) and renal function (serum creatinine concentration > 2.5 mg/dl)
; ongoing infections; autoimmune disorders; steroid treatment; nutritional oral supple-
mentation in the previous 6 months; and severe malnourishment (weight loss > 10% of
body weight).”
Interventions Intervention group:
Enteral diet supplemented with arginine and fibre (n = 23)
Comparator group:
Isocaloric, isonitrogenous enteral formula (n = 24)
Enteral feeding was started within 24 hours of surgery
Use of additional interventions: Quote: “Prophylactic antibiotic treatment was given
for 7 days postoperatively (ceftazidime, 500 mg three times daily i.v. and clyndamicine
300 mg three times daily i.v.)”
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “Perioperatively and on postoperative days 7 and 14 the following parameters
were evaluated: serum values of prealbumin (mg/dl), transferrin (mg/dl), albumin (g/dl)
and total number of lymphocytes (106/ml). Postoperative complications were recorded
as none, general infections (respiratory tract infection was diagnosed when the chest
radiographic examination showed new or progressive unfiltration, temperature above
38.5°C and isolation of pathogens from the sputum or blood culture and/or urinary
tract infection was diagnosed if the urine culture showed at least 105 colonies of a
pathogen) and local complications such as fistula and/or wound infection, assessing
all complications using standard methods and the same investigator. Gastrointestinal
problems related to enteral feeding were also recorded (diarrhoea, > 5 liquid stools in a
24 h period or an estimated volume > 2000 ml/day). Mortality was assessed 3 months
after hospital discharge.”
Funding sources None stated
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De Luis 2002 (Continued)
Declarations of interest None stated
Notes Participants lost to follow-up: stated that an ITT analysis was conducted
Quote: “Sample size was calculated to decrease fistula complication by 20% with 80%
power and 5% significance.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No statement in manuscript on the gen-
eration of random sequence. Author con-
tacted: tables of random numbers used
Allocation concealment (selection bias) Unclear risk No statement in manuscript as to how al-
location was concealed. Author contacted:
sealed envelopes used (but not known if
these were opaque)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The main investigator and pa-
tients remained blind to the treatment
group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The main investigator and pa-
tients remained blind to the treatment
group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data.
Quote: “Any drop-outs were present in the
study”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Assessment of wound infection poorly de-
scribed (Quote: “using standard methods
by the same investigator”) and no descrip-
tion of how length of stay was determined
De Luis 2003
Methods Design: double-blind, parallel-group randomised controlled trial with an average du-
ration of treatment of 20 days (in the supplemented group) and a 5-day duration of
follow-up
Participants Setting: author affiliations: Valladolid, Spain
Sample size:
• Number randomised: 36
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• Number completed: 36
Participant (baseline) characteristics:
• Age: mean age was 59.6 ± 10.9 years (63.1 ± 12.7 years in group 1 and 59.3 ± 10.
5 years in group 2)
• Gender: 2 females, 34 males
• Baseline differences/other characteristics: Quote: “Characteristics of the
patients on enrollment were similar for the two groups”
Inclusion criteria: a previous weight loss of 5% to 10% (6months) and oral or laryngeal
cancer
Exclusion criteria: Quote: “Exclusion criteria included severely impaired hepatic func-
tion (total bilirubin concentration > 3.5 mg/dl) and renal function (serum creatinine
concentration > 2.5 mg/dl), ongoing infections, autoimmune disorders, steroids treat-
ment and well-nourished (weight loss < 10% of body weight).”
Interventions Intervention group:
Enteral diet supplemented with arginine (n = 18)
Comparator group:
Isoenergetic, isonitrogenous enteral formula (n = 18)
Quote: “Enteral feeding was started within 24 h of surgery”
Quote: “Group I received a daily dose of arginine of 12.5 g during an average of 20 days”
Use of additional interventions: Quote: “Prophylactic antibiotic treatment was given
for 3 days postoperatively (ceftazidime, 500 mg three times daily i.v. and clyndamicine
300 mg three times daily i.v.)”
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Perioperatively and on postoperative day 5 the following parameters were evaluated:
serum values of prealbumin, transferrin, albumin, total number of lymphocytes, inter-
leukin 6, tumour necrosis factor-α and C-reactive protein
Funding sources None stated
Declarations of interest None stated
Notes Participants lost to follow-up: stated that an ITT analysis was conducted. No postop-
erative deaths (information from authors)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Author contacted: tables of random num-
bers used
Allocation concealment (selection bias) Unclear risk Quote: “At surgery patients were randomly
allocated (sealed envelopes) to two groups”.
Also states that the study was a “prospec-
tive concealed randomized trial” but no in-
formation available on how allocation was
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concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The study was blinded (patients
and investigator)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The study was blinded (patients
and investigator)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data
Quote: “all randomized patients were in-
cluded in the comparisons, irrespective of
whether or not and for how long they com-
plied with their allocated regimen (inten-
tion-to-treat analysis).”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None
De Luis 2004
Methods Design: blinded (information from author but not stated who was blinded), parallel-
group randomised controlled trial with ≥ 10 days duration of treatment and 14 days
duration of follow-up
Participants Setting: author affiliations: Valladolid, Spain
Sample size:
• Number randomised: 90
• Number completed: 90
Participant (baseline) characteristics:
• Age: mean age was 60.57 ± 12.3 years (60.2 ± 12.5 years in group 1 and 60.6 ±
11.5 years in group 2)
• Gender: 6 females, 84 males
• Baseline differences/other characteristics: Quote: “The characteristics of the
patients on enrollment were similar for the two groups”
Inclusion criteria: oral and laryngeal cancer
Exclusion criteria:Quote: “Exclusion criteria included: severely impaired hepatic func-
tion (total bilirubin concentration > 3.5 mg/dl) and renal function (serum creatinine
concentration > 2.5 mg/dl), ongoing infections, autoimmune disorders, steroids treat-
ment, nutritional oral supplementation in previous 6months, and severelymalnourished
(weight loss > 10% of body weight).”
Interventions Intervention group:
Enteral diet supplemented with arginine (n = 45)
Comparator group:
Isoenergetic, isonitrogenous enteral formula (n = 45)
Enteral feeding was started within 12 hours of surgery
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Use of additional interventions: Quote: “In all patients, prophylactic antibiotic treat-
ment was given for 7 days postoperatively (ceftazidime, 500 mg tid i.v. and clyndamicine
300 mg tid i.v.)”
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “Perioperatively and on postoperative day 14 the following parameters were
evaluated: serum values of prealbumin (mg/dl), transferrin (mg/dl), albumin (g/dl),
and total number of lymphocytes (106 /ml). Postoperative complications were recorded
as none, general infections (respiratory tract infection was diagnosed when the chest
radiographic examination showed new or progressive unfiltration, temperature above 38.
5°C and isolation of pathogens from the sputum or blood culture and/or urinary tract
infection was diagnosed if the urine culture showed at least 105 colonies of a pathogen)
, and wound complications such as fistula and/or wound infection. All complications
were assessed with standard methods by the same investigator. Gastrointestinal problems
related to enteral feeding were also recorded (diarrhoea, > 5 liquid stools in a 24-h period
or an estimated volume > 2000 ml/day).”
Funding sources None stated
Declarations of interest None stated
Notes Participants lost to follow-up:Quote: “No dropouts were present in the study” and an
ITT analysis was conducted
Quote: “The sample size was calculated to decrease 20% of fistula complication with
90% power and 5% significance.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Author contacted: tables of random num-
bers used
Allocation concealment (selection bias) Unclear risk Sealed envelopes used for allocation con-
cealment (information from authors) but
not known if envelopes were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States blinded (information from authors)
but no indication as to who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk States blinded (information from authors)
but no indication as to who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data
Quote: “all randomized patients were in-
cluded in the comparisons, irrespective of
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whether or not and for how long they com-
plied with their allocated regimen (inten-
tion-to-treat analysis).” Also stated “There
were no dropouts due to intolerance”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Assessment of wound infection poorly de-
scribed (Quote: “with standardmethods by
the same investigator”) and no description
of how length of stay was determined
De Luis 2005
Methods Design: blinded (information from author but not stated who was blinded), parallel-
group randomised controlled trial with an average duration of treatment of 20 days (in
the supplemented group) and 6-day duration of follow-up
Participants Setting: author affiliations: Valladolid, Spain
Sample size:
• Number randomised: 29
• Number completed: 29
Participant (baseline) characteristics:
• Age: mean age was 61.1 ± 10.8 years (60.7 ± 11.6 years in group 1 and 62.96 ±
11.6 years in group 2)
• Gender: 5 females, 24 males
• Baseline differences/other characteristics: Quote: “Characteristics of the
patients and tumour stage... on enrollment were similar for the two groups”
Inclusion criteria: Quote: “patients with a previous weight loss of 5-10% (6 months),
(IL-6 levels 45 pg/ml) and oral or laryngeal cancer were enrolled.”
Exclusion criteria:Quote: “Exclusion criteria included; severely impaired hepatic func-
tion (total bilirubin concentration > 3.5 mg/dl) and renal function (serum creatinine
concentration > 2.5 mg/dl), ongoing infections, steroid treatment and well nourished
(weight loss < 10% of body weight).”
Interventions Intervention group:
Enteral diet supplements with arginine (n = 14)
Comparator group:
Isocaloric, isonitrogenous enteral formula without arginine (n = 15)
Quote: “Group I received a daily dose of arginine of 12.5 g during an average of 20 days”
Use of additional interventions: none described
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Perioperatively and on postoperative day 6, the following blood parameters were evalu-
ated: prealbumin (mg/dl), transferrin (mg/dl), albumin (g/dl), total number of lympho-
cytes (106 /ml), IL-6 (pg/ml), TNFa (pg/ml) and c-reactive protein (mg/dl)
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Funding sources None stated
Declarations of interest None stated
Notes Participants lost to follow-up: an ITT analysis was conducted. No postoperative deaths
(information from authors)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Author contacted: tables of random num-
bers used
Allocation concealment (selection bias) Unclear risk Quote: “At surgery, patientswere randomly
allocated (sealed envelops) to two groups”
Also states that the study was a “prospective
concealed randomized trial” but no state-
ment on how concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Study was blinded” but no indica-
tion as to who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Study was blinded” but no indica-
tion as to who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data
Quote: “all randomized patients were in-
cluded in the comparisons, irrespective of
whether or not and for how long they com-
plied with their allocated regimen (inten-
tion-to-treat analysis).”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None
Felekis 2005
Methods Design: parallel-group randomised controlled trial (no statement on blinding) with 6
days pre- and 8 days postoperative duration of treatment and unclear duration of follow-
up
Participants Setting: Greece
Sample size:
• Number randomised: 37
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• Number completed: 37
Participant (baseline) characteristics:
• Age: not stated
• Gender: not stated
• Baseline differences/other characteristics: 35 were well nourished and 2 (1 in
each group) were severely malnourished
Inclusion criteria: patients undergoing major head and neck surgery (for cancer)
Exclusion criteria: none stated
Interventions Intervention group:
Enteral immunonutrition for 6 days preoperatively and for 8 days postoperatively (n =
20)
Comparator group:
Regular oral diet and standard polymeric enteral feeding (n = 17)
Quote: “Both groups received isocaloric and isonitrogenous regimens”
Use of additional interventions: none stated
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “The parameters analyzed were the incidence of postop. complications and mor-
tality”
Funding sources Not stated
Declarations of interest Not stated
Notes Participants lost to follow-up: not stated
Note: abstract only. There is a linked reference: Felekis D, Eleftheriadou A, Papadakos G,
Bosinakou I, Ferekidou E, Kandiloros D, et al. Effect of perioperative immuno-enhanced
enteral nutrition on inflammatory response, nutritional status, and outcomes in head
and neck cancer patients undergoing major surgery. Nutrition and Cancer 2010;62(8):
1105-12. We tried to contact the corresponding author by email and telephone but were
unable to get a response using the information given in the above paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No statement on the generation of random
sequence
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No statement on blinding
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unable to judge from the published data
(abstract only)
Selective reporting (reporting bias) Unclear risk Unable to judge from the published data
(abstract only)
Other bias Unclear risk unable to judge from the published data
(abstract only)
De Luis 2007
Methods Design: blinded (information from author but not stated who was blinded), parallel-
group randomised controlled trial with ≥ 10 days duration of treatment and 12 days
duration of follow-up
Participants Setting: author affiliations: Valladolid, Spain
Sample size:
• Number randomised: 72
• Number completed: 72
Participant (baseline) characteristics:
• Age: mean age was 61.8 ± 13.3 years (62.1 ± 12 years in group 1 and 61.5 ± 11
years in group 2)
• Gender: 7 females, 65 males
• Baseline differences/other characteristics: epidemiological data for the patients
on enrollment were similar for the 2 groups
Inclusion criteria: patients with oral and laryngeal cancer
Exclusion criteria:Quote: “Exclusion criteria included: severely impaired hepatic func-
tion (total bilirubin concentration > 3.5 mg/dl and serum glutamic pyruvate > 150 UI/
l) and renal function (serum creatinine concentration > 2.5 mg/dl), ongoing infections,
autoimmune disorders, steroids treatment, nutritional oral supplementation in previous
6 months and severely malnourished (weight loss > 10% of body weight).”
Interventions Intervention group:
Enteral diet supplements with arginine (n = 35)
Comparator group:
Isocaloric, isonitrogenous enteral formula (n = 37)
Enteral feeding was started within 8 to 12 hours of surgery
Use of additional interventions: Quote: “In all patients, prophylactic antibiotic treat-
ment was given for 7 days postoperatively (ceftazidime, 500 mg t.i.d. intravenously (i.v.
) and clyndamicine 300 mg t.i.d. i.v.)”
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “Perioperatively and on postoperative day 12, the following parameters were
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evaluated: serum values of prealbumin (mg/ dl), transferrin (mg/dl), albumin (g/dl)
and total number of lymphocytes (106 /ml). Postoperative complications were recorded
as none; general infections (respiratory tract infection was diagnosed when the chest
radiographic examination showed new or progressive unfiltration, temperature above
38.5°C and isolation of pathogens from the sputum or blood culture and/or urinary
tract infection was diagnosed if the urine culture showed at least 105 colonies of a
pathogen) and wound complications, such as fistula and/or wound infection, assessed all
complications with standard methods by the same investigator surgeon. Gastrointestinal
problems related to enteral feeding were also recorded (diarrhoea, > 5 liquid stools in a
24-h period or an estimated volume > 2000 ml/day).”
Funding sources Not stated
Declarations of interest Not stated
Notes Participants lost to follow-up: stated that an ITT analysis was conducted and “No
drop-outs were present in the study”
Quote: “Sample size was calculated to decrease 25% of wound complication with 90%
power and 5% significance.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Author contacted: tables of random num-
bers used
Allocation concealment (selection bias) Unclear risk Envelopes (information from authors) but
not known if these were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding stated (information from authors)
but no indication as to who was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding stated (information from authors)
but no indication as to who was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data:
Quote: “all randomized patients were in-
cluded in the comparisons, irrespective of
whether or not and for how long they com-
plied with their allocated regimen (inten-
tion-to-treat analysis).” Also stated “There
were no dropouts due to intolerance”
Selective reporting (reporting bias) Unclear risk Protocol not available
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Other bias High risk Assessment of wound infection poorly de-
scribed (Quote: “with standardmethods by
the same investigator surgeon”) and no de-
scription of how length of stay was deter-
mined
Casas-Rodera 2008
Methods Design: parallel-group randomised controlled trial (no statement on blinding) with
average duration of treatment of 14.5 ± 8 days and 14 days duration of follow-up
Participants Setting: La Paz University Hospital, Spain. Trial carried out for 12 months
Sample size:
• Number randomised: 44
• Number completed: 44
Participant (baseline) characteristics:
• Age: group 1: 59.67 ± 9.07, group 2: 54.27 ± 13.04, group 3: 50.07 ± 13.79
• Gender: group 1: 13 men, 2 women, group 2: 15 men, 0 women, group 3: 14
men, 0 women
• Baseline differences/other characteristics: Quote: “The characteristics of the
patients on enrolment were similar for the three groups, reflecting the homogeneity of
patients. There were no significant differences with respect to gender, mean age, body
weight, location, and stage of tumor”
Inclusion criteria: oral and laryngeal cancer
Exclusion criteria: Quote: “Severely impaired hepatic function (total bilirubin concen-
tration over 43.5 mg/dl) and renal function (serum creatinine concentration over 42.5
mg/dl), ongoing infections, autoimmune disorders, steroids treatment, nutritional oral
supplementation in previous 6 months.”
Interventions Intervention group:
Group 1 (enteral diet supplemented with arginine) (n = 15)
Group 3 (enteral diet supplemented with arginine, RNA and omega-3 fatty acids) (n =
14)
Comparator group:
Group 2 (standard polymeric enteral formula) (n = 15)
Quote: “Enteral feeding was started within 12 h of surgery, via an intraoperatively placed
nasogastric tube.”
Use of additional interventions: none stated
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “Perioperatively and on postoperative day 7 and day 14 the following parameters
were evaluated: serum values of transferrin (mg/dl), albumin (g/dl), and total number
of lymphocytes (106/ml), IL-6 (mg/dl), TNFa (pg/dl) and CPR (mg/dl). Postoperative
complications were recorded as none, general infections (respiratory tract infection was
diagnosed when the chest radiographic examination showed new or progressive infiltra-
tion, temperature above 38.5 ºC and isolation of pathogens from the sputum or blood
culture and/or urinary tract infection was diagnosed if the urine culture showed at least
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106 colonies of a pathogen), and wound complications such as fistula and/or wound in-
fection. All complications were assessed with standard methods by the same investigator.
Gastrointestinal problems related to enteral feeding were also recorded (diarrhoea, > 5
liquid stools in a 24-h period or an estimated volume > 2,000 ml/day). The duration of
hospitalisation was based on the date that the patient was medically eligible for discharge.
”
Funding sources None stated
Declarations of interest None stated
Notes Participants lost to follow-up:Quote: “No dropouts were present in the study”
The comparison used is group 2 (standard polymeric feed) and group 3 (arginine, RNA
and omega-3 fatty acids). Data from group 1 (arginine only) were not used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “At surgery, patientswere randomly
allocated to three groups” but does not say
how sequence was generated
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No statement on blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data
Quote: “No dropouts were present in the
study”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Assessment of wound infection poorly de-
scribed (Quote: “with standardmethods by
the same investigator”)
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Methods Design: double-blind (NB: some outcome assessors not blinded - see Table 3 for more
information), parallel-group randomised controlled trial with 7 days pre- and 7 days
postoperative duration of treatment and 29 days duration of follow-up
Participants Setting: Department of Surgery, Otolaryngology - Head and Neck Surgery Service,
Madigan Army Medical Center, Tacoma, Washington, USA
Sample size:
• Number randomised: 15
• Number completed: 15
Participant (baseline) characteristics:
• Age: mean age 60.6 years (SD 8.2, range 46 to 73 years), group 1 mean age 61.9
years (SD 8.5, range 46 to 73 years), group 2 mean age 58.9 years (SD 7.4, range 48 to
67 years)
• Gender: all male
• Baseline differences/other characteristics: Quote: “Nutritional status was
similar for patients in both groups upon enrollment. Baseline values of height, weight,
body mass index, weight loss in previous 6 months, subjective global assessment,
nutritional risk, albumin, and prealbumin showed no statistically significant
differences.” and “Immunologic measures...of white blood cell, TLC, and lymphocyte
subsets were not different between groups at baseline. CRP did not pass Levene’s test
for equality of variances at baseline (P = .023), but was not statistically significantly
different between groups”
Inclusion criteria: age > 18 years, histologically documented squamous cell carcinoma
of the head and neck, candidates for curative surgery
Exclusion criteria: history of renal, hepatic or cardiopulmonary dysfunction, ongoing
infection and immune deficiency
Interventions Intervention group:
Impact Recover oral drink or Impact Glutamine tube feeding (Novartis Nutrition) (n =
8)
Comparator group:
Standard supplement (Isosource 1.5 from Novartis Nutrition) (n = 7)
Participants received/were asked to drink about 1 L per day for 7 days preoperatively
and 7 days postoperatively. Postoperative feeding began within 24 hours post surgery
Use of additional interventions: none stated
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
The following were measured at baseline, day of surgery and postoperative days 1, 4
and 8: complete blood count, total lymphocyte count, T-lymphocyte subsets (CD3,
CD4, CD8, CD4:8 ratio, CD19, CD56), albumin, prealbumin and CRP. Cell mediated
immunity was evaluated by delayed-type hypersensitivity. Serious wound complications
included wound infection, wound dehiscence and wound fistula. Wound assessments
used the ASEPSIS scoring method
Funding sources Quote: “Sponsored by the TriService Nursing Research Program and supported by a
grant of $35,884.”
Declarations of interest None stated
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Notes Participants lost to follow-up: no statement about dropouts. Few participants com-
pleted the delayed-type hypersensitivity (DTH) skin test
Power/sample size calculation not done as it was a feasibility study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to have a “Randomized design” but
no statement on the generation of the ran-
dom sequence
Allocation concealment (selection bias) Unclear risk Envelopes used but not known if these were
opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The principal investigator and
otolaryngology head and neck service resi-
dents were blinded to study group, an asso-
ciate investigators (AI) and research assis-
tant (RA) were not.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The principal investigator and
otolaryngology head and neck service resi-
dents were blinded to study group, an asso-
ciate investigators (AI) and research assis-
tant (RA) were not.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No statement on dropouts
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None
De Luis 2009
Methods Design: double-blind, parallel-group randomised controlled trial with ≥ 10 days dura-
tion of treatment and 10 days duration of follow-up
Participants Setting: author affiliations: Valladolid, Spain
Sample size:
• Number randomised: 72
• Number completed: 72
Participant (baseline) characteristics:
• Age: mean age was 62.3 ± 11.3 years (63.1 ± 13 years in group 1 and 61.2 ± 9.9
years in group 2)
• Gender: 15 females, 57 males (8 females, 30 males in group 1 and 7 females, 27
males in group 2)
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• Baseline differences/other characteristics: “Epidemiological data of the patients
on enrollment were similar for the two groups, reflecting the homogeneity of patients.
There were no significant differences with regard to gender, mean age, body weight,
location, and stage of tumor”
Inclusion criteria: oral and laryngeal cancer
Exclusion criteria: Quote: “Exclusion criteria included: severely impaired renal func-
tion (serum creatinine concentration > 2.5 mg/dl) and hepatic function (total bilirubin
concentration > 3.5mg/dl and serum glutamic pyruvate > 150 UI/l), ongoing infections,
autoimmune disorders, steroids treatment, nutritional oral supplementation in previous
6 months and severely malnourished (weight loss > 10% of body weight)”
Interventions Intervention group:
Enteral diet supplements with arginine and fibre (n = 38)
Comparator group:
Isocaloric, isonitrogenous enteral formula (n = 34)
Quote: “Enteral feeding was started within 24 hours of surgery”
Use of additional interventions: Quote: “In all patients, prophylactic antibiotic treat-
ment was given for 7 days postoperatively (ceftazidime, 500 mg t.i.d. intravenously (i.v.
) and clyndamicine 300 mg t.i.d. i.v.).”
Outcomes Primary outcome and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “Perioperatively and on postoperative day 10, the following parameters were
recorded: serum values of prealbumin (mg/dl), transferrin (mg/dl), albumin (g/dl), total
number of lymphocytes (106 /ml). Postoperative complications were registered as none;
general infections (urinary tract infection was diagnosed if the urine culture showed at
least 105 colonies of a pathogen and/or respiratory tract infection was diagnosed when
the chest radiographic examination showed new or progressive unfiltration, temperature
above 38,5°C and isolation of pathogens from the sputum or blood culture) and local
complications such as fistula and/or wound infection, assessed all complications with
standard methods by the same investigator. Gastrointestinal problems related to enteral
feedingwere also recorded (diarrhoea, > 5 liquid tools in a 24-hour period or an estimated
volume > 2000 mL/d).”
Data on length of stay were also presented
Funding sources None stated
Declarations of interest None stated
Notes Participants lost to follow-up: stated that an ITT analysis was conducted
Quote: “Sample size was calculated to decrease 20% of wound complication with 80%
power and 5% significance.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “At surgery, patientswere randomly
allocated to two groups”, but no statement
on the generation of random sequence
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Main investigator and patients re-
mained blind to the treatment group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Main investigator and patients re-
mained blind to the treatment group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data
Quote: “all randomized patients were in-
cluded in the comparisons, irrespective of
whether or not and for how long they com-
plied with their allocated regimen (inten-
tion-to-treat analysis).” Also stated “There
were no drop outs due to intolerance”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Assessment of wound infection poorly de-
scribed (Quote: “with standardmethods by
the same investigator”) and no description
of how length of stay was determined
Felekis 2010
Methods Design: double-blind, parallel-group randomised controlled trial with 5 days pre- and
8 days postoperative duration of treatment and 8 days duration of follow-up
Participants Setting: First Department of Otolaryngology, University of Athens, Greece
Sample size:
• Number randomised: 40
• Number completed: 40
Participant (baseline) characteristics:
• Age: mean age 62.1 ± 2.6 years, group 1 mean age 63.2 ± 3.9 years, group 2 mean
age 61.0 ± 3.8 years
• Gender: 4 females, 36 males (2 females and 18 males in each of the 2 treatment
groups)
• Baseline differences/other characteristics: Quote: “Characteristics of the
patients on enrollment were similar for the two groups” and “There were no significant
differences with regard to gender, mean age, nutritional status, location, and stage of the
disease.” Also stated that there were no baseline differences in the outcome variables.
Inclusion criteria: Quote: “In all cases, there was a histologically proven diagnosis of
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squamous cell carcinoma of head and neck eligible for surgical treatment. No previous
radiotherapy or chemotherapy was applied. Patients did not receive immunoglobulin
before the study.”
Exclusion criteria: Quote: “Exclusion criteria included severely impaired renal and
hepatic function and autoimmune disorders.”
Interventions Intervention group:
Oral Impact (Novartis) for 5 days pre-operatively and enteral Impact for 8 days postop-
eratively (n = 20)
Comparator group:
No pre-operative nutritional support and enteral Nutrison (Nutricia) for 8 days postop-
eratively (n = 20)
Quote: “The immuno-enhanced formula was incorporated in a way that caloric equiv-
alence between Groups 1 and 2 was preserved.”
Enteral feeding was started within 24 hours of surgery
Use of additional interventions: none stated
Outcomes Primary and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “Five days before and8days after surgery the followingparameterswere evaluated:
Albumin (g/dl), prealbumin (mg/dl), fibrinogen (mg/dl), and C-reactive protein (CRP;
mg/dl), Il-6 (pg/ml), and TNF-α (pg/ml) by ELISA.”
Postoperative complications were also assessed but not mentioned in the methods. Re-
sults that were presented suggest that the following were assessed: minor complications
(increase of temperature), major complications (pneumonia, urinary tract infection, fis-
tula, wound infection)
Funding sources Quote: “The authors declare that there is no conflict of interest and no funding also.”
Declarations of interest Quote: “The authors declare that there is no conflict of interest and no funding also.”
Notes Participants lost to follow-up:Quote: “No dropouts occurred because of intolerance”
Of the 40 participants, 30 were considered well nourished (< 10% weight loss in last 6
months) and 10 malnourished (> 10% weight loss in last 6 months). Subgroup analyses
conducted with the 30 well nourished participants and the 10 malnourished participants
No description of how the postoperative complications were assessed.We tried to contact
the corresponding author by email and telephone but were unable to get a response using
the information given in the paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization was based on
known techniques (using a randomization
generator).”
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Allocation concealment (selection bias) Unclear risk Quote: “We generated a series of random
numbers that ranged from 1 to 32 for oper-
ated patients for the larynx- or hypophar-
ynx-sited tumours and 1 to 8 for operated
patients for the oral cavity or tongue-sited
tumours. We then tabulated the two series
according to their randomization rating.
We assigned the solution for each number,
following the randomized sequence, using
an alternating mode. Patients were num-
bered from 1 to 32 if they were in the first
category according to the site of the tu-
mour, and from 1 to 8 for the second cat-
egory, following the sequence of their ar-
rival, and they were introduced to the solu-
tion according to the randomization table.
”
The authors also stated that theymonitored
the distribution of gender and age within
groups, but observednodifference (anddid
not need to interrupt the randomisation
procedure to balance the groups with re-
spect to these 2 parameters)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated “double-blinded” in the methods
section but no indication as to who was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated “double-blinded” in the methods
section but no indication as to who was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data: no
loss to follow-up described
Quote: “No dropouts occurred because of
intolerance”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Assessment of complications (wound infec-
tion) poorly described
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Methods Design: double-blind, parallel-group randomised controlled trial with 5 days pre- and
7 days postoperative duration of treatment and 30 days duration of follow-up
Participants Setting: Aintree University Hospitals NHS Foundation Trust, Liverpool, UK. Patients
randomised between November 2005 and July 2008
Sample size:
• Number randomised: 60
• Number completed: 57
Participant (baseline) characteristics:
• Age: median age was 62 (IQR 57 to 65) in the Impact group and 60 (IQR 53 to
66) in the control group
• Gender: 50 males (24 in Impact group, 26 in control group), 7 females (4 in
Impact group, 3 in control group)
• Baseline differences/other characteristics: some imbalances were anticipated
and confirmed: the Impact group had more patients with oral cavity tumours, more
with later stage tumours and less co-morbidity
Inclusion criteria: Quote: “Eligible patients were those with advanced squamous cell
carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, for whom surgery +/-
adjuvant radiotherapy or chemoradiotherapy had been decided upon as the treatment of
choice and for whom enteral feeding was considered appropriate. Previous radiotherapy
was not an exclusion criterion.”
Exclusion criteria:Quote: “Specific exclusion criteria included patients with malabsorp-
tion syndromes; primary immune disorders; active infection on presentation; patients
undergoing secondary surgical reconstruction; patients aged under 18 years, and patients
who were pregnant or breast feeding.”
Interventions Intervention group:
Impact (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) - contains supplemental
L-arginine (1.25 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form
of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L)
(n = 28)
Comparator group:
Isocaloric isonitrogenous control feed manufactured for the trial (n = 29)
The feed was given enterally by NG or PEG tube (to enhance blinding) for 5 days pre-
and 7 days post-surgery
Quote: “The target duration and rate of feeding was 500 ml/day for 5 days pre-surgery
and 1 L/day for 7 days post-surgery. Patients, who were able, were allowed to eat or drink
in addition to their supplemental enteral feeds.”
Use of additional interventions: none stated
Outcomes Primary outcome:Quote: “The primary outcome event was defined as any patient with
an infection of the lower respiratory tract, gastro-intestinal tract, urinary tract or blood
which required antibiotic treatment and occurred at any time, up to the 30th post-
operative day.”
Quote: “surgical site/wound infections were defined according to CDC Definitions of
Nosocomial Surgical Site infections, 1992, and the ASEPSISwound score. The diagnosis
of the non-wound infection was as stipulated in the Trial Antibiotic Policy”
Secondary outcomes: Quote: “Secondary outcome measures included infections of
primary surgical site, neck wound, PEG site, tracheostomy, free-flap or split skin graft
donor site and the length of hospital stay e defined as the time from surgery to the date
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when the patient was deemed medically fit for discharge.”
Funding sources Quote: “Nestlé Healthcare Nutrition provided the control and experimental feeds, to-
gether with the giving sets free of charge. Novartis UK granted £4000 towards the run-
ning costs of the trial.”
Declarations of interest Quote: “Neither do any of the authors have any other potential conflict of interest to
declare.”
Notes Participants lost to follow-up: 3 early withdrawals (post-randomisation). Quote: “One
who stopped feeding following the decision to proceed with radical radiotherapy rather
than surgery; one was deemed inoperable following clinical review after randomisation,
and one patient opted to withdraw.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The Trust Pharmacy Clinical Trials Unit
generated randomisation lists
Allocation concealment (selection bias) Low risk Quote: “The allocation of patients to trial
groups was administered independently by
the Trust Pharmacy Clinical Trials Unit us-
ing randomisation lists which were strat-
ified on the basis of clinical specialty to
whom the patient presented (Otorhino-
laryngology/Head and Neck Surgery or
Maxillofacial Surgery) and whether pa-
tients had previously received radiotherapy
or not.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “To enhance blinding, and allow
a more accurate assessment of compliance,
both groupswere fed enterally, either by na-
sogastric (NG) or percutaneous endoscopic
gastrostomy (PEG) feeding tube depend-
ing on clinical appropriateness. Feed bottles
containing either Impact or control feed
were packaged identically.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated that study personnel were blinded
(feed bottles were packaged identically and
both groups fed enterally)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Stated that an ITT analysis was conducted.
Also states that “Of the 60 patients ran-
domised therewere three earlywithdrawals:
Onewho stopped feeding following the de-
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cision to proceed with radical radiother-
apy rather than surgery; one was deemed
inoperable following clinical review after
randomisation, and one patient opted to
withdraw”. NB: length of stay analysis “ex-
cludes 4 patients who died as inpatients, 3
from the Impact group (LOS 18, 22 & 32
days) and 1 from the control group (LOS
30 days)”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Sample size calculation done, but “The trial
was discontinued before achieving the cal-
culated sample size as our rate of recruit-
ment was insufficient to enable study com-
pletion in a practical time-frame and in
the absence of funding to allow the in-
clusion of additional centres.” Also quoted
that “some imbalances were anticipated
and confirmed: the Impact group hadmore
patients with oral cavity tumours, more
with later stage tumours, and less co-mor-
bidity.”
Turnock 2013
Methods Design: non-blinded, parallel-group randomised controlled trial with 5 days pre- and
≥ 5 days postoperative duration of treatment and duration of follow-up to hospital
discharge
Participants Setting: head and neck outpatient clinics at Auckland City Hospital, New Zealand.
Carried out between May 2007 and January 2008
Sample size:
• Number randomised: 8
• Number completed: 8
Participant (baseline) characteristics:
• Age: ranged from 28 to 68 years in the immunonutrition group and from 17 to
79 years in the control group
• Gender: 6 males (3 per treatment group) and 2 females (1 per treatment group)
• Baseline differences/other characteristics: not specifically reported, but no
major differences reported/presented in the paper
Inclusion criteria: Quote: ”patients who were scheduled for radical resection of the
oral cavity, pharynx or larynx and who were expected to require artificial feeding by the
enteral route postoperatively.“
Exclusion criteria: Quote: ”Patients were excluded if they were: aged < 16 year, mal-
nourished (weight loss ≥ 10% of body weight within the last 6 months), had under-
gone previous wide-field radical radiotherapy, or were pregnant, diabetic or immuno-
58Immunonutrition for patients undergoing surgery for head and neck cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Turnock 2013 (Continued)
suppressed.“
Interventions Intervention group:
Preoperative oral Impact and postoperative enteral Impact (n = 4)
Quote: ”IMN patients were provided with three 74 g sachets per day of powdered
Oral Impact® (Novartis Consumer Health, Nyon, Switzerland) to be taken for 5 days
immediately preceding day of surgery“ and IMN patients received enteral Impact®
(Novartis) post-operatively. If tube feeding was discontinued, nutritional support was
continued with Oral Impact until at least POD5.”
Comparator group:
Patients did not receive preoperative nutritional supplement and received standard hos-
pital enteral nutrition (Isosource Standard®, Novartis) postoperatively (n = 4)
Postoperative feeding began as soon as tolerated via an intraoperatively placed nasogastric
tube
Use of additional interventions: Quote: “Prophylactic antibiotic treatment was given
to all patients for 7 days postoperatively.”
Outcomes Primary and secondary outcomes:
Primary and secondary outcomes not separated out
Blood samples taken at baseline, day of surgery, immediately preceding induction of
anaesthesia and on postoperative days (POD) 2, 4 and 10: measured for plasma fatty
acids, immunoglobulins (A, G and M), inflammatory markers (tumour necrosis factor
(TNF)-α, interleukin (IL)-6 and IL-10, and C-reactive protein) and full blood count
determinations
Quote: “Assessment of clinical outcome was undertaken until discharge and included
postoperative complications and length of hospital stay. General infections (urinary tract
infection, respiratory tract infection), flap anastomosis complications (venous or arterial)
, and wound complications (dehiscence, tissue necrosis, haematoma, chyle leak, salivary
fistula or wound infection) were recorded. Infectious complications were judged using
CDC criteria and were considered significant if antibiotic therapy was instituted.”
Funding sources Quote: “This study was supported by a grant from the Greenlane Research and Educa-
tional Fund”
Declarations of interest Quote: “LDP has received funding support from Novartis/Nestle, Nutricia and Abbott
Laboratories, and honoraria from Baxter Healthcare. PCC is a consultant to Danone
ResearchCenter for SpecialisedNutrition and Pronova Biopharma; has received speaking
honoraria from Fresenius Kabi, B. Braun, Baxter Healthcare, Abbott Nutrition, and
Nestle; and has research funding from Abbott Nutrition. The authors report no other
conflicts of interest.”
Notes Participants lost to follow-up: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “The allocation sequence was de-
rived from a computer-generated random
enumeration.”
Allocation concealment (selection bias) Low risk Opaque, sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was non-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was non-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No attrition according to number of par-
ticipants included in results
Selective reporting (reporting bias) High risk Not all primary outcomes stated in the
protocol were presented (data for CD3,
CD4 and CD8 were not included in the
manuscript). Additional outcomes to those
stated in the protocol were presented in
themanuscript (IL-10, length of stay, EPA,
DHA, AA)
Other bias High risk Target sample size was 30 (15 per treatment
group); only recruited 8
De Luis 2014
Methods Design: double-blind, parallel-group randomised controlled trial with minimum of 15
days duration of treatment and 10 days duration of follow-up
Participants Setting: author affiliations: Valladolid, Spain
Sample size:
• Number randomised: 82
• Number completed: 82
Participant (baseline) characteristics:
• Age: mean age 64.6 years (SD 11.4)
• Gender: male n = 72, female n = 10
• Baseline differences/other characteristics: no differences at baseline in age,
gender, weight, tumour location or stage
Inclusion criteria: Quote: “The study protocol was designed to study patients with
head and neck cancer after a surgery in abcense of type 2 diabetes mellitus or alteration
of fasting glucose, diagnosed by fasting plasma glucose less than 110 mg/ dl.” and “All
patients have a histologically proven squamous cell carcinoma of the oral cavity, larynx,
oropharyns or hypopharynx and required major ablative surgery.”
Exclusion criteria:Quote: “Patients were excluded from the study if they were impaired
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renal function (serum creatinine concentration > 2.5 mg/ dl), ongoing infections, au-
toimmune disorders, steroids treatment, nutritional oral supplementation in previous 6
months and severely malnourished (weight loss > 10% of body weight).”
Interventions Intervention group:
Group 1 received an enteral diet supplements with a high dose of L-arginine (20 g per
day) (n = 42)
Comparator group:
Group 2 received an isocaloric, isonitrogenous enteral formula without L-arginine (n =
40)
Both groups were tube fed for 15 days post surgery. The rate of feed was increased so
the target rate of 35 kcal/kg (1.7 g protein/kg) was reached within 4 days
Use of additional interventions: none stated
Outcomes Primary and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “At basal time and on postoperative day 10, the following parameters were
recorded: glucose, c-reactive protein (CRP), insulin, HOMA (homeostasis model assess-
ment), leptin and adiponectin.” Also measured weight, waist and hip circumferences,
and body composition via bioelectrical impedance, and reported on BMI
Funding sources None declared
Declarations of interest None declared
Notes Participants lost to follow-up:Quote: “No drop-outs were present in the study”
Outcomes: no relevant outcomes for this review
Other: stated that an ITT analysis was conducted
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned”
but no other information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Blinding of patients and dietitians
involved in patient treatment was main-
tained”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Blinding of patients and dietitians
involved in patient treatment was main-
tained”, but no indication of who outcome
assessor was
61Immunonutrition for patients undergoing surgery for head and neck cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
De Luis 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data
Quote: “No drop-outs were present in the
study”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None
Falewee 2014
Methods Design: double-blind, parallel-group randomised controlled trial with 7 days pre- and
7 to 15 days postoperative duration of treatment and 90 days duration of follow-up
Participants Setting: 8 centres in France; conducted between July 2007 and April 2011
Sample size:
• Number randomised: 298
• Number completed: 205
Participant (baseline) characteristics:
• Age: Group A: 59.5 (SD 9.6) years, group B: 59 (SD 9.7) years, group C: 58.2
(SD 8.7) years
• Gender: Group A: 12 female, 52 male, group B: 11 female, 57 male, group C: 10
female, 63 male
• Baseline differences/other characteristics: no evidence of baseline differences
between groups
Inclusion criteria:Quote: “To enter the study, patients must have confirmed squamous
cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, with anticipated
surgery and postoperative enteral feeding for a minimum of seven days. They had to
be aged ≥ 18 and ≤ 75, with adequate hematopoietic function [absolute neutrophil
count > 1.8 109 /l, haemoglobin level≥ 9 g/dl], adequate hepatic function [total serum
bilirubin, serum aminotransferases ≤ 3 x institutional upper limit of normal (ULN)],
and adequate renal function [serum creatinine ≤ 2 ULN], urea ≤ 1.5 ULN], glucose <
1.5 g/L, sodium < 145 mmol/L.”
Exclusion criteria:Quote: “Ineligible patients included: patients treated with neo-adju-
vant chemotherapy, radiation therapy delivered on head and neck area during the previ-
ous year, patients having received oral supplements containing immune nutrients before
study entry, patients testing positive for HIV, pregnant or breast-feeding women.”
Interventions Intervention group:
Group B: pre-operative Impact and postoperative standard diet (n = 68)
Group C: pre- and postoperative Impact (n = 73)
Comparator group:
Group A: control, i.e. ’standard diet’ - Impact without immune nutrients that had been
manufactured for the study (n = 64)
Pre-operatively: Quote: “For seven days before surgery, well-nourished patients with no
dysphagia received three sachets per day of nutrition according to the randomization
(Oral Impact or standard diet). Each sachet dissolves in 250 ml of water and represents
303 kcal and 2.88 g of nitrogen. Patients with severe malnutrition or presenting a
significant dysphagia received standard enteral nutrition according to their needs (French
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recommendations). Seven days before surgery, they switched 1000 kcal from their intake
to the investigational nutrition according to the randomization.”
Postoperatively: Quote: “For a minimum of 7 days and a maximum of 15 days after
surgery, all patients received enteral nutrition according to randomization”
Use of additional interventions: “Antibiotic prophylaxis was allowed for 24 h following
the surgery, according to the guidelines published in 1998.”
Randomly allocated to 3 groups: a) perioperative formula of Impact without immune
nutrients, named “reference diet” (group A, control); b) preoperative Impact and “refer-
ence diet” postoperatively (group B); c) Impact perioperatively (group C)
Outcomes Primary outcome:
Infectious complications
Quote: “The primary outcome event was defined as any patient with a systemic in-
fection requiring antibiotic treatment (septicaemia, bacteraemia), surgical site infection
(according to CDC Definitions of Nosocomial Surgical Site infections), documented
nosocomial pneumopathy, up to the 30th post-operative day. It was named ’infectious
complications’ (IC).”
Secondary outcomes:
Surgical site infections and length of hospital stay
Quote: “Secondary outcome measures included: surgical site infections (SSI) (primary
surgical site, neck wound, free-flap or split skin graft donor site, and tracheotomy) and
length of hospital stay (LOS) defined as the time from surgery to the date when the
patient was deemed medically fit for discharge.”
Funding sources Quote: “Nestlé Health Science, Switzerland kindly supplied Impact and the formula of
Impact without immune nutrients. The study was supported by grants from the French
National Cancer Institute (Hospital Clinical Research Program 2006).”
Declarations of interest Quote: “PB has perceived honoraria from Nestlé as member of the scientific board of
the journal Nutrizoom until December 2012.”
Notes Participants lost to follow-up: extra data obtained to enable intention-to-treat analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was centralized
and carried out by the CS RANDOM-
IZATION module from Clinsight soft-
ware. The stratification consisted of search-
ing with an algorithm, for the less-often
allocated treatment code among patients
whose randomisation criteria matched the
ongoing patient.”
Allocation concealment (selection bias) Low risk Quote: “To ensure the blinding of study
personnel, the allocation of patients to trial
groups was carried out independently by
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the Pharmacy Clinical trials Units using
randomisation lists.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double-blinding with adequate
labels was used to minimize bias with bed-
side physicians and nurses.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Double-blinding with adequate
labels was used to minimize bias with bed-
side physicians and nurses.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Manuscript did not present an ITT analy-
sis, but additional data obtained from au-
thors to enable ITT analysis to be con-
ducted
Selective reporting (reporting bias) Low risk Rate of infectious complications stated
as a primary outcome in the pro-
tocol (see: https://clinicaltrials.gov/show/
NCT00765440) and presented in the
manuscript. No secondary outcomes spec-
ified in protocol
Other bias High risk Quote: “The recruitment was discontinued
in April 2011 before reaching the calcu-
lated sample size. The rate was too low to
enable study completion in the scheduled
time frame and with the funding received.
”
Azman 2015
Methods Design: non-blinded, parallel-group randomised controlled trial with 4 weeks duration
of treatment and 4 weeks duration of follow-up
Participants Setting: Department of Otorhinolaryngology and Oral and Maxillofacial Surgery, Uni-
versiti Kebangsaan Malaysia Medical Centre, between January 2011 and June 2012
Sample size:
• Number randomised: 46
• Number completed: 44
Quote: “One patient (control group) had to be excluded from the study as the patient
died during the study period, and the other requested to be withdrawn from the study.”
Additional information was provided on the latter patient within the discussion section
of the manuscript. Quote: “Only 1 patient had persistent diarrhea and abdominal dis-
comfort after supplementation, hence, requested to be discontinued from supplements.
The abdominal side effects resolved completely after a day of discontinuation from treat-
ment and this patient was excluded from the study.”
Participant (baseline) characteristics:
• Age: median age 49 years (range 22 to 74)
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• Gender: 24 male, 20 female
• Race: 26 were Malays (59.1%), 14 were Chinese (31.8%) and 4 were Indians (9.
1%)
• Baseline differences/other characteristics: no differences in baseline
demographics
Inclusion criteria:Quote: “Patients diagnosed as having any head and neck malignancy
being scheduled for surgery to address primary tumor site or nodal disease (clinical
staging of tumor based on American Joint Committee on Cancer staging T1-4, N0-3,
and M0). Patients age 20 to 75 years old.”
Exclusion criteria:Quote: “Those contraindicated to enteral nutrition (maldigestion or
malabsorption, such as in gut, atonia, ileus). Severe liver (serum bilirubin > 30 mmol/
L or serum alanine transaminase > 100 IU/L or serum alkaline phosphatase > 200 IU/
L) or renal insufficiency (serum urea > 20 mmol/L, serum creatinine > 300 mmol/L, or
urine output < 500 mL/day). Severe malnutrition not amendable to enteral nutritional
optimization (patients who cannot swallow at all and refuse any form of enteral feeding
via Ryle’s tube, gastrostomy, and jejunostomy tubes with fat-free mass < 14.6 kg/m² in
men or < 11.4 kg/m² in women or serum albumin of < 15 g/dL). Severe cancer cachexia
or sarcopenia (fat-free mass < 14.6 kg/m² in men or < 11.4 kg/m² in women or serum
albumin of < 15 g/ dL). Patients with inborn errors of metabolism of nutrients contained
in Glutamine Plus. Patients with head and neck malignancy going for chemoradiother-
apy, including patients who are irradiated while on glutamine supplementation. Patients
with head and neck malignancy who had any form of concurrent treatment protocols
(hormonal, alternative, antiviral, or photodynamic therapy) during the study duration.”
Interventions Intervention group:
Glutamine Plus (Fresenius Kabi, Bad Homburg, Germany), 10 g 3 times a day for 4
weeks post surgery (n = 22)
Comparator group:
No supplement (n = 22)
Patients in both groups received protein/calorie optimisation from dietary modifications
as well as nutritional supplements
Outcomes Primary and secondary outcomes:
Primary and secondary outcomes not separated out
Quote: “At the first visit, which was before surgery, demographic data, fat-free mass
measurement using body impedance analysis, quality of life score, serum albumin mea-
surement, and daily caloric intake (via 24-hour dietary recall) were assessed. At the end
of 4-week duration, which corresponded to 4 weeks postsurgery, the investigator assessed
the patients recruited to both groups with regard to 24-hour dietary recall, quality of life
scores, serum albumin, and body composition analysis.”
NB: data included: age, sex, race, cancer type, staging, surgical procedures performed,
height, weight and liver function (assessed at baseline and 4 weeks)
Funding sources Quote: “Contract grant sponsor: Universiti Kebangsaan Malaysia Fundamental Grant”
Declarations of interest None declared
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Notes Participants lost to follow-up:Quote: “One patient (control group) had to be excluded
from the study as the patient died during the study period, and the other requested to
be withdrawn from the study.” (The latter patient was from the intervention group and
was due to diarrhoea)
Other:
• Overall compliance was 94.4%
• Quote: “The sample size calculation for this interventional study was performed
using Power and Sample Size (PS3) software (2009) by Dupont and Plummer from
Vanderbilt University. The method used was the formula for prospective studies with
dichotomous outcome and analyzed by t tests. Forty-four patients with 22 patients
from the interventional population were needed to make the study statistically
significant with 95% confidence intervals to detect significant differences between the
control and interventional groups.”
• Quote: “Patients in both groups received protein calorie optimization from
dietary modifications as well as nutritional supplements, such as Nutren Optimum
(Nestle, South Africa), Glucerna (Abbott Laboratories, United States), and Myotein
(Pharm-D, Malaysia), where applicable.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Themethodof randomizationwas
random ballot picking of sealed envelopes
that were assigned numbers from 1 to 44.
Odd numbers meant recruitment into the
control group and even numbers meant re-
cruitment into the interventional group.”
Allocation concealment (selection bias) Unclear risk Sealed envelopes used (but not known if
these were opaque)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “No blinding was used”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “No blinding was used”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated whether any dropouts occurred
and unclear how many data points are in-
cluded in each figure
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None
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Methods Design: parallel-group randomised controlled trial (not stated if blinded) with 14 days
pre- and 14 days postoperative duration of treatment and 14 days duration of follow-up
Participants Setting: author affiliations: Department of Head andNeck Surgery, Aichi Cancer Center
Hospital, Nagoya, Aichi, and Department of Otorhinolaryngology, Head and Neck
Surgery, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa,
Japan
Sample size:
• Number randomised: 28
• Number completed: 27
Participant (baseline) characteristics:
• Age: average age was 61.5 (range 45 to 77) years in the intervention group and
66.1 (range 47 to 76) years in the comparator group
• Gender: 16 male (8 per treatment group), 11 female (5 in the intervention group
and 6 in the comparator group)
• Baseline differences/other characteristics: Quote: “There were no significant
differences in the background factors of the patients in the two arms”. Authors also
quoted “Seven of the 13 patients in the experimental arm and 8 of the 14 patients in
the control arm received preoperative chemotherapy.”
Inclusion criteria: Quote: “patients undergoing head and neck cancer surgery who
required resection and free flap reconstruction and who exhibited ≥ 5% weight loss”.
Quote: “Eligibility criteria: (1) histopathologically diagnosed head and neck squamous
cell carcinoma, (2) indication for free flap reconstruction, (3) the subject intended to
participate in this test and provided their written consent, (4) the age at the time of
registration was 20-80 years, (5) an ECOG performance status of 0-2, (6) ≥ 5% weight
loss within the past 6 months, (7) life expectancy≥6 months and (8) the patient’s major
organ function was maintained.”
Exclusion criteria: Quote: “Patients who met any of the following exclusion criteria
were excluded from the study: (1) intestinal occlusion and serious enterostenosis (enteral
feeding intolerance), (2) combined resection of other organs, (3) obvious focal infection
before surgery, (4) serious heart, liver or kidney disease, (5) uncontrolled diabetes, (6) re-
fractory hyperlipemia, (7) a past history of chronic inflammatory disease, (8) continuous
or general administration (oral or intravenous) of steroids, (9) subjects taking EPA, (10)
a past history of anaphylaxis against components of Prosure® (e.g. milk and soybean)
, (11) patients who are pregnant, lactating or possibly pregnant and (12) patients who
were deemed ineligible for other reasons by the principal investigator of the test.”
Interventions Intervention group: Prosure® (an eicosapentaenoic acid (EPA)-enriched oral nutri-
tional supplement) was administered at a dose of 2 packs/day (480 mL) during the 28-
day intervention period (14 days before surgery and 14 days after surgery) in addition
to a normal diet (or in lieu of part of a normal diet) (n = 14, but 13 analysed)
Comparator group: no intervention (n = 14)
Use of additional interventions: none stated
Outcomes Primary outcome:
Postoperative nutritional status (weight, lean body mass, albumin, prealbumin)
Secondary outcomes:
Inflammatory marker levels (CRP, IL6, white blood cell count, body temperature), com-
pliance with the Prosure® dosage and the occurrence of postoperative complications
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Hanai 2018 (Continued)
Funding sources None declared
Declarations of interest None declared
Notes Participants lost to follow-up:Quote: “For the intent-to-treat analysis, the object of the
analysis included the registered subjects in each arm.” NB: according to the CONSORT
diagram in the manuscript, one person in the intervention group was, quote: “Excluded
due to incomplete data”, to give a sample size for analysis of 13
Other: Quote: “nine subjects in each arm would be required to detect a statistically
significant difference by Student’s t-test [α = 0.1 (bilateral), 1 − β = 0.8].”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No statement on the generation of the ran-
dom sequence
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No statement on blinding, but we pre-
sumed non-blinded as the intervention
group received sachets and the control
group received no intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding or who outcome
assessors were
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence from the published data
Quote: “For the intent-to-treat analysis, the
object of the analysis included the regis-
tered subjects in each arm”
NB: 1 patient randomised to the interven-
tion group was, quote: “Excluded due to
incomplete data”
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk No evidence from the published data
AA: (EPA+DHA)/arachidonic acid ratio
ASEPSIS: Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissues, Isolation of bacteria, Stay
duration as inpatient
COOP-WONCA:Dartmouth-NorthernNewEnglandPrimaryCareCooperative InformationProject-WorldOrganizationofNational
Colleges, Academies and Academic Associations of general Practitioners
CRP: C-reactive protein
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DHA: docosahexaenoic acid
ENT: ear, nose and throat
EORTC: European Organisation for Research and Treatment of Cancer
EPA: eicosapentaenoic acid
ICU: intensive care unit
IQR: interquartile range
IL-10: interleukin 10
ITT: intention-to-treat
i.v.: intravenous
NG: nasogastric
PEG: percutaneous endoscopic gastrostomy
POD: postoperative day
QOL: quality of life
RNA: ribonucleic acid
SD: standard deviation
STD: standard group
TLC: total lymphocyte count
Characteristics of excluded studies [ordered by year of study]
Study Reason for exclusion
Linn 1988 Allocation: not randomised
De Luis 2005a Allocation: randomised
Participants: post hospital discharge after head and neck surgery
Interventions: immunonutrition only (no standard diet comparison)
Buijs 2010 Allocation: randomised
Participants: head and neck cancer patients who were malnourished
Interventions: standard feed or standard feed plus immunonutrition perioperatively
Outcomes: patients and outcome data included in another trial
De Luis 2010 Allocation: randomised
Participants: head and neck cancer patients
Interventions: 2 doses of arginine (high and medium)
De Luis 2013 Allocation: not randomised
De Luis 2015 Allocation: randomised
Participants: head and neck cancer patients
Interventions: 3 different doses of arginine (low, medium, high) but no standard polymeric feed as a comparison
Palma-Milla 2016 Allocation: randomised
Participants: head and neck cancer patients
Interventions: “new immunomodulatory formula or that commonly used in clinical practice” (i.e. both groups
received immunonutrition)
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(Continued)
Reis 2016 Allocation: not randomised (systematic review - not head and neck cancer patients)
Characteristics of ongoing studies [ordered by study ID]
NCT03261180
Trial name or title ’Nestle Impact Advanced Recovery in improving surgery recovery in patients with head and neck cancer
(official title “Perioperative nutritional optimization in head and neck cancer patients”)
Methods Non-blinded, parallel-group randomised controlled trial with 5 days pre- and 5 days postoperative duration
of treatment and 30 days duration of follow-up
Participants Sample size: 330 participants
Inclusion criteria:
Quote:
• “Members of all races and ethnic groups will be included
• Patients must be diagnosed with cancer of the head and neck and must be surgical candidates
• Patients must be indicated for major head and neck surgery, defined as surgeries with an anticipated
post-surgical hospital stay of 4 or more days; examples of major surgeries include, but are not limited to,
total laryngectomy, large oral cavity, oropharyngeal, salivary gland, or soft tissue resections requiring free
flap or major regional flap (e.g. pectoralis major flap), and large skull base procedures requiring extensive
skull base reconstruction
• Patients must have cross-sectional body imaging (positron emission tomography [PET]-computed
tomography [CT] or equivalent) performed within 4 weeks of study enrollment and available for review
• Patient must be willing to receive Nestle IMPACT Advance Recovery for five days prior to planned
surgery as well as for 5 days after surgery
• Ability to understand and the willingness to sign a written informed consent document”
Exclusion criteria:
Quote:
• “Patients with known distant metastases or other malignancies
• Patients unable to tolerate oral intake by mouth or per enteral feeding tube
• Patients with galactosemia
• Patients who have received any investigational medication within 6 weeks of enrollment, or who are
scheduled to receive an investigational drug during the course of the study
• Patients currently taking IMPACT or other immunonutrition products (arginine-containing
supplements) will be excluded; other forms of nutritional supplementation, such as caloric
supplementation, tube feeding, or other dietary supplements are allowed on study
• Patients currently taking anabolic steroids will be excluded; patients taking corticosteroids are allowed
on study
• Psychiatric illness/social situations that would limit compliance with study requirements
• Excluded patients will be allowed to participate in the trial on an observational basis only”
Interventions Intervention group: Nestlé Impact AR (Group I). Patients receive Nestlé Impact AR for 5 days before and
after surgery in addition to regular diet
Comparator group: regular diet (Group II). Patients receive regular diet.
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NCT03261180 (Continued)
Outcomes Primary outcome:
Quote: “Primary: Rate of post-operative wound complications” (within 30 days after major head and neck
surgery)
Secondary outcomes:
Rate of other postoperative complications (within 30 days after surgery) and sarcopenia (within 30 days after
major head and neck surgery)
Other:
Sarcopenia-related gene expression (up to 30 days post-surgery)
Starting date Estimated: 30 April 2018
Contact information Daniel R. Clayburgh (503-494-5355), OHSU Knight Cancer Institute
Notes Study not yet recruiting (https://clinicaltrials.gov/ct2/show/NCT03261180 accessed 9 May 2018)
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D A T A A N D A N A L Y S E S
Comparison 1. Immunonutrition versus standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Postoperative length of hospital
stay
10 757 Mean Difference (IV, Random, 95% CI) -2.50 [-5.11, 0.12]
1.1 Pre-operative and
postoperative feeding
4 403 Mean Difference (IV, Random, 95% CI) -0.30 [-2.82, 2.21]
1.2 Postoperative feeding only 6 354 Mean Difference (IV, Random, 95% CI) -4.47 [-8.46, -0.48]
2 Wound infection 12 812 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.70, 1.26]
2.1 Pre-operative and
postoperative feeding
6 458 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.72, 1.33]
2.2 Postoperative feeding only 6 354 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.19, 1.59]
3 Fistula formation 10 747 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.27, 0.85]
3.1 Pre-operative and
postoperative feeding
4 393 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.33, 1.62]
3.2 Postoperative feeding only 6 354 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.14, 0.71]
4 Adverse events 9 719 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.86, 2.06]
4.1 Pre-operative and
postoperative feeding
2 325 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.30, 2.50]
4.2 Postoperative feeding only 7 394 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.82, 2.46]
5 All-cause mortality 14 776 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.48, 3.66]
5.1 Pre-operative and
postoperative feeding
6 357 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.28, 4.60]
5.2 Postoperative feeding only 8 419 Risk Ratio (M-H, Random, 95% CI) 1.57 [0.29, 8.53]
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Analysis 1.1. Comparison 1 Immunonutrition versus standard care, Outcome 1 Postoperative length of
hospital stay.
Review: Immunonutrition for patients undergoing surgery for head and neck cancer
Comparison: 1 Immunonutrition versus standard care
Outcome: 1 Postoperative length of hospital stay
Study or subgroup Immunonutrition Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD)[days] N Mean(SD)[days] IV,Random,95% CI IV,Random,95% CI
1 Pre-operative and postoperative feeding
Snyderman 1999 82 15.3 (9.1) 47 17.4 (11.9) 20.1 % -2.10 [ -6.03, 1.83 ]
Ghosh 2012 28 31.1 (20.52) 29 35.3 (32.61) 3.1 % -4.20 [ -18.29, 9.89 ]
Turnock 2013 4 18 (16.7) 4 18.5 (7.7) 2.0 % -0.50 [ -18.52, 17.52 ]
Falewee 2014 105 23.6 (13.7) 104 22.3 (11.5) 22.6 % 1.30 [ -2.13, 4.73 ]
Subtotal (95% CI) 219 184 47.8 % -0.30 [ -2.82, 2.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.94, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Postoperative feeding only
Riso 2000 23 25 (11.6) 21 28 (12.6) 9.8 % -3.00 [ -10.18, 4.18 ]
De Luis 2002 23 22.8 (11.5) 24 31.2 (19.1) 6.9 % -8.40 [ -17.37, 0.57 ]
De Luis 2004 45 25.8 (15) 45 35 (24.6) 7.6 % -9.20 [ -17.62, -0.78 ]
De Luis 2007 35 27.9 (21) 37 28.2 (12) 8.4 % -0.30 [ -8.26, 7.66 ]
Casas-Rodera 2008 14 18.57 (7.75) 15 18.27 (7.51) 13.8 % 0.30 [ -5.26, 5.86 ]
De Luis 2009 38 24.3 (14) 34 36.1 (27) 5.7 % -11.80 [ -21.91, -1.69 ]
Subtotal (95% CI) 178 176 52.2 % -4.47 [ -8.46, -0.48 ]
Heterogeneity: Tau2 = 8.96; Chi2 = 7.87, df = 5 (P = 0.16); I2 =36%
Test for overall effect: Z = 2.19 (P = 0.028)
Total (95% CI) 397 360 100.0 % -2.50 [ -5.11, 0.12 ]
Heterogeneity: Tau2 = 4.82; Chi2 = 12.89, df = 9 (P = 0.17); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 2.99, df = 1 (P = 0.08), I2 =67%
-20 -10 0 10 20
Favours immunonutrition Favours standard care
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Analysis 1.2. Comparison 1 Immunonutrition versus standard care, Outcome 2 Wound infection.
Review: Immunonutrition for patients undergoing surgery for head and neck cancer
Comparison: 1 Immunonutrition versus standard care
Outcome: 2 Wound infection
Study or subgroup Immunonutrition Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pre-operative and postoperative feeding
Falewee 2014 23/105 28/104 38.0 % 0.81 [ 0.50, 1.32 ]
Felekis 2010 1/20 0/20 0.9 % 3.00 [ 0.13, 69.52 ]
Ghosh 2012 17/28 17/29 48.1 % 1.04 [ 0.68, 1.59 ]
Snyderman 1999 4/82 2/47 3.2 % 1.15 [ 0.22, 6.02 ]
Sorensen 2009 2/8 0/7 1.1 % 4.44 [ 0.25, 79.42 ]
Turnock 2013 1/4 0/4 1.0 % 3.00 [ 0.16, 57.36 ]
Subtotal (95% CI) 247 211 92.2 % 0.98 [ 0.72, 1.33 ]
Total events: 48 (Immunonutrition), 47 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.78, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Postoperative feeding only
Casas-Rodera 2008 1/14 2/15 1.7 % 0.54 [ 0.05, 5.28 ]
De Luis 2002 1/23 3/24 1.8 % 0.35 [ 0.04, 3.11 ]
De Luis 2004 0/45 0/45 Not estimable
De Luis 2007 0/35 0/37 Not estimable
De Luis 2009 1/38 1/34 1.2 % 0.89 [ 0.06, 13.76 ]
Riso 2000 2/23 3/21 3.1 % 0.61 [ 0.11, 3.29 ]
Subtotal (95% CI) 178 176 7.8 % 0.55 [ 0.19, 1.59 ]
Total events: 5 (Immunonutrition), 9 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 425 387 100.0 % 0.94 [ 0.70, 1.26 ]
Total events: 53 (Immunonutrition), 56 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.12, df = 9 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Chi2 = 1.04, df = 1 (P = 0.31), I2 =4%
0.001 0.01 0.1 1 10 100 1000
Favours immunonutrition Favours standard care
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Analysis 1.3. Comparison 1 Immunonutrition versus standard care, Outcome 3 Fistula formation.
Review: Immunonutrition for patients undergoing surgery for head and neck cancer
Comparison: 1 Immunonutrition versus standard care
Outcome: 3 Fistula formation
Study or subgroup Immunonutrition Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pre-operative and postoperative feeding
Snyderman 1999 4/82 1/47 7.0 % 2.29 [ 0.26, 19.92 ]
Sorensen 2009 0/8 2/7 3.9 % 0.18 [ 0.01, 3.18 ]
Felekis 2010 0/20 2/20 3.7 % 0.20 [ 0.01, 3.92 ]
Falewee 2014 7/105 9/104 36.1 % 0.77 [ 0.30, 1.99 ]
Subtotal (95% CI) 215 178 50.7 % 0.72 [ 0.33, 1.62 ]
Total events: 11 (Immunonutrition), 14 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.74, df = 3 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
2 Postoperative feeding only
Riso 2000 1/23 1/21 4.4 % 0.91 [ 0.06, 13.69 ]
De Luis 2002 0/23 5/24 4.0 % 0.09 [ 0.01, 1.62 ]
De Luis 2004 2/45 5/45 12.9 % 0.40 [ 0.08, 1.96 ]
De Luis 2007 1/35 7/37 7.8 % 0.15 [ 0.02, 1.17 ]
Casas-Rodera 2008 1/14 2/15 6.2 % 0.54 [ 0.05, 5.28 ]
De Luis 2009 2/38 6/34 13.9 % 0.30 [ 0.06, 1.38 ]
Subtotal (95% CI) 178 176 49.3 % 0.31 [ 0.14, 0.71 ]
Total events: 7 (Immunonutrition), 26 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.15, df = 5 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0052)
Total (95% CI) 393 354 100.0 % 0.48 [ 0.27, 0.85 ]
Total events: 18 (Immunonutrition), 40 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.99, df = 9 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 2.07, df = 1 (P = 0.15), I2 =52%
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.4. Comparison 1 Immunonutrition versus standard care, Outcome 4 Adverse events.
Review: Immunonutrition for patients undergoing surgery for head and neck cancer
Comparison: 1 Immunonutrition versus standard care
Outcome: 4 Adverse events
Study or subgroup Immunonutrition Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pre-operative and postoperative feeding
Falewee 2014 1/99 2/97 3.3 % 0.49 [ 0.05, 5.31 ]
Snyderman 1999 7/82 4/47 13.6 % 1.00 [ 0.31, 3.25 ]
Subtotal (95% CI) 181 144 16.9 % 0.87 [ 0.30, 2.50 ]
Total events: 8 (Immunonutrition), 6 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
2 Postoperative feeding only
Casas-Rodera 2008 1/14 1/15 2.7 % 1.07 [ 0.07, 15.54 ]
De Luis 2002 4/23 2/24 7.4 % 2.09 [ 0.42, 10.32 ]
De Luis 2004 18/45 6/45 27.0 % 3.00 [ 1.31, 6.86 ]
De Luis 2007 8/35 8/37 24.7 % 1.06 [ 0.45, 2.51 ]
De Luis 2009 3/38 2/34 6.3 % 1.34 [ 0.24, 7.56 ]
Felekis 2010 0/20 0/20 Not estimable
Riso 2000 4/23 6/21 15.0 % 0.61 [ 0.20, 1.86 ]
Subtotal (95% CI) 198 196 83.1 % 1.42 [ 0.82, 2.46 ]
Total events: 38 (Immunonutrition), 25 (Standard care)
Heterogeneity: Tau2 = 0.08; Chi2 = 6.08, df = 5 (P = 0.30); I2 =18%
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 379 340 100.0 % 1.33 [ 0.86, 2.06 ]
Total events: 46 (Immunonutrition), 31 (Standard care)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.11, df = 7 (P = 0.42); I2 =2%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 0.66, df = 1 (P = 0.42), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours immunonutrition Favours standard care
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Analysis 1.5. Comparison 1 Immunonutrition versus standard care, Outcome 5 All-cause mortality.
Review: Immunonutrition for patients undergoing surgery for head and neck cancer
Comparison: 1 Immunonutrition versus standard care
Outcome: 5 All-cause mortality
Study or subgroup Immunonutrition Standard care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pre-operative and postoperative feeding
Van Bokhorst 2000/2001 2/17 1/15 19.5 % 1.76 [ 0.18, 17.56 ]
Felekis 2005 0/20 1/17 10.5 % 0.29 [ 0.01, 6.59 ]
Sorensen 2009 0/8 0/7 Not estimable
Ghosh 2012 4/28 1/29 22.8 % 4.14 [ 0.49, 34.82 ]
Turnock 2013 0/3 0/4 Not estimable
Falewee 2014 0/105 2/104 11.3 % 0.20 [ 0.01, 4.08 ]
Subtotal (95% CI) 181 176 64.1 % 1.13 [ 0.28, 4.60 ]
Total events: 6 (Immunonutrition), 5 (Standard care)
Heterogeneity: Tau2 = 0.34; Chi2 = 3.59, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.17 (P = 0.86)
2 Postoperative feeding only
Riso 2000 0/23 0/21 Not estimable
De Luis 2002 3/23 2/24 35.9 % 1.57 [ 0.29, 8.53 ]
De Luis 2003 0/18 0/18 Not estimable
De Luis 2004 0/45 0/45 Not estimable
De Luis 2005 0/14 0/15 Not estimable
De Luis 2007 0/37 0/35 Not estimable
Casas-Rodera 2008 0/14 0/15 Not estimable
De Luis 2009 0/38 0/34 Not estimable
Subtotal (95% CI) 212 207 35.9 % 1.57 [ 0.29, 8.53 ]
Total events: 3 (Immunonutrition), 2 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 393 383 100.0 % 1.33 [ 0.48, 3.66 ]
Total events: 9 (Immunonutrition), 7 (Standard care)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.66, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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A D D I T I O N A L T A B L E S
Table 1. Interventions
Duration of supplements
Study Groups Control Active Isocaloric/
isonitroge-
nous
Target en-
ergy intake
Pre-
operation
Post-
operation
Length of
follow-up
Snyderman
1999
1.
Active pre-
and postop-
erative
2. Ac-
tive postop-
erative only
3.
Control pre-
and postop-
erative
4. Con-
trol postop-
erative only
Polymeric
(Replete,
Resource,
Isosource,
Jevity,
Vivonex,
Osmolite)
Polymeric +
arginine
(Impact)
Not stated 500 mL per
day pre-op-
eration (500
kcal)
1000 mL
per day post-
operation
(1000 kcal)
≥ 5 days ≥ 7 days 1
month post-
operation
Riso 2000 1. Active
postopera-
tive enteral
2. Control
postopera-
tive enteral
Both groups
received par-
enteral nu-
trition for 3
days postop-
eratively to
achieve nu-
tritional
goal
Polymeric
(Nutri-
son protein
plus)
Poly-
meric + argi-
nine (Nutri-
son
intensive)
Yes 31 kcal/kg
per day by
POD4
None ≥ 10 follow-
ing total la-
ryn-
gectomy, ≥
21 days fol-
lowing par-
tial laryn-
gectomy
To hospital
discharge
Van
Bokhorst
2000/2001
1. No pre-
operative
nutritional
support
+ postopera-
tive standard
formula
2. Pre-oper-
ative
+ postopera-
tive standard
Polymeric Polymeric +
arginine
(“41% of ca-
sein proteins
were
replaced by
arginine”)
Yes 150%
of basal re-
quirement
7 to 10 days ≥ 10 days 7 days post-
op-
eration and
greater than
or equal to
16 months
(survival)
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Table 1. Interventions (Continued)
formula
3. Argi-
nine supple-
mented pre-
and postop-
erative
De Luis
2002
1. Postoper-
ative supple-
ment with
arginine + fi-
bre
2. Postop-
erative poly-
meric con-
trol
Polymeric Poly-
meric + argi-
nine (0.625
g/100 mL)
+ fibre (0.
9 g/100 mL)
(NB control
and active
formulas
contained
the same ra-
tio of ω6:ω3
fats)
Yes 32 kcal/kg
per day by
POD4
None Average
duration 22
days (± 12
days) across
groups
14 days
postopera-
tively, and 3
months post
hospi-
tal discharge
(mortality)
De Luis
2003
1. Postoper-
ative en-
teral supple-
ment with
arginine + fi-
bre
2. Postop-
erative poly-
meric con-
trol
Polymeric Poly-
meric + argi-
nine (0.625
g/100 mL)
+ fibre (0.
9 g/100 mL)
(NB control
and active
formulas
contained
the same ra-
tio of ω6:ω3
fats)
Yes 32 kcal/kg
per day by
POD4
None Average du-
ra-
tion 20 days
in group 1
5 days post-
operation
De Luis
2004
1. Postop-
erative poly-
meric + argi-
nine + fibre
2. Postop-
erative poly-
meric con-
trol + fibre
Polymeric +
fibre (0.9 g/
100 mL)
Poly-
meric + argi-
nine (0.625
g/100 mL)
+ fibre (0.
9 g/100 mL)
(NB control
and active
formulas
contained
the same ra-
tio of ω6:ω3
fats)
Yes 32 kcal/kg
per day by
POD4
None ≥ 10 days Day 14
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Table 1. Interventions (Continued)
De Luis
2005
1. Postop-
erative poly-
meric + argi-
nine
2. Postop-
erative poly-
meric con-
trol
Polymeric +
fibre (0.9 g/
100 mL)
Polymeric +
arginine
(12.5 g/day)
+ fibre (0.9
g/100 mL)
Yes Not stated None Average du-
ra-
tion 20 days
in group 1
6 days post-
operation
Felekis 2005 1.
Active pre-
and postop-
erative
2. Regular
oral diet and
standard
polymeric
enteral feed-
ing pre- and
postopera-
tively
Polymeric Unde-
fined enteral
immunonu-
trition
Yes Not stated 6 days 8 days Not stated
De Luis
2007
1. Postop-
erative poly-
meric + argi-
nine
2. Postop-
erative poly-
meric con-
trol
Polymeric +
fibre (0.9 g/
100 mL)
Polymeric +
arginine (0.
85
g/100 mL)
+ fibre (0.
9 g/100 mL)
(NB control
and active
formulas
contained
the same ra-
tio of ω6:ω3
fats)
Yes 32 kcal/kg
per day by
POD4
None ≥ 10 days 12 days
post-
operation
Casas-
Rodera
2008
1. Postoper-
ative
arginine en-
hanced for-
mula
2. Polymeric
control
3. Postoper-
ative
arginine en-
hanced for-
mula RNA
and omega-
Group 2
polymeric
Group 1
arginine-en-
hanced for-
mula (NB
data from
Group 1 not
used in anal-
yses)
Group 3
arginine (1.
3 g/100 mL)
, RNA (0.12
No (control
122 kcal/
100 mL, ac-
tive 101
kcal/100
mL)
Require-
ments (used
Harris Bene-
dict formula
with a stress
factor cor-
rection of 1.
4) by POD3
None Average du-
ration of 14.
5 ± 8 days
14 days
post-surgery
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Table 1. Interventions (Continued)
3 fatty acids g/100
mL) and ra-
tio of ω6:ω3
fats noted as
“0.7 g”
De Luis
2009
1. Ac-
tive postop-
erative (argi-
nine) + fibre
2. Control
postoper-
ative (stan-
dard enteral
nutrition)
Polymeric Polymeric +
arginine (0.
85
g/100 mL)
+ fibre (0.
9 g/100 mL)
(NB control
and active
formulas
contained
the same ra-
tio of ω6:ω3
fats)
Yes 32
kcal/kg; 1.7
g protein/kg
on POD4
None ≥ 10 days 10 days
post-
operation
Sorensen
2009
1.
Active pre-
and postop-
erative (argi-
nine, glu-
tamine, nu-
cleotides
and omega-
3 enriched)
2. Con-
trol pre- and
postoper-
ative (stan-
dard enteral
nutrition)
Isosource Polymeric +
arginine and
glu-
tamine (Im-
pact Recover
(oral drink,
contain-
ing 16.3 g
arginine, 20
g glutamine,
1.6 g nu-
cleotides,
and 1.7 gω3
fatty acids/
L) or Impact
glutamine
(tube feed,
contain-
ing 16.3 g
arginine, 15
g glutamine,
1.6 g nu-
cleotides
and 2.7 gω3
fatty acids/
L))
No (Impact
Recover =
960 kcal/L;
Impact glu-
tamine
= 1300 kcal/
L; Isosource
= 1440 kcal/
L)
~1 L per day
pre-op-
eratively, at
least 1 L per
day postop-
eratively
(~50% to
60% of basal
require-
ments from
interven-
tion)
7 days 7 days 29 days
post-
operation
Felekis 2010 1.
Control pre-
Poly-
meric (Nu-
Polymeric +
ω3 fatty
Yes Require-
ment (based
5 days 8 days 8 days post-
operation
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Table 1. Interventions (Continued)
and postop-
erative
2.
Active pre-
and postop-
erative
trison, Nu-
tricia)
acids, argi-
nine, RNA
(Impact,
Novartis)
on Harris
and
Benedict
equations)
by POD4
Ghosh 2012 1.
Control pre-
and postop-
erative
2.
Active pre-
and postop-
erative
Polymeric Polymeric +
ω3 fatty
acids (1.7 g/
L), arginine
(1.25 g/L),
RNA (1.2 g/
L) (Impact)
Yes Nutritional
require-
ments based
on Schofield
calculation,
500 mL/day
pre-oper-
atively, 1000
mL/
day postop-
eratively
(also al-
lowed to eat
and drink if
able).
Any calorific
shortfall was
made up us-
ing standard
proprietary
feeds
5 days 7 days 30 days
post-
operation
Turnock
2013
1. Control -
no supple-
ments pre-
operation,
postopera-
tive standard
supplements
2. Active
- pre- (oral)
and postop-
era-
tive (enteral
then oral to
day 5) sup-
plements
Isosource
standard
(postopera-
tive only)
Poly-
meric + ω3
fatty acids
(3.3 and 1.7
g/L EPA and
DHA for
oral and en-
teral prod-
ucts, respec-
tively), argi-
nine (12.
6 and 12.5
g/L for oral
and enteral
prod-
ucts), RNA
(1.3 and 1.2
g/L for oral
and enteral
products)
(Impact)
No (oral/en-
teral Impact
1000 kcal/L;
Isosource
standard
1200 kcal/
L)
Require-
ments (25 to
30 kcal/kg)
5 days ≥ 5 days Hospital
discharge
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Table 1. Interventions (Continued)
De Luis
2014
1.
Active post-
operative
2. Con-
trol postop-
erative
Polymeric Polymeric +
arginine
(8 g/L, 20
g/day) (NB
control and
active for-
mulas con-
tained
the same ra-
tio of ω6:ω3
fats and the
same
amount
of fibre 13.8
g/L)
No (control
1.118 kcal/
L, active 1.
020 kcal/L)
Require-
ments
(35 kcal/kg,
1.7 g pro-
tein/kg)
None Minimal of
15 days
10 days
post-surgery
Falewee
2014
1. Pre- and
postopera-
tive control
2. Pre-
operative ac-
tive, postop-
erative con-
trol
3. Pre- and
postopera-
tive active
Im-
pact without
immunonu-
trients
Polymeric +
ω3 fatty
acids (1.0 g
per
sachet (oral)
and 1.65 g/
500 mL (en-
teral)), argi-
nine (3.8 g
per
sachet (oral)
and 6.5 g/
500 mL (en-
teral)), RNA
(0.45 g per
sachet (oral)
and 0.65 g/
500 mL (en-
teral)) (Oral
Impact pre-
operatively
and Enteral
Impact post-
operatively)
Yes Require-
ments (cal-
culated us-
ing SFNEP
French rec-
ommenda-
tions)
7 days 7 to 15 days 90 days
post-surgery
Azman
2015
1. Postoper-
ative active
2. Postoper-
ative no in-
tervention
None Glutamine
powder (30
g/day) (Glu-
tamine Plus,
Fresenius
Kabi)
No control
intervention
30 to 40
kcal/kg/day
None 4 weeks 4
weeks post-
operation
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Table 1. Interventions (Continued)
Hanai 2018 1. Pre- and
postopera-
tive active
2. Pre-and
post-
operative no
intervention
None Prosure (an
eicosapen-
taenoic acid
(EPA) en-
riched oral
nutritional
supplement)
at a dose of 2
packs
per day (480
mL)
No control
intervention
Prosure was
admin-
istered in ad-
dition to a
normal diet
(or in lieu
of part of a
normal diet)
. Quote:
“The dietary
intake was
not limited”
14 days 14 days 14 days
post-
operation
DHA: docosahexaenoic acid
EPA: eicosapentaenoic acid
POD: postoperative day
RNA: ribonucleic acid
SFNEP: Société Francophone de Nutrition Entérale et Parentérale
Table 2. Baseline patient characteristics
Number Mean age Sex M:F Mean weight (kg) BMI
Study Control Interven-
tion
Control Interven-
tion
Control Interven-
tion
Control Interven-
tion
Control Interven-
tion
Snyder-
man
1999
47 82 61 63 32:15 63:19 67 71 Not
reported
Not
reported
Riso
2000
21 23 63 61 18:3 21:2 66 64 23.2 22.1
Van
Bokhorst
2000/
2001
15 17 60 59 7:8 12:5 55 62 Not
reported
Not
reported
De Luis
2002
24 23 59 63 3:21 2:21 68 68 24.1 26.2
De Luis
2003
18 18 59 63 1:27 1:17 69 69 24.1 26.2
De Luis
2004
45 45 61 60 3:42 3:42 69 70 25.1 25.2
84Immunonutrition for patients undergoing surgery for head and neck cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Baseline patient characteristics (Continued)
De Luis
2005
15 14 63 61 3:12 2:12 Not
reported
Not
reported
24.1 24.6
Felekis
2005
17 20 Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
De Luis
2007
37 35 62 62 3:34 4:31 69 68 25.1 24.0
Casas-
Rodera
2008*
15 14 54 50 15:0 14:0 66 68 Not
reported
Not
reported
De Luis
2009
34 38 61 63 27:7 30:8 71 73 26.4 26.5
Sorensen
2009
7 8 59 62 7:0 8:0 69 71 22.3 22.7
Felekis
2010
20 20 63 61 18:2 18:2 Not
reported
Not
reported
Not
reported
Not
reported
Ghosh
2012**
29 28 60 62 26:3 24:4 65 72 24 26
Turnock
2013
4 4 47 51 3:1 3:1 67 67 Not
reported
Not
reported
De Luis
2014
40 42 63.6 65.5 35:5 37:5 70 72 25.1 25.7
Falewee
2014***
104 105 59 59 86:18 87:18 69 70 23.7 23.6
Azman
2015****
22 22 Not
reported
Not
reported
15:7 9:13 Not
reported
Not
reported
Not
reported
Not
reported
Hanai
2018
14 13 66.1 61.5 8:6 8:5 Not
reported
Not
reported
Not
reported
Not
reported
* Two different values for weight reported in manuscript: data from Table II in manuscript are reported here.
** Data reported in manuscript (and here) as median values for age, weight and body mass index (BMI).
*** Additional data supplied by authors.
**** Median age across both treatment groups was 49 years (range 22 to 74 years). No data by treatment group available.
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Table 3. Methodological quality of trials
Study Generation
of allocation se-
quence
Allocation con-
cealment
Power calcula-
tions
Patients
blinded
Assessors
blinded
Analysed
as intention-to-
treat (ITT)
Snyderman
1999
Tables Not stated Not stated Unclear
which treatment
groups were
blinded
Unclear
which treatment
groups were
blinded
Yes - stated ITT
Riso 2000 Computer-
generated*
Sealed en-
velopes* (not de-
fined as opaque)
Not done* Stated “dou-
ble-blindly per-
formed” but no
indi-
cation as to who
was blinded*
Stated “dou-
ble-blindly per-
formed” but no
indi-
cation as to who
was blinded*
Yes - no attri-
tion according to
number of par-
ticipants
included in anal-
yses
Van Bokhorst
2000/2001
Computer-
generated
Not stated Yes Yes** Yes** Yes - no attri-
tion according to
number of par-
ticipants
included in anal-
yses for relevant
outcomes
De Luis 2002 Tables* Sealed en-
velopes* (not de-
fined as opaque)
Yes Yes Yes Yes - stated “Any
drop-outs were
present in the
study”
De Luis 2003 Tables* Sealed envelopes
(not defined as
opaque)
Yes* Yes Yes Yes - stated ITT
De Luis 2004 Tables* Sealed en-
velopes* (not de-
fined as opaque)
Yes States blinded,
but no indica-
tion as to who
was blinded*
States blinded,
but no indica-
tion as to who
was blinded*
Yes - stated ITT
De Luis 2005 Tables* Sealed envelopes
(not defined as
opaque)
Yes* Stated “Study
was blinded” but
no indi-
cation as to who
was blinded
Stated “Study
was blinded” but
no indi-
cation as to who
was blinded
Yes - stated ITT
Felekis 2005 Not stated Not stated Not stated Not stated Not stated Not stated
De Luis 2007 Tables* En-
velopes* (not de-
fined as opaque)
Yes States blinded,
but no indica-
tion as to who
States blinded,
but no indica-
Yes - stated ITT
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Table 3. Methodological quality of trials (Continued)
was blinded* tion as to who
was blinded*
Casas-Rodera
2008
Stated “ran-
domly allocated”
but no informa-
tion on how se-
quence was gen-
erated
Not stated Not stated Not stated Not stated Yes -
stated “no drop-
outs were present
in the study”
De Luis 2009 Stated “ran-
domly allocated”
but no informa-
tion on how se-
quence was gen-
erated
Not stated Yes Yes Yes Yes - stated ITT
Sorensen 2009 Stated as a “ran-
domized design”
but no informa-
tion on how se-
quence was gen-
erated
En-
velopes (not de-
fined as opaque)
Not done Partial Partial Unclear -
no statement on
dropouts
Felekis 2010 Stated “random-
ization
generator”
Not clear Not done* Stated “double
blinded” but no
indication as to
who was blinded
Stated “double
blinded” but no
indication as to
who was blinded
Yes -
no loss to follow-
up described and
stated
“no dropouts oc-
curred due to in-
tolerance”
Ghosh 2012 “Ran-
domisation lists”
(pharmacy clini-
cal trials unit)
Pharmacy (cen-
tral telephone as-
signment)
Yes Yes Yes Yes - stated ITT
Turnock 2013 Computer-
generated
Opaque, sealed
envelopes
Pilot study No No Yes - no attri-
tion according to
number of par-
ticipants
included in anal-
yses
De Luis 2014 Not stated Not stated Not stated Yes Yes Yes - no attrition
Falewee 2014 Computer-
generated
Pharmacy clini-
cal trials unit
Yes Yes Yes Yes*
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Table 3. Methodological quality of trials (Continued)
Azman 2015 Random ballot
picking
Sealed envelopes
(not defined as
opaque)
Yes No No Yes
Hanai 2018 Not stated Not stated Yes Not stated, but
assumed non-
blinded as in-
tervention group
received sachets
and
control group re-
ceived no inter-
vention
Not stated Yes - stated ITT
(NB: 1 patient,
quote “Excluded
due to incom-
plete data”)
* Additional information provided by authors.
** Groups 2 and 3 included in analyses; authors stated that these groups were blinded.
Table 4. Other complications
Number Other
complica-
tions defi-
nition
Other complications -
total
Pneumonia Urinary tract
Study Control Interven-
tion
Control Interven-
tion
Control Interven-
tion
Control Interven-
tion
Pre- and postoperative feeding
Snyder-
man
1999
47 82 “...in-
fectious
complica-
tions were
judged us-
ing CDC
criteria
and were
considered
significant
if antibi-
otic ther-
apy was
instituted”
(NB: total
for other
complica-
tions pro-
vided here
19 19 - - - -
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Table 4. Other complications (Continued)
include
“postop-
erative
infection”
butnot
“wound
healing
problem”
or “fistula”)
Van
Bokhorst
2000/
2001
15 17 “Postop-
erative
complica-
tions were
categorized
as absent,
minor
(including
minor
wound
infections,
redness
and in-
duration of
the wound,
pulmonary
infections,
and uri-
nary tract
infections)
, or major
(including
wound
infections
requiring
surgical
drainage,
orocuta-
neous or
pharyngo-
cutaneous
fistula, flap
failure,
radiologic
signs of
anasto-
motic
leakage,
7 major 10 major - - - -
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Table 4. Other complications (Continued)
respiratory
insuffi-
ciency,
cardiac
failure,
and septic
shock)
” (NB:
data on
individual
complica-
tions not
given in
manuscript
so the total
for other
compli-
cations
provided
here may
include
fistula and
wound
infection)
Felekis
2005
17 20 Reported
as major
and minor,
but oth-
erwise not
defined
9 (6 major,
3 minor)
4 (2 major,
2 minor)
- - - -
Sorensen
2009
7 8 “Serious
wound
complica-
tions were
recorded
as they oc-
curred and
included
wound
infection,
wound de-
hiscence,
and wound
fistula.
Wound as-
sessments
using the
2 (0 major
2 minor)
5 (1major -
wound de-
hiscence; 4
minor)
- - - -
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Table 4. Other complications (Continued)
ASEPSIS
scoring
method
were per-
formed
daily and
photo-
graphic
images
were taken
on several
postop-
erative
days.” Au-
thors also
noted that
“Patients
may have
had more
than one
complica-
tion” (NB:
figures pro-
vided here
include
“wound
dehis-
cence”
(classed as
major) and
“other”
(urinary
tract infec-
tion and
nosoco-
mial pneu-
monia
combined
as one
group)
(classed as
minor) but
exclude
“wound
fistula” and
“wound
infection”).
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Table 4. Other complications (Continued)
Felekis
2010
20 20 Minor de-
scribed
in results as
“a slight in-
crease
of the tem-
perature (<
38°), with-
out
an identifi-
able source
of infec-
tion”. Ma-
jor de-
scribed in
results
as includ-
ing pneu-
monia, uri-
nary
tract infec-
tion, fistula
and wound
infec-
tion. NB:
figures pro-
vided here
do not in-
clude
fistula and
wound in-
fection.
6 (3 minor,
3 major -
2 pneumo-
nia, 1UTI)
2 (2 minor,
0 major)
2 0 1 0
Ghosh
2012
29 28 “The
primary
outcome
event was
defined as
any patient
with an in-
fection of
the lower
respiratory
tract,
gastro-
intestinal
tract, uri-
nary tract
8
with chest,
urinary,
gastroin-
testinal or
blood
infection
17 with
neck, pri-
mary site,
donor site,
or PEG site
infection
12
with chest,
urinary,
gastroin-
testinal or
blood
infection
17 with
neck, pri-
mary site,
donor site,
or PEG site
infection
4 9 1 2
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Table 4. Other complications (Continued)
or blood
which
required
antibiotic
treatment
and oc-
curred at
any time,
up to the
30th post-
operative
day.”
“Sec-
ondary
outcome
measures
included
infections
of primary
surgical
site, neck
wound,
PEG
site, tra-
cheostomy,
free-flap or
split skin
graft donor
site.”
“...the
surgical
site/wound
infections
were
defined
according
to CDC
Defini-
tions of
Noso-
comial
Surgical
Site infec-
tions, 1992
and the
ASEPSIS
wound
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Table 4. Other complications (Continued)
score. The
diagnosis
of the non-
wound
infection
was as
stipulated
in the Trial
Antibiotic
Policy,
which also
governed
how any
infective
compli-
cation
diagnosed
through-
out the
trial was to
be treated.
”
Turnock
2013
4 4 “General
infections
(urinary
tract in-
fection,
respiratory
tract infec-
tion), flap
anastomo-
sis com-
plications
(venous or
arterial),
and wound
complica-
tions (de-
hiscence,
tissue
necrosis,
haematoma,
chyle leak,
salivary
fistula or
wound
infection)
2 (infec-
tious)
0 - - - -
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Table 4. Other complications (Continued)
were
recorded.
Infectious
complica-
tions were
judged us-
ing CDC
criteria
and were
considered
significant
if antibi-
otic ther-
apy was
instituted.
” (NB:
figures pro-
vided here
do not
include
wound
infection).
Falewee
2014*
104 105 Infectious
compli-
cations:
“systemic
infection
requiring
antibiotic
treatment
(septi-
caemia,
bacter-
aemia),
surgical
site in-
fection
(according
to CDC
Defini-
tions of
Nosoco-
mial Sur-
gical Site
infections)
, docu-
mented
- - - - - -
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Table 4. Other complications (Continued)
nosoco-
mial pneu-
mopathy,
up to the
30th post-
operative
day.”
Surgical
site infec-
tions (SSI)
: “primary
surgical
site, neck
wound,
free-flap or
split skin
graft donor
site, and
tra-
cheotomy”
Hanai
2018
14 13 Clini-
cal compli-
cations
presented
as numbers
of pa-
tients with
“wound
complica-
tions” clas-
sified
according
to Clavien-
Dindo sys-
tem
7 4 - - - -
Postoperative feeding only
Riso 2000 21 23 “Post-
operative
complica-
tions were
recorded
as none,
minor (uri-
nary tract
infection;
respira-
4 major (1
flap necro-
sis, 3 puru-
lent
drainage)
1 minor
(respira-
tory tract)
2 (purulent
drainage)
1 (respira-
tory tract)
0 0 0
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Table 4. Other complications (Continued)
tory tract
infection:
abnormal
chest X-
ray), and
major
(fistula;
wound
infection;
sponta-
neous or
surgical
purulent
drainage
and flap
necrosis;
anasto-
motic
leakage)
.” (NB:
figures pro-
vided here
exclude
reported
fistula).
De Luis
2002
24 23 “Postop-
erative
complica-
tions were
recorded
as none,
general
infections
(respira-
tory tract
infection
was di-
agnosed
when the
chest ra-
diographic
exami-
nation
showed
new or
progressive
unfiltra-
4 5 - - - -
97Immunonutrition for patients undergoing surgery for head and neck cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Other complications (Continued)
tion, tem-
perature
above 38.
5°C and
isolation of
pathogens
from the
sputum
or blood
culture
and/or
urinary
tract infec-
tion was
diagnosed
if the urine
culture
showed at
least 105
colonies
of a
pathogen)
and local
compli-
cations
such as
fistula and/
or wound
infection,
assessing
all com-
plications
using
standard
methods
and the
same in-
vestigator.
” (NB:
figures pro-
vided here
exclude
reported
fistula).
De Luis
2003
18 18 Not
collected
- - - - - -
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Table 4. Other complications (Continued)
De Luis
2004
45 45 “Postop-
erative
complica-
tions were
recorded
as none,
general
infections
(respira-
tory tract
infection
was di-
agnosed
when the
chest ra-
diographic
exami-
nation
showed
new or
progressive
unfiltra-
tion, tem-
perature
above 38.
5°C and
isolation of
pathogens
from the
sputum
or blood
culture
and/or
urinary
tract infec-
tion was
diagnosed
if the urine
culture
showed at
least 105
colonies
of a
pathogen)
and local
compli-
4 2 - - - -
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Table 4. Other complications (Continued)
cations
such as
fistula and/
or wound
infection.
All com-
plications
were as-
sessed with
standard
methods
by the
same in-
vestigator.
” (NB:
figures pro-
vided here
exclude
reported
fistula).
De Luis
2005
15 14 Not
collected
- - - - - -
De Luis
2007
37 35 “Postop-
erative
complica-
tions were
recorded
as none;
general
infections
(respira-
tory tract
infection
was di-
agnosed
when the
chest ra-
diographic
exami-
nation
showed
new or
progressive
unfiltra-
tion, tem-
perature
2 2 - - - -
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Table 4. Other complications (Continued)
above 38.
5°C and
isolation of
pathogens
from the
sputum
or blood
culture
and/or
urinary
tract infec-
tion was
diagnosed
if the urine
culture
showed at
least 105
colonies
of a
pathogen)
and wound
compli-
cations,
such as
fistula and/
or wound
infection,
assessed all
complica-
tions with
standard
methods
by the
same in-
vestigator
surgeon.
” (NB:
figures pro-
vided here
exclude
reported
fistula).
Casas-
Rodera
2008
15 14 “Postop-
erative
complica-
tions were
recorded
as none,
1 0 1 0 0 0
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Table 4. Other complications (Continued)
general
infections
(respira-
tory tract
infection
was di-
agnosed
when the
chest ra-
diographic
exami-
nation
showed
new or
progressive
unfiltra-
tion, tem-
perature
above 38.
5°C and
isolation of
pathogens
from the
sputum
or blood
culture
and/or
urinary
tract infec-
tion was
diagnosed
if the urine
culture
showed at
least 105
colonies
of a
pathogen),
and wound
compli-
cations
such as
fistula and/
or wound
infection.
All com-
plications
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Table 4. Other complications (Continued)
were as-
sessed with
standard
methods
by the
same in-
vestigator.
” (NB:
figures pro-
vided here
exclude
reported
fistula and
wound
infection).
De Luis
2009
34 38 “Postop-
erative
complica-
tions were
registered
as none,
general
infections
(urinary
tract infec-
tion was
diagnosed
if the urine
culture
showed at
least 105
colonies of
a pathogen
and/or
respiratory
tract infec-
tion was
diagnosed
when the
chest ra-
diographic
exami-
nation
showed
new or
progressive
unfiltra-
8 9 - - - -
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Table 4. Other complications (Continued)
tion, tem-
perature
above 38.
5°C and
isolation of
pathogens
from the
sputum
or blood
culture)
and local
compli-
cations
such as
fistula and/
or wound
infection,
assessed all
complica-
tions with
standard
methods
by the
same in-
vestigator.
” (NB:
figures pro-
vided here
exclude
reported
fistula and
wound
infection).
De Luis
2014
40 42 No clini-
cal compli-
cations
recorded
- - - - - -
Azman
2015
22 22 No clini-
cal compli-
cations
recorded
- - - - - -
* Additional data supplied by authors for intention-to-treat (ITT) analysis to be conducted; as such, total n differs from that in the
published manuscript.
ASEPSIS: Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissues, Isolation of bacteria, Stay
duration as inpatient
CDC: Centers for Disease Control and Prevention
PEG: percutaneous endoscopic gastrostomy
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UTI: urinary tract infection
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (via Cochrane Register of
Studies)
PubMed EMBASE (Ovid)
#1 MESH DESCRIPTOR Head and
Neck Neoplasms EXPLODE ALL TREES
WITH QUALIFIERS SU
#2 MESH DESCRIPTOR Otorhino-
laryngologic Neoplasms EXPLODE ALL
TREES WITH QUALIFIERS SU
#3 MESH DESCRIPTOR Otorhino-
laryngologic Neoplasms EXPLODE ALL
TREES
#4MESHDESCRIPTORHead andNeck
Neoplasms EXPLODE ALL TREES
#5 (head near neck):TI,AB,KY
#6 ((larynx or laryngeal or glottis or glot-
tic or “oral cavity” or nasopharynx or na-
sopharyngeal or hypopharynx or hypopha-
ryngeal or pharynx or pharyngeal or para-
pharyngeal or mouth)):TI,AB,KY
#7 (face or facial or oesophageal or
esophageal or oesophagus or esophagus or
thyroid or salivary or paranasal or “aero di-
gestive” or aerodigestive or aero-digestive):
TI,AB,KY
#8 #5 OR #6 OR #7
#9 ((cancer* or carcinoma* or neoplasm*
or tumor* or tumour* or metastas*)):TI,
AB,KY
#10 MESH DESCRIPTOR Neoplasms
EXPLODE ALL TREES
#11 #9 OR #10
#12 #8 AND #11
#13 #3 OR #4 OR #12
#14 MESH DESCRIPTOR Surgical
Procedures, Operative EXPLODE ALL
TREES
#15 ((surg* or resect* or reconstruct*)):TI,
#1 (“Head and Neck Neoplasms/
surgery”[Mesh])
#2 “Otorhinolaryngologic Neoplasms/
surgery”[Mesh]
#3 (“Head and Neck Neoplasms”[Mesh])
#4 “Otorhinolaryngologic
Neoplasms”[Mesh]
#5 (“head neck” OR head-neck OR “head
and neck” OR head-and-neck[Title/Ab-
stract])
#6 (larynx or laryngeal or glottis or glot-
tic or “oral cavity” or nasopharynx or na-
sopharyngeal or hypopharynx or hypopha-
ryngeal or pharynx or pharyngeal or para-
pharyngeal or mouth[Title/Abstract])
#7 (face or facial or oesophageal or
esophageal or oesophagus or esophagus or
thyroid or salivary or paranasal or “aero
digestive” or aerodigestive or aero-diges-
tive[Title/Abstract])
#8 (#5 OR #6 OR #7)
#9 (cancer* or carcinoma* or neoplasm*
or tumor* or tumour* or metastas*[Title/
Abstract])
#10 “Neoplasms”[Mesh]
#11 (#9 OR #10)
#12 (#8 AND #11)
#13 (#3 OR #4 OR #12)
#14 “Surgical Procedures,
Operative”[Mesh]
#15 (surg* or resect* or reconstruct*[Title/
Abstract])
#16 (pharyngectomy or laryngopharyngec-
tomy or laryngectomy or mandibulectomy
1 exp “head and neck tumor”/su [Surgery]
2 exp *“head and neck tumor”/
3 (head adj3 neck).tw.
4 (larynx or laryngeal or glottis or glottic or
“oral cavity” or nasopharynx or nasopha-
ryngeal or hypopharynx or hypopharyngeal
or pharynx or pharyngeal or parapharyn-
geal or mouth).tw
5 (face or facial or oesophageal or
esophageal or oesophagus or esophagus or
thyroid or salivary or paranasal or “aero di-
gestive” or aerodigestive or aero-digestive).
tw
6 3 or 4 or 5
7 (cancer* or carcinoma* or neoplasm* or
tumor* or tumour* or metastas*).tw
8 exp *neoplasm/
9 7 or 8
10 6 and 9
11 2 or 10
12 exp surgery/
13 (surg* or resect* or reconstruct*).tw.
14 (pharyngectomy or laryngopharyngec-
tomy or laryngectomy or mandibulectomy
or commando or esophagectomy or oe-
sophagectomy).tw
15 (neck and dissect*).tw.
16 exp neck dissection/
17 ((free or myocutaneous) and flap).tw.
18 12 or 13 or 14 or 15 or 16 or 17
19 11 and 18
20 1 or 19
21 exp arginine/
22 exp omega 3 fatty acid/ or exp omega 6
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AB,KY
#16 ((pharyngectomy or laryngopharyn-
gectomy or laryngectomy or mandibulec-
tomy or commando or esophagectomy or
oesophagectomy)):TI,AB,KY
#17 ((neck and dissect*)):TI,AB,KY
#18 MESH DESCRIPTOR Neck Dissec-
tion EXPLODE ALL TREES
#19 (((free or myocutaneous) and flap)):
TI,AB,KY
#20 #14 OR #15 OR #16 OR #17 OR #
18 OR #19
#21 #13 AND #20
#22 #1 OR #2 OR #21
#23 MESH DESCRIPTOR Arginine EX-
PLODE ALL TREES
#24 (immuno or arginine* or glutamine*
or nucleotide* or omega-3 or omega3 or
omega-6 or omega6 or “ω-3” or nucleo-
side* or fibre* or fiber* or IMP1000 or
IMP500 or immunostimulat* or immuno-
stimulat*):TI,AB,KY
#25 MESH DESCRIPTOR Fatty Acids,
Omega-3 EXPLODE ALL TREES
#26 MESH DESCRIPTOR Fatty Acids,
Omega-6 EXPLODE ALL TREES
#27 MESH DESCRIPTOR Glutamine
EXPLODE ALL TREES
#28 MESH DESCRIPTOR Nucleotides
EXPLODE ALL TREES
#29 MESH DESCRIPTOR Dietary Fiber
EXPLODE ALL TREES
#30 (Argininosuccinic* or Benzoylargi-
nine* or Homoarginine* or Nitroarginine*
or Tosylarginine* or Methylarginine* or
NO2Arg or NOARG or L-NMMA or D-
NMMA or TAME or Proglumide* or Xy-
lamide* or Xilamide or Milid or PUFA*
or “n-3 fatty acid*” or Docosahexaen*
or Neuroprostane* or Icosapentaenoic* or
Timnodonic or Linoleic* or Linolenic* or
Octadecadienoic* or Linoleate* or Linoe-
laidic or “n-6 fatty acid*” or Eicosapen-
taenoic or EPA or O-3FA* or O-6FA*):TI,
AB,KY
#31 #23 OR #24 OR #25 OR #26 OR #
27 OR #28 OR #29 OR #30
#32 (enteral or polymeric* or Parenteral or
diet* or feed* or food* or supplement* or
or commando or esophagectomy or oe-
sophagectomy[Title/Abstract])
#17 (neck and dissect*[Title/Abstract])
#18 “Neck Dissection”[Mesh]
#19 ((free or myocutaneous[Title/Ab-
stract])) AND flap[Title/Abstract]
#20 (#14 OR #15 OR #16 OR #17 OR #
18 OR #19)
#21 (#13 AND #20)
#22 (#1 OR #2 OR #21)
#23 “Arginine”[Mesh]
#24 (immuno or arginine* or glutamine*
or nucleotide* or omega-3 or omega3 or
omega-6 or omega6 or “ω-3” or nucleo-
side* or fibre* or fiber* or IMP1000 or
IMP500 or immunostimulat* or immuno-
stimulat*[Title/Abstract])
#25 (“Fatty Acids, Omega-3”[Mesh] OR
“Fatty Acids, Omega-6”[Mesh])
#26 “Glutamine”[Mesh]
#27 “Nucleotides”[Mesh]
#28 “Dietary Fiber”[Mesh]
#29 (Argininosuccinic* or Benzoylargi-
nine* or Homoarginine* or Nitroarginine*
or Tosylarginine* or Methylarginine* or
NO2Arg or NOARG or L-NMMA or D-
NMMA or TAME or Proglumide* or Xy-
lamide* or Xilamide or Milid or PUFA*
or “n-3 fatty acid*” or Docosahexaen*
or Neuroprostane* or Icosapentaenoic* or
Timnodonic or Linoleic* or Linolenic*
or Octadecadienoic* or Linoleate* or Li-
noelaidic or “n-6 fatty acid*” or Eicos-
apentaenoic or EPA or O-3FA* or O-
6FA*[Title/Abstract])
#30 (#23 OR #24 OR #25 OR #26 OR #
27 OR #28 OR #29)
#31 (enteral or polymeric* or Parenteral or
diet* or feed* or food* or supplement* or
nutri* or formul* or tpn or enteric or Nu-
traceutical* or tube* or pn or SEN or “En-
sure Liquid*”[Title/Abstract])
#32 “Nutrition Therapy”[Mesh]
#33 “Nutritional Support”[Mesh]
#34 “Dietary Supplements”[Mesh]
#35 “Food, Formulated”[Mesh]
#36 (#31 OR #32 OR #33 OR #34 OR #
35)
fatty acid/
23 exp glutamine/
24 exp nucleotide/
25 exp dietary fiber/
26 (Argininosuccinic* or Benzoylargi-
nine* or Homoarginine* or Nitroarginine*
or Tosylarginine* or Methylarginine* or
NO2Arg or NOARG or L-NMMA or D-
NMMA or TAME or Proglumide* or Xy-
lamide* or Xilamide or Milid or PUFA*
or “n-3 fatty acid*” or Docosahexaen*
or Neuroprostane* or Icosapentaenoic* or
Timnodonic or Linoleic* or Linolenic* or
Octadecadienoic* or Linoleate* or Linoe-
laidic or “n-6 fatty acid*” or Eicosapen-
taenoic or EPA or O-3FA* or O-6FA*).tw
27 21 or 22 or 23 or 24 or 25 or 26
28 (enteral or polymeric* or Parenteral or
diet* or feed* or food* or supplement* or
nutri* or formul* or tpn or enteric or Nu-
traceutical* or tube* or pn or SEN or “En-
sure Liquid*”).tw
29 diet therapy/ or diet supplementation/
or nutritional support/
30 exp elemental diet/
31 28 or 29 or 30
32 27 and 31
33 (immunonutri* or immunoenhanc* or
imn or ied or Pharmaconutri* or immune-
modulat* or immunomodulat* or IMEN
or immunoenteral or IEEN or ien or im-
munodiet* or ((immune* or immuno*)
adj6 (enhanc* or enrich*)) or immunoen-
rich* or ief or ieef ).tw
34 (isosource or jevity or vivonex or osmo-
lite or nutrison or “oral impact” or replete
or alitraQ or immun-aid or optimental or
perative or pivot or stresson or immunaid
or nutrisource orOxepa or immunex or cu-
bitan or dipeptiven or omegaven or Recon-
van or anom or oligopeptic or prosure* or
Prem-8 or racol or RAC or rakol or ((im-
pact or crucial) and (nestle or novartis))).
tw
35 32 or 33 or 34
36 20 and 35
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nutri* or formul* or tpn or enteric or Nu-
traceutical* or tube* or pn or SEN or “En-
sure Liquid*”):TI,AB,KY
#33 MESH DESCRIPTOR Nutrition
Therapy EXPLODE ALL TREES
#34 MESH DESCRIPTOR Nutritional
Support EXPLODE ALL TREES
#35 MESH DESCRIPTOR Dietary Sup-
plements EXPLODE ALL TREES
#36MESHDESCRIPTOR Food, Formu-
lated EXPLODE ALL TREES
#37 #32 OR #33 OR #34 OR #35 OR #
36
#38 #31 AND #37
#39 (immunonutri* or immunoenhanc*
or imn or ied or Pharmaconutri* or im-
mune-modulat* or immunomodulat* or
IMENor immunoenteral or IEENor ien or
immunodiet* or ((immune* or immuno*)
near (enhanc* or enrich*)) or immunoen-
rich* or ief or ieef ):TI,AB,KY
#40 (isosource or jevity or vivonex or os-
molite or nutrison or rna or Ribonucleic or
“oral impact” or replete or alitraQ or im-
mun-aid or optimental or perative or pivot
or stresson or immunaid or nutrisource or
Oxepa or immunex or cubitan or dipep-
tiven or omegaven or Reconvan or anom or
oligopeptic or prosure* or Prem-8 or racol
or RAC or rakol or ((impact or crucial) and
(nestle or novartis)))
#41 #38 OR #39 OR #40
#42 #22 AND #41
#37 (#30 AND #36)
#38 (immunonutri* or immunoenhanc* or
imn or ied or Pharmaconutri* or immune-
modulat* or immunomodulat* or IMEN
or immunoenteral or IEEN or ien or im-
munodiet* or immunoenrich* or ief or
ieef[Title/Abstract])
#39 (immune* enhanc* or immune* en-
rich* or immuno* enhanc* or immuno* en-
rich*[Title/Abstract])
#40 (isosource or jevity or vivonex or osmo-
lite or nutrison or “oral impact” or replete
or alitraQ or immun-aid or optimental or
perative or pivot or stresson or immunaid
or nutrisource orOxepa or immunex or cu-
bitan or dipeptiven or omegaven or Recon-
van or anom or oligopeptic or prosure* or
Prem-8 or racol or RAC or rakol[Title/Ab-
stract])
#41 ((impact or crucial[Title/Abstract]))
AND (nestle or novartis[Title/Abstract])
#42 (#37 OR #38 OR #39 OR #40 OR #
41)
#43 (#22 AND #42)
Web of Science (Web of Knowledge) CINAHL (EBSCO) Trial Registries
#1 TOPIC: (larynx or laryngeal or glottis
or glottic or “oral cavity” or nasopharynx
or nasopharyngeal or hypopharynx or hy-
popharyngeal or pharynx or pharyngeal or
parapharyngeal or mouth or face or facial
or oesophageal or esophageal or oesopha-
gus or esophagus or thyroid or salivary or
paranasal or “aero digestive” or aerodiges-
tive or aero-digestive or (head near/3 neck)
)
#2TOPIC: (cancer* or carcinoma* or neo-
plasm* or tumor* or tumour* or metastas*)
#3 TOPIC:
S40 S22 AND S39
S39 S36 OR S37 OR S38
S38 TX isosource or jevity or vivonex or
osmolite or nutrison or “oral impact” or re-
plete or alitraQ or immun-aid or optimen-
tal or perative or pivot or stresson or immu-
naid or nutrisource or Oxepa or immunex
or cubitan or dipeptiven or omegaven or
Reconvan or anom or oligopeptic or pro-
sure* or Prem-8 or racol or RAC or rakol or
((impact or crucial) and (nestle or novartis)
)
S37 TX immunonutri* or immunoen-
ICTRP
immunonutri* AND head AND neck or
immunoenhanc* ANDhead AND neck or
Pharmaconutri* AND head AND neck or
immune-modulat* AND head AND neck
or immunomodulat* AND head AND
neck or immunoenteral AND head AND
neck or immunodiet* AND head AND
neck or immunoenrich*AND head AND
neck or immune* AND enhanc* AND
head AND neck OR immune AND en-
rich* AND head AND neck OR immuno*
AND enhance* ANDhead ANDneckOR
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(surg* or resect* or reconstruct* or pharyn-
gectomy or laryngopharyngectomy or la-
ryngectomy or mandibulectomy or com-
mando or esophagectomy or oesophagec-
tomy or (neck and dissect*) OR ((free or
myocutaneous) and flap))
#4 #3 AND #2 AND #1
#5 TOPIC: (Argininosuccinic* or Benzoy-
larginine* or Homoarginine* or Nitroargi-
nine* or Tosylarginine* orMethylarginine*
or NO2Arg or NOARG or L-NMMA or
D-NMMA or TAME or Proglumide* or
Xylamide* or Xilamide or Milid or PUFA*
or “n-3 fatty acid*” or Docosahexaen*
or Neuroprostane* or Icosapentaenoic* or
Timnodonic or Linoleic* or Linolenic* or
Octadecadienoic* or Linoleate* or Linoe-
laidic or “n-6 fatty acid*” or Eicosapen-
taenoic or EPA or O-3FA* or O-6FA*)
#6 (enteral or polymeric* or Parenteral or
diet* or feed* or food* or supplement* or
nutri* or formul* or tpn or enteric or Nu-
traceutical* or tube* or pn or SEN or “En-
sure Liquid*”)
#7 #6 AND #5
#8TOPIC: (immunonutri* or immunoen-
hanc* or imn or ied or Pharmaconutri*
or immune-modulat* or immunomodulat*
or IMEN or immunoenteral or IEEN or
ien or immunodiet* or ((immune* or im-
muno*) near/6 (enhanc* or enrich*)) or im-
munoenrich* or ief or ieef )
#9 TOPIC: (isosource or jevity or vivonex
or osmolite or nutrison or “oral impact”
or replete or alitraQ or immun-aid or
optimental or perative or pivot or stres-
son or immunaid or nutrisource or Ox-
epa or immunex or cubitan or dipeptiven
or omegaven or Reconvan or anom or
oligopeptic or prosure* or Prem-8 or racol
or RAC or rakol or ((impact or crucial) and
(nestle or novartis)))
#10 #9 OR #8 OR #7
#11 #10 AND #4
hanc* or imn or ied or Pharmaconutri* or
immune-modulat* or immunomodulat* or
IMENor immunoenteral or IEENor ien or
immunodiet* or ((immune* or immuno*)
N6 (enhanc* or enrich*)) or immunoen-
rich* or ief or ieef
S36 S30 AND S35
S35 S31 OR S32 OR S33 OR S34
S34 (MH “Food, Formulated+”)
S33 (MH “Dietary Supplements+”)
S32 (MH “Nutritional Support+”)
S31 TX enteral or polymeric* or Parenteral
or diet* or feed* or food* or supplement*
or nutri* or formul* or tpn or enteric or
Nutraceutical* or tube* or pn or SEN or
“Ensure Liquid*”
S30 S23ORS24OR S25ORS26OR S27
OR S28 OR S29
S29 TX Argininosuccinic* or Benzoylargi-
nine* or Homoarginine* or Nitroarginine*
or Tosylarginine* or Methylarginine* or
NO2Arg or NOARG or L-NMMA or D-
NMMA or TAME or Proglumide* or Xy-
lamide* or Xilamide or Milid or PUFA*
or “n-3 fatty acid*” or Docosahexaen*
or Neuroprostane* or Icosapentaenoic* or
Timnodonic or Linoleic* or Linolenic* or
Octadecadienoic* or Linoleate* or Linoe-
laidic or “n-6 fatty acid*” or Eicosapen-
taenoic or EPA or O-3FA* or O-6FA*
S28 (MH “Dietary Fiber”)
S27 (MH “Nucleotides+”)
S26 (MH “Glutamine”)
S25 (MH “Fatty Acids, Omega-6+”) OR
(MH “Fatty Acids, Omega-3+”)
S24 TX immuno or arginine* or glu-
tamine* or nucleotide* or omega-3 or
omega3 or omega-6 or omega6 or “ω-3” or
nucleoside* or fibre* or fiber* or IMP1000
or IMP500 or immunostimulat* or im-
muno-stimulat*
S23 (MH “Arginine”)
S22 S1 OR S2 OR S21
S21 S13 AND S20
S20 S14ORS15OR S16ORS17OR S18
OR S19
S19 (MH “Neck Dissection”)
S18 TX (free or myocutaneous) and flap
immuno* AND enrich* AND head AND
neck
ClinicalTrials.gov (via clinicaltrials.gov)
immunonutrition OR immunoenhanced
OR Pharmaconutrition OR immunomod-
ulated OR immunomodulating OR im-
munoenteral OR immunodiet OR immu-
noenriched OR ((immuno OR immune)
AND(enhancedORenrichedOR enhanc-
ing OR enriching)) OR immune-modulat-
ing OR immune-modulated OR imn OR
ied OR IMEN OR IEEN OR ien OR ief
OR ieef
+
Condition: head and neck
ClinicalTrials.gov (Cochrane ENT Reg-
ister)
1 (immuno or arginine* or glutamine* or
nucleotide* or
omega-3 or omega3 or omega-6 or omega6
or “ω-3” or nucleoside* or fibre* or fiber*
or IMP1000 or IMP500 or immunostim-
ulat* or immuno-stimulat*):AB,EH,KW,
KY,MC,MH,TI,TOANDINSEGMENT
2 (Argininosuccinic* or Benzoylarginine*
or Homoarginine* or Nitroarginine* or
Tosylarginine* or Methylarginine* or
NO2Arg or NOARG or L-NMMA or D-
NMMA or TAME or Proglumide* or Xy-
lamide* or Xilamide or Milid or PUFA*
or “n-3 fatty acid*” or Docosahexaen*
or Neuroprostane* or Icosapentaenoic* or
Timnodonic or Linoleic* or Linolenic* or
Octadecadienoic* or Linoleate* or Linoe-
laidic or “n-6 fatty acid*” or Eicosapen-
taenoic or EPA orO-3FA* orO-6FA*):AB,
EH,KW,KY,MC,MH,TI,TO AND IN-
SEGMENT
3 #1 OR #2 AND INSEGMENT
4 (enteral or polymeric* or Parenteral or
diet* or feed* or food* or supplement*
or nutri* or formul* or tpn or enteric
or Nutraceutical* or tube* or pn or SEN
or “Ensure Liquid*”):AB,EH,KW,KY,MC,
MH,TI,TO AND INSEGMENT
5 #3 AND #4
6 (immunonutri* or immunoenhanc* or
imn or ied or Pharmaconutri* or im-
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S17 TX neck and dissect*
S16 TX pharyngectomy or laryngopharyn-
gectomy or laryngectomy or mandibulec-
tomy or commando or esophagectomy or
oesophagectomy
S15 TX surg* or resect* or reconstruct*
S14 (MH “Surgery, Operative+”)
S13 S3 OR S4 OR S12
S12 S8 AND S11
S11 S9 OR S10
S10 (MH “Neoplasms+”)
S9TX cancer* or carcinoma* or neoplasm*
or tumor* or tumour* or metastas*
S8 S5 OR S6 OR S7
S7 TX face or facial or oesophageal or
esophageal or oesophagus or esophagus or
thyroid or salivary or paranasal or “aero di-
gestive” or aerodigestive or aero-digestive
S6 TX larynx or laryngeal or glottis or glot-
tic or “oral cavity” or nasopharynx or na-
sopharyngeal or hypopharynx or hypopha-
ryngeal or pharynx or pharyngeal or para-
pharyngeal or mouth
S5 TX head N3 neck
S4 (MH “Otorhinolaryngologic Neo-
plasms+”)
S3 (MH “Head and Neck Neoplasms+”)
S2 (MH “Otorhinolaryngologic Neo-
plasms+/SU”)
S1 (MH “Head and Neck Neoplasms+/
SU”)
mune-modulat* or immunomodulat* or
IMEN or immunoenteral or IEEN or
ien or immunodiet* or immunoenrich*
or ief or ieef ):AB,EH,KW,KY,MC,MH,
TI,TO AND INSEGMENT
7 ((immune* or immuno*) near (enhanc*
or enrich*)):AB,EH,KW,KY,MC,MH,TI,
TO AND INSEGMENT
8 (isosource or jevity or vivonex or osmo-
lite or nutrison or rna or Ribonucleic or
“oral impact” or replete or alitraQ or im-
mun-aid or optimental or perative or pivot
or stresson or immunaid or nutrisource or
Oxepa or immunex or cubitan or dipep-
tiven or omegaven or Reconvan or anom
or oligopeptic or prosure* or Prem-8 or
racol or RAC or rakol):AB,EH,KW,KY,
MC,MH,TI,TO AND INSEGMENT
9 ((impact or crucial) and (nes-
tle or novartis)):AB,EH,KW,KY,MC,MH,
TI,TO AND INSEGMENT
10 #5 OR #7 OR #6 OR #8 OR #9
11 (nct*):AU AND INSEGMENT
12 #10 AND #11
C O N T R I B U T I O N S O F A U T H O R S
Noah Howes (NH), Charlotte Atkinson (CA), Steven Thomas (ST), Stephen J Lewis (SJL).
• Conceiving the review: NH, SJL and ST
• Designing the review: NH, SJL and ST
• Co-ordinating the review: NH and CA
• Undertaking manual searches: NH and SJL
• Screening search results: NH, CA, SJL and ST
• Organising retrieval of papers: SJL
• Screening retrieved papers against inclusion criteria: NH, CA, SJL and ST
• Appraising quality of papers: NH, CA, SJL and ST
109Immunonutrition for patients undergoing surgery for head and neck cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Abstracting data from papers: NH, CA, SJL and ST
• Writing to authors of papers for additional information: SJL
• Obtaining and screening data on unpublished studies: SJL
• Data management for the review: NH, CA and SJL
• Entering data into Review Manager (RevMan 5.3): NH and SJL
• RevMan statistical data: NH, CA, SJL and ST
• Other statistical analysis not using RevMan: NH and ST
• Double entry of data: (data entered by person one: NH; data entered by person two: ST)
• Interpretation of data: NH, CA, SJL and ST
• Writing the review: NH, CA, SJL and ST
• Providing guidance on the review: JB, SJL and ST
• Securing funding for the review: N/A
• Performing previous work that was the foundation of the present study: SJL and ST
• Guarantor for the review (one author): SJL
• Person responsible for reading and checking review before submission: NH
D E C L A R A T I O N S O F I N T E R E S T
Noah Howes: no known conflicts of interest to declare.
Charlotte Atkinson: no known conflicts of interest to declare.
Steven Thomas: Steven Thomas was involved in the design, conduct and publication of a study of postoperative feeding in colorectal
surgery (Lidder 2013) - funding support for that study was provided by Nutricia Ltd. He has no pecuniary interest in the product used
in any of the studies.
Stephen J Lewis: Stephen J Lewis was involved in the design, conduct and publication of a study of postoperative feeding in colorectal
surgery (Lidder 2013) - funding support for that study was provided by Nutricia Ltd. He has no pecuniary interest in the product used
in any of the studies.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
110Immunonutrition for patients undergoing surgery for head and neck cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• National Institute for Health Research, UK.
Infrastructure funding for Cochrane ENT
• National Institute for Health Research Bristol Biomedical Research Centre, UK.
This research was supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre. The views
expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have made the following changes from the protocol (Howes 2014):
• Authorship has changed from: Noah Howes, Stephen J Lewis, Steven Thomas to Noah Howes, Charlotte Atkinson, Steven
Thomas, Stephen J Lewis.
• The Background has been reworked and updated.
• The outcome wound infection/fistula has been separated into two separate outcomes.
• We have clarified the measurement of some of the outcomes as follows:
◦ wound infections “as measured by the proportion of patients in whom any type or degree of wound infection was recorded,
at any point postoperatively”;
◦ fistula formation “as measured by the proportion of patients in whom a fistula was recorded at any point postoperatively”;
◦ adverse events/tolerance of feeds “as defined by trial authors: as measured by the proportion of patients in whom adverse
events relating to tolerance of feed was recorded, at any point postoperatively”;
◦ all-cause mortality “as measured by the proportion of patients recorded as having died at any point postoperatively”;
◦ postoperative complications as defined by trial authors “as measured by the proportion of patients in whom any type or
degree of complication (other than wound infection, fistula formation or relating to tolerance of feed) was recorded, at any point
postoperatively”.
• We added “tolerance of feeds, as defined by trial authors” to the outcome “Adverse events” so that it now reads “Adverse events/
tolerance of feeds, as defined by trial authors”.
• We added the following clarifying statement to Types of outcome measures: “We assessed the following outcomes in the review,
but we did not use them as a sole basis for excluding studies”.
• We have added a description of the method used to create a ’Summary of findings’ table and carry out GRADE quality
assessment.
• We did not conduct the planned sensitivity analysis to look at trial influence by sequentially excluding each trial due to the
increased potential for obtaining spurious low P values resulting from repeated analyses.
• We did not conduct the planned subgroup analysis of “preoperative immunonutrition versus placebo drink” because only one
study (with three treatment groups) gave pre-operative immunonutrition alone in one group (Falewee 2014). However, eight studies
gave immunonutrition pre- and postoperatively and the remaining 10 studies gave immunonutrition only postoperatively; we
conducted analyses for these subgroups.
• We removed “Biochemical changes, as defined by trial authors” and “Immunological changes, as defined by trial authors” from
the secondary outcomes and have not formally assessed these because very few papers commented on immunological and biochemical
parameter changes, and in each paper the markers chosen were different and assessed at differing time intervals. Meta-analysis of the
few papers was thus not possible. Given the expected profound influence of the operative inflammatory response on levels of such
markers, their interpretation is not straightforward.
111Immunonutrition for patients undergoing surgery for head and neck cancer (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
